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HIStory oF MycoPHeNolIc AcID
In 1896 Gosic isolated for the first time mycophenolic acid (MPA) from Penicillium 
glaucum.1 It was subsequently isolated from Penicillium stoloniferum Thom (synonym P. 
brevi-compactum Dierckx) by Alsberg and Black in 1913 who gave the acid phenolic sub-
stance its name mycophenolic acid (MPA).2 From 1931 to 1933 a series of studies in the 
biochemistry of micro-organisms was published by Clutterbuck, Raistrick and Oxford 
of the division of biochemistry from the University of London. These series described 
in detail the isolation and characterization of MPA.3-6 The structure of MPA was finally 
established in 1952 (Figure 1).7 In the first decades, MPA was eventually found to have 
antineoplastic, antibacterial, antifungal and antiviral properties and was investigated by 
a few groups.8 In 1969, Planterose et al described an effect of MPA most likely to an im-
munosuppressive effect,9 and Mitsui et al reported in the same year for the first time the 
immunosuppressive effect of MPA in mice, at the cellular and humoral levels of antibody 
formation.10 In the following years, more and more research was done on the efficacy 
of MPA as an immunosuppressant.11-14 Mycophenolate mofetil (MMF) was developed at 
Syntex Corporation to be a more bioavailable form of MPA.15 The first human trials of 
MMF in kidney recipients were conducted by Sollinger et al,16 leading to the registration 
of the pharmaceutical compound as immunosuppressant in 1995.
MycoPHeNolIc AcID AS IMMuNoSuPPreSSANt
Currently, two mycophenolate compounds are available as immunosuppressant: myco-
phenolate mofetil (MMF, CellCept®, Roche) and enteric-coated mycophenolate sodium 
(EC-MPS, Myfortic®, Novartis). In 1995 MMF was approved in the US for prophylaxis of 
organ rejection in kidney transplantation. Its approval was initially based on data from 
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Figure 1. Molecule structures of mycophenolic acid and its drug derivatives.
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three, randomized, double-blind, controlled, multicenter phase III trials performed in 
de novo kidney transplant recipients.17-19 The enteric-coated, slow release MPA variant 
EC-MPS was approved in 2004. MPA has proven to be effective in the prevention of acute 
rejection in combination therapy consisting of MPA, a calcineurin inhibitor (CNI) such as 
ciclosporin or tacrolimus and corticosteroids. MPA has gained widespread acceptance 
as the antimetabolite immunosuppressant of choice in solid organ transplant regimens 
and has largely replaced azathioprine. An estimated 79% of kidney, 48% of liver and 
75% of heart transplant recipients use MPA at hospital discharge.20 The success of MPA in 
solid organ transplantation has also led to its application for prevention of graft-versus-
host disease after haematopoietic stem cell transplantation,21 as well as for treatment 
of autoimmune diseases such as systemic lupus erythematosus and psoriasis.22 MMF is 
considered to be used with a fixed dose recommendation of 1000mg twice a day after 
kidney transplantation23 and 1500mg twice a day after liver or heart transplantation.24 An 
equimolar dose of EC-MPS can be obtained by multiplying the MMF dose with 0.720.25 
Distinctly adverse effects of MPA are gastrointestinal effects (diarrhea, vomiting, nausea, 
abdominal cramps), hematological effects (leukopenia, thrombocytopenia, anemia) and 
infections (viral: cytomegalovirus, herpes zoster, polyomavirus; bacterial: urinary tract, 
pneumonia).24,25
PHArMAcokINetIcS oF MMF
After oral administration, MMF is extensively hydrolyzed presystemic to MPA by ester-
ases in the stomach, small intestine, blood, and liver.26,27 The absorption of MPA is fast 
and almost complete, with maximum plasma concentrations generally occurring within 
1 hour after MMF administration.27 It is possible that poor postoperative absorption or 
gastrointestinal tract metabolism may play a role in the initial disposition of MPA in some 
transplant recipients.28 In whole blood, 99.99% of MPA is found in the plasma fraction 
with only 0.01% in cellular compartments.29,30 MPA binds extensively to serum albumin 
in the order of 97-99% in patients with normal renal and liver function.30-32 The unbound 
fraction of MPA is thought to be responsible for immunosuppressive activity.30
Uridine diphosphate glucuronosyltransferases (UGTs) metabolize MPA to the phar-
macologically inactive metabolite 7-O-MPA-glucuronide (MPAG) in the liver, kidney, and 
intestinal mucosa.33-35 MPAG is usually present in plasma at approximately 20- to 100-
fold higher concentrations than MPA. The minor but active metabolite acyl-glucuronide 
(AcMPAG) is also formed and has a 10-fold lower affinity for inosine 5’-monophosphate 
dehydrogenase (IMPDH).33,36-38 AcMPAG may contribute to hypersensitivity, drug toxicity 
and immune response in patients receiving MPA therapy.39 High AcMPAG concentra-
tions may also be associated with MPA-related gastrointestinal adverse effects that are 
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frequently observed, and which are an important reason for MMF dose reductions or for 
discontinuation of the drug.40,41 MPA is excreted in the urine for 93%, of which approxi-
mately 87% as MPAG, and for 6% in the faeces.27 Excretion of MPAG formed in the liver 
into the bile appears to involve by the enzyme multidrug resistant protein-2 (MRP-2).42,43 
In the intestine MPAG is deconjugated back to MPA and reabsorbed in the colon. This 
enterohepatic recirculation contributes 10% to 60% to the total MPA exposure.27,31 The 
often-used immunosuppressant cyclosporine A inhibits the biliary excretion of MPAG 
by the MRP-2 transporter, which results in a reduction of the enterohepatic recirculation 
and a decreased MPA exposure.44
MPA is believed to undergo restrictive clearance, because only the unbound MPA 
fraction is presumed to be available for metabolism into MPAG.38,45 Especially during 
renal insufficiency the unbound MPA fraction would increase, due to the uremic state 
and to displacement of MPA from its albumin binding sites by high concentrations of 
the MPAG that is cleared by the kidneys.46 In patients with poor renal function, total MPA 
concentrations are low due to increased clearance, but at the same time the non-protein 
bound fraction is high (fractions up to 18.3% are reported47) and free MPA concentra-
tions may be unaltered or even elevated.48,49
clINIcAl PHArMAcokINetIc StuDIeS
The pharmacokinetics of MMF have been extensively investigated in renal transplant 
recipients. Several studies have investigated the MPA concentration-effect relation-
ship in renal transplant recipients for the risk of acute rejection. Studies with patients 
receiving ciclosporin as CNI showed a higher risk for acute rejections with a low MPA 
exposure (AUC0-12),
50-56 while in patients treated with tacrolimus as CNI a significant MPA 
concentration-effect relationship was not found.57-60 The clinical studies also found a 
large between- and within-patient variability in the pharmacokinetics of MPA, up to 
50-fold range in trough levels and up to 10-fold range in AUC.51,56,58,60-63 The pharmaco-
kinetics of MPA are further characterized by a gradual rise in MPA exposure of at least 
30 to 50% from the first weeks relative to the stable period at 1 to 6 months after renal 
transplantation despite the use of fixed32,58,62,64-66 or even reduced doses of MMF51.
Even though the “one-size-fits-all” dose regimen may have contributed to the 
widespread use of MMF, a growing amount of data suggests that this may not be the 
optimal therapeutic option for MMF. It is suggested that individualization of MMF 
dose can further improve clinical outcome.51,65,67 Based on the large between-patient 
variability in pharmacokinetics and on the repeatedly shown relationship between MPA 
exposure early after transplantation and acute rejection, therapeutic drug monitoring 
(TDM) strategies have been developed.68,69 The added value of TDM has been tested in 
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two prospective randomized trials. The Apomygre-study showed that using a limited 
sampling strategy, adjusting the dose of MMF based on MPA exposure, the risk of treat-
ment failure could be significantly reduced, without an increase in adverse events. The 
study showed the supremacy of a concentration controlled therapy above a fixed dose 
regimen in kidney transplant recipients.70 The FDCC-trial was not able to show the same 
result. In the FDCC-trail the applied protocol of MMF dose adjustments based on target 
MPA exposure was not successful, partly because physicians seemed reluctant to imple-
ment substantial dose changes.71
PHArMAcoloGy oF MycoPHeNolIc AcID
Inosine 5’-monophosphate dehydrogenase (IMPDH) is an enzyme that catalyzes the oxi-
dation of inosine monophosphate (IMP) to the intermediate xanthine monophosphate 
(XMP), which is a metabolite for the synthesis of the purine nucleotide guanosine tri-
phosphate (GTP). IMPDH is the key enzyme in the de novo synthesis of these nucleotides 
and induces the rate-limiting step in this synthesis (Figure 2).14,65,72 The proliferation of 
lymphocytes depends on this pathway of synthesis of nucleotides, while other types of 
cells have a salvage pathway for the synthesis of nucleotides. MPA is a non-competitive 
inhibitor of IMPDH and it will react on the MPA/NAD binding pocket. This makes MPA a 
drug that specifically inhibits the proliferation of the lymphocytes.73
5-phosphoribosyl-
1-pyrophosphate
IMP XMP GMP
GDP
GTP
dGTP
dGDP
Guanosine
Guanine
De novo pathway
Salvage pathway
DNA synthesis RNA synthesis
Glucoprotein synthesis
IMPDH GMP synthase HGPRT
Figure 2. Schematic representation of the de novo and salvage pathways of guanine nucleotide biosynthesis. The enzymes involved in the 
biosynthesis are IMPDH, GMP synthase (both in the de novo pathway), hypoxanthine guanine phosphoribosyltransferase (HGPRT) and purine 
nucleoside phosphorylase (PNP, both in the salvage pathway).
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In humans there are two isoforms of IMPDH, type I and II, which are encoded by 
two different genes, located on two different chromosomes, respectively chromosome 
seven and three. IMPDH type I is constitutively present in different cells, e.g. leukocytes, 
lymphocytes and erythrocytes. On the other hand, IMPDH type II is expressed in cells 
stimulated to proliferation, mainly in cells in the growth or differentiation phase.74,75 The 
active site of IMPDH type II is Cys331.73 In mature resting lymphocytes IMDPH type I is 
the dominant species. In activated lymphocytes IMPDH type II predominates over type I. 
This difference in expression suggests different regulatory mechanisms for IMPDH type 
I and type II.72,76,77 Human IMPDH type I and type II cDNAs encode the same size proteins 
of 514 amino acids with 84% sequence identity.78 Both isoforms show similar affinities 
for the substrates, with similar Km values for nicotinamide adenine dinucleotide (NAD) 
and IMP and similar Ki values for the reduced form of NAD and XMP.
74,79 MPA was found 
to inhibit both IMPDH isoforms by the same mechanism.77 However, IMPDH type II (Ki = 
9.5nM) is 3.9 to 5.0-fold more sensitive to MPA than the type I isoform (Ki = 37nM).
72,74,76,77,80 
The selective inhibition of IMPDH type II is thought to explain the relatively mild side 
effects of MMF in clinical trials.74,75
The overall activity of IMPDH increases in erythrocytes after exposure to MPA, but the 
IMPDH activity decreases in lymphocytes.75,77 The regulation of IMPDH type I and type II 
mRNA and the levels of protein will not alter after MPA exposure in these cells. Hence, to 
measure the IMPDH activity in patients treated with MMF, measuring the IMPDH activity 
in peripheral blood mononuclear cells (PBMCs) is abided.77,80,81 Lymphocytes are primar-
ily responsible for the induction or rejection of the transplanted organ, so measuring the 
activity of IMPDH in these cells may best reflect the relevant biologic activity.
PHArMAcoGeNetIcS oF IMPDH
IMPDH type I
Several studies have demonstrated pathogenicity correlated with polymorphisms of the 
IMPDH type I gene in patients with retinitis pigmentosa.82-84 A group of seven single 
nucleotide polymorphisms (SNPs) was investigated on a pathogenic relationship at 
autosomal dominant retinitis pigmentosa (313C>T, 349C>T, 594T>G, 671C>G, 676G>A, 
971G>A, 1115A>C). Though there was a correlation between some of the polymor-
phisms and clinical outcome, none of them affected enzyme activity.84 An altering in 
folding and aggregation of the enzyme was noticeable,82 but obviously there was not an 
alteration in activity. Other investigated SNPs had no effect on enzyme activity, protein 
stability, or protein aggregation.83
In a group of inflammatory bowel disease (IBD) patients resistant to azathioprine 
twelve IMPDH type I SNPs were characterized (-91-83ins9bp, 76T>C, 69A>G, 66A>G, 
16
11401G>C, 14805C>T, 15328G>A, 15489G>A, 17493G>A, 17509T>C, 17529C>T, 
17535A>C).85 There was no measurement of IMPDH activity, only alteration in promoter 
activity was measured using luciferase reporter vector for only mutations in the pro-
moter P3 sequence. Because mutations in P3 were not found in non-IBD patients, the 
authors concluded that the promoter activity decreasing mutations in P3 only occur in 
IBD patients. Although, this mutations collectively produced a relatively small decrease 
in IMPDH type I P3 promoter activity in vitro, it suggests the variant promoter has altered 
function which may be important in vivo.85
One study performed in renal transplant patients showed an association between 
two IMPDH type I SNPs (IVS7+125G>A, IVS8-106G>A) and biopsy proven acute rejection 
in the first year post-transplantation. One possible explanation is their linkage to other 
SNPs that may control IMPDH type I mRNA expression, enzyme activity, and ultimately 
lymphocyte proliferation.86
IMPDH type II
Different SNPs for IMPDH type II were investigated. The IMPDH type II 4999C>T SNP was 
also described in the group IBD patients resistant to azathioprine, but no effect on IMPDH 
activity was reported.85 Digits et al have constructed and characterized three mutants in 
the human IMPDH type II gene with the goal of identifying structural features that de-
termine species selectivity of MPA (322Arg>Lys, 441Gln>Glu, 322Arg>Lys/441Gln>Glu). 
The activity of these mutants was too low (less then 0.045% of wild type IMPDH type II 
activity) to thoroughly characterize them. The mutant 441Gln>Ala increased the MPA 
sensitivity with 20-fold, and also the activity decreased with 20-fold.87 An MPA-resistant 
neuroblastoma cell line showed two mutant enzymes (333Thr>Ile and 351Ser>Tyr). This 
mutation is less sensitive to MPA, and also much less active than wild type.75 The CEASAR 
study presented the IMPDH type II 3757T>C mutation, located in an intron of the mRNA. 
This mutation showed a significant (P = 0.012) correlation with biopsy proven acute 
rejection in kidney transplant recipients.88 The results of the FDCC trial did not prove this 
correlation, although a trend was noticeable. The FDCC-trial investigated also five other 
mutations (192A>G, 915C>G, 1253A>G, 720C>T and 460T>C). None of these SNPs were 
presented in the included patients.89 Another polymorphism, which was investigated 
by kidney transplant recipients was 787C>T. This SNP reduced the IMPDH activity in the 
variant carrier group to 10% of the wild type, but had an allele frequency of only 1.0%. 
In the same study eight other SNPs were investigated, but none of them showed any 
significance with clinical outcomes.90 So far, only two IMPDH type II polymorphisms are 
correlated to decreased IMPDH activity and increased risk of biopsy proven acute rejec-
tion (BPAR) in kidney transplant recipients.
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IMPDH ActIvIty ASSAyS
History of the IMPDH activity assay 
Already in 1957 Magasanik et al published the first IMPDH activity assay. Their method 
was based on the oxidation of IMP or the formation of reduced diphosphophyridine 
nucleotide (DPN), followed by observing the increase in optical density of XMP or DPNH 
by a spectophotometric ultraviolet (UV)-assay.91 The major aim of the paper was not 
to describe an IMPDH activity method; the first aim was to isolate and to identify the 
enzyme in Aerobacter aerogenes which was responsible for the irreversible enzymatic 
conversion of IMP into XMP. A reaction mix that contained IMP, DPN serving as hydrogen 
acceptor, K+ or NH4
+ and glutathione or cysteine in Tris buffer was used. The enzyme 
reaction occurred at room temperature and was unattached to pH.91 Nevertheless, the 
main disadvantage was that this method was only usable in bacterial extracts. Although 
the main goal was to converse IMP into XMP, nowadays this method has inspired many 
people to develop IMPDH activity assays.
Radiochemical assays
Saccoccia et al discussed the spectrophotometric IMPDH activity technique in 1969 
and concluded that the assay based on the change in optical density was incapable 
of detecting the rapid degradation of IMP by IMP phosphatase activity, an enzyme 
frequently present in mammalian tissues.92 Therefore, a new method based on a radio-
chemical assay to measure IMPDH activity was developed. The used reaction mixture 
contained Tris buffer (pH 7.5), magnesium chloride, potassium chloride (KCl), NAD as 
hydrogen acceptor and the radioactive agent [14C]IMP. After adding the IMPDH enzymes 
the reaction was inhibited at room temperature. After thin layer chromatography (TLC) 
the radioactivity of the separated XMP and IMP spots were measured.92 Although this 
radiochemical method greatly increased the sensitivity of detecting IMPDH activity, it 
was still limited to tissues such as liver, kidney and heart.
In 1983 Proffitt et al modified the method of Saccoccia et al. Their assay incorporated 
inhibitors of several interfering enzyme activities and allowed the accurate measurement 
of IMPDH activity in crude tissue supernatants. The used reaction mixture contained Tris 
buffer (pH 8.0), KCl, EDTA, α-β-methylene adenosne 5’-diphosphate, allopurinol, NAD 
and [14C]IMP. The enzyme suspension was incubated with the mixture at 37°C . After TLC 
the radioactivity of the separated XMP and IMP spots were measured.93 This was the first 
assay showing a linear increased XMP formation over time and extreme purification of 
the enzyme suspension was no longer needed. 
The last interesting modification to this [14C]-assay for determination of IMPDH activ-
ity was made by Ikegami et al in 1985. Due to using a high-voltage electrophoresis, the 
separation of IMP and XMP has improved and the assay has become faster (45 minutes), 
18
more sensitive, and required less tissue sample.94 Nowadays, this [14C]-IMPDH activity 
assay is used incidentally in published papers.
In 1983 Cooney et al published the radioactive method to measure IMPDH activity 
using the isotope [3H]IMP. Approximately 95% of the formed [3H]XMP was countable, 
versus 30% to 80% of the [14C]XMP when crude extracts were used. For this reason, this 
new method was exceptionally uncomplicated and well-suited for pharmacodynamic 
– pharmacokinetic studies. The major disadvantage of this technique was the commer-
cial unavailability of the required isotope.95 A few years later, [3H]IMP became commer-
cially available and in 1992 Balzarini et al developed a useful, convenient and sensitive 
method for measuring IMPDH activity in intact human lymphocytes.96 Langman et al 
measured the IMPDH activity using a modification of this assay in the first pharmaco-
dynamic studies of MPA induced immunosuppression.72,97,98 After these studies, this 
radioactive [3H]-assay became the first choice in radioactive IMPDH activity assays.
Spectrophotometric assays
While the accuracy of the radioactive assays is high, these techniques tend to be cum-
bersome. Therefore, Anderson et al used the IMPDH activity method of Magasanik et al 
to improve the spectrophotometric-assay in 1968. The reaction mixture was optimized 
for mammalian cells and the incubation temperature was increased to the physiologi-
cally temperature of 37°C. The main finding of this study was that K+ stimulates IMPDH 
activity by a direct interaction with the enzyme, so a potassium salt should be part of the 
reaction mixture.99 Nevertheless, the non-radioactive assay for measuring IMPDH activity 
was developed slowly, because of the disadvantages of the spectrophotometric assay 
compared to the established [3H]-assay. Also the publications of methods by Gilbert et al 
in 1979100 and Proffitt et al in 198393 did not give a new impulse for development, despite 
the fact that Proffitt used a mixture of enzyme inhibitors, so the required purification of 
the enzymes was no longer needed.
The real break-through of the spectrophotometric assay was started by Montero et al 
in 1995. At that time, current methods were less sensitive and required a large volume of 
blood. 93,94,100,101 Montero et al isolated IMPDH enzymes from erythrocytes obtained from 
whole blood. Erythrocyte lysate was added to the reaction mixture and was incubated 
for 2 hours at 37°C. After the incubation was terminated and the protein precipitate had 
been removed, the supernatant was extracted five times and analyzed using an ion-pair 
reversed-phase high-performance liquid chromatography (HPLC) method. The formed 
XMP was monitored using UV absorption at 254 nm and normalized to the protein con-
centration of the sample.102 Montero et al described for the first time a non-radioactive 
IMPDH activity assay for enzymes easily isolated from bacterial as mammalian blood 
cells. The assay provided a sensitive and accurate method of measuring even low IMPDH 
activity in normal human erythrocytes. The assay was dealing with the degradation of 
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IMP by IMP phosphatase activity and other enzyme activities. The spectrophotometric 
assay by Montero et al had shown its superiority compared to the assay of Magasanik 
et al. 
Whole blood or isolated blood cells
As soon as this reproducible and sensitive non-radioactive method of determining 
IMPDH activity was described, other blood compartments containing IMPDH were 
measured for IMPDH activity based on the method Montero et al had described for 
erythrocytes.102 In 1997 Griesmacher et al published a modification of the method 
described by Montero for measuring IMPDH activity in isolated human lymphocytes 
(exhibiting mainly type I activity) and lymphoblasts (exhibiting mainly type II activity). 
After isolating the different cell types, the cell suspension was incubated 2.5 hours for 
lymphocytes and 1.5 hours for lymphoblasts, in a phosphate buffered reaction mixture 
(pH 7.5) containing IMP, NAD and KCl.103 Albrecht et al described a modified method 
for measuring IMPDH activity of whole blood cells (WBC) lysate and PBMC lysate. WBCs 
and PBMCs were pre-treated with a mixture of Tris buffer (pH 8.0), EDTA and allopurinol, 
just like Proffitt et al did in 198393 and were ultrasonically treated. The reaction mixture 
contained no potassium salts; only NAD and IMP were added to the pre-treated lysates. 
The incubation time was 0.5 or 1 hour at 37°C. The formed XMP was measured using a 
reversed phase HPLC method and was normalized to the used volume of whole blood.104 
The authors discussed the importance of whole blood inhibition profiles. IMPDH activity 
is predominantly located in erythrocytes while the contribution of IMPDH activity from 
PBMC remained less than 10% of the total IMPDH activity in patients who received MMF. 
The authors validated therefore the assay only for pharmacodynamic monitoring of MPA 
in WBC.104
In 2006 Vethe et al described a modified IMPDH assay to measure the activity in 
CD4+ cells. The major fraction of the circulating CD4+ cells is constituted of T-helper cells, 
which play important roles in graft rejection and inflammation. These cells were directly 
isolated from whole blood using paramagnetic beads coated with antibodies. The great 
advantage of this method is the minimal manipulation of cells during isolation. After 
the intracellular MPA concentration was restored by incubation in ultrafiltrated plasma 
obtained from the original whole blood sample, cells were resuspended in phosphate 
buffered saline. The cell suspension was incubated for 2 hours at 37°C in the same reac-
tion mixture used by Albrecht. XMP was measured using a reversed phase HPLC method 
and was normalized to the number of CD4+ cells.105
In 2001 Glander et al published a modified method for PBMCs based on the method 
of Montero et al. PBMCs were isolated using Ficoll-Paque and the cells were lysated. The 
obtained lysate was incubated for 2.5 hours and the produced XMP was measured by 
a validated ion-pair reversed-phase HPLC method. XMP was normalized to the protein 
20
concentration in the used lysate sample. The authors showed that the isolation of the 
PBMCs was a critical step in the assay. Reducing the washing procedure resulted in a 
decrease of IMPDH activity, because less MPA was washed out the cells. The measured 
IMPDH activity comes closer to the in vivo IMPDH activity, using a less intensive washing 
procedure. Unavoidable dilution of the samples may lead to an underestimation of the 
inhibition of IMPDH activity in MMF treated patients.106 In 2002 Daxecker et al published 
a slightly different method. Despite the proven critical isolation step, this method had 
an extensively washing procedure. The concentrations of the compounds in the reaction 
mixture was different and the produced XMP was normalized to the amount of cells in 
the used samples.107 
Comparison of the methods
Since the first description of a method to measure IMPDH activity by Magasanik et al in 
1957, many methods and modifications to measure IMPDH activity have been published. 
Three main methods can be distinguished, namely the radioactive [3H]IMP and [14C]IMP 
methods and the non-radioactive spectrophotometric method. The development of 
these assays has led to precise and accurate methods. The laboratory equipment and 
facilities used for non-radioactive spectrophotometric methods are more standard and 
less complicated than for the radioactive methods. For that reason, the non-radioactive 
spectrophotometric methods are preferred for measuring IMPDH activity above radio-
active methods. Table 1 shows the specifications of the different currently used non-
radioactive methods.
For a good reflection of the in vivo activity measured in vitro, it is necessary to make 
the right choice in the compartment where IMPDH activity will be measured. The easiest 
way is to measure in whole blood (Albrecht et al104) or erythrocytes (Montero et al102), 
because no additional isolation of particular cells is necessary. The great disadvantage 
of whole blood is the increased IMPDH activity and GTP levels under prolonged MMF 
therapy in erythrocytes.108,109 Even during a one dose interval the IMPDH activity in-
creased after inhibition by MPA to a level above pre-dose IMPDH activity.81 The effects 
of increased IMPDH activity under prolonged MMF therapy are characteristic for IMPDH 
activity measurements in whole blood and erythrocytes.
Because the target for MPA therapy is the lymphocyte compartment, measuring 
IMPDH activity in this compartment seems more appropriate.77,80,81 This is enforced by 
data showing that MPA causes a significantly reduction in GTP in PBMC, with a paradoxi-
cal simultaneous elevation of GTP in erythrocytes.108,110 A few authors discussed the rel-
evance of measuring IMPDH activity in PBMCs or circulating lymphocytes compared with 
erythrocytes.77,111 Nevertheless, it is widely accepted that PBMCs or subpopulations of 
circulating lymphocytes are the most relevant cell population for measuring IMPDH ac-
tivity. Glander et al and Daecker et al have published IMPDH activity assays in PBMCs.106,107 
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Cells were isolated using the relative simple technique of Ficoll-Paque gradient. The mea-
sured activity corresponds better with the immunosuppressive effect of MMF. However, 
due to the isolation of PBMCs using a Ficoll-Plaque gradient and the necessary wash steps 
afterwards, the MPA concentration in the PBMCs was altered and thereby the IMPDH 
activity.106 Griesmacher et al isolated lymphocytes and lymphoblasts from PBMCs, which 
resulted in even more washing steps.103 Accurate and appropriate isolation of PBMCs ap-
pears to be a limiting feature of any of the IMPDH activity isolation methods presented.112
Another potentially useful approach would be to measure IMPDH activity in the CD4+ 
cell population – which is mainly T-helper cells – described by Vethe.105 Monitoring IMPDH 
activity in this compartment is supposed to be approaching in vivo. Nevertheless, the used 
method is a time-consuming process.112 However, T- and B-lymphocytes are the targets of 
inhibition and therefore it would be the most appropriate compartment to evaluate.
The perfect IMPDH activity assay
Several IMPDH activity assays are being used for preclinical and clinical studies, but 
a golden standard to measure IMPDH activity is still not pointing out.112 Three major 
steps are noticed in all assays. The first step is the isolation of the cells and the IMPDH 
enzymes. The fragile balance has to be found in isolating the most proper cells in a less 
manipulating way. Furthermore, small sampling volume is preferred to use the assay 
in clinical practice. Because lymphocytes play important roles in the acute rejection 
episodes isolating lymphocytes seems to be the best choice. However, for high-quality 
isolation, the cells must be isolated without manipulation of the cells and without wash-
ing out the intercellular MPA concentration.
The second step in the IMPDH activity assay is the ex vivo incubation of the IMPDH 
enzymes and the measurement of the enzyme product XMP. A reaction mixture close 
to the in vivo environment would be the most natural environment for the enzymes. 
IMPDH enzymes are dependent on potassium,72,99 so the incubation mixture should 
be a physiologically buffered mixture containing at least potassium, IMP as substrate 
and NAD as hydrogen acceptor. The incubation temperature should be 37°C. After the 
incubation, the enzymatic reaction has to be terminated without harming XMP. The 
enzymatic product XMP has to be determined with a validated HPLC method. An IMPDH 
activity assay will be more useable in clinical and research practice when the time of 
incubation and the time of determination of XMP are short.
The third step of the IMPDH activity assays is the way to express the activity. The 
measured product XMP has to be normalized to the number of enzymes that par-
ticipated in the conversion of IMP into XMP. The used volume of whole blood, protein 
concentration or cell count of the measured sample can be used, provided that there is 
a correlation with the involved IMPDH enzymes in the incubation.
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An ideal IMPDH activity assay should have optimized all these three steps. So far, 
the known assays are not optimized for all three steps. A more robust and reproduc-
ible IMPDH activity assay has to be found for multicenter and longitudinal studies to 
evaluate the additional value of any pharmacodynamic monitoring among a diversity of 
patients treated with MPA.
Table 1. Comparison of the different currently used non-radioactive IMPDH activity assays
Author Montero, 1995102 Griesmacher, 1997103 Albrecht, 2000104 Glander, 2001106 Daxecker, 2002107 vethe, 2006105
Compartment erythrocytes
Lymphocytes, 
lymphoblasts
whole blood PBMC PBMC CD4+ cells
Sample blood volume (mL) 10 N.A. 7.5 5 30 4
Reaction mixture
IMP (mmol/L) 1 1 0.25 1 0.273 1.79
NAD (mmol/L) 0.5 0.5 0.25 0.5 0.273 0.38
KCl (mmol/L) 100 200 - 100 200 -
EDTA (mmol) - - 3.0 - - 3.0
Allopurinol (mmol/L) - - 0.058 - - 0.058
Buffer; concentration (mmol/L) Phosphate; 40 Phosphate; 80 Tris; 0.1 Phosphate; 40 Phosphate; 80 Tris; 0.1
pH 7.4 7.5 8.0 7.4 7.4 8.0
IMPDH assay
Incubation time (h) 2 2.5 or 1.5 0.5 and 1 2.5 2 2
Incubation temperature (°C) 37 37 37 37 37 37
Incubation termination 40% trichloroacetic acid perchloric acid 4 mol/L perchloric acid 4 mol/L perchloric acid 2.5 mol/L perchloric acid 4 mol/L perchloric acid
Neutralization of sample
Extracted, water-saturated 
diethyl ether pH > 5.0
potassium carbonate
1h heated 100°C, 4M 
KOH pH 2-3
5M potassium carbonate 3M K2HPO4 pH > 7.2 1h heated 100°C, 4M KOH pH 2-3
HPLC specifications
Injection volume (μL) 50 100 200 15 20 100
Column
125x4.6mm 3μm ODS2 
Hypersil
CNU-010
2x 150x4.6mm 5μm ID 
C18 Nucleosil
250x3.1mm 5μm ODS AQ Prontosil 
120
250x4.0mm ID RP-18 LiChroCART 
Superspher 100
100x4.6mm Chromolith + 
150x4.6mm 5 μm C18 Nucleosil
Type of HPLC Ion exchange Reversed phase Reversed phase Ion exchange Ion exchange Reversed phase
Flow rate (mL/min) 1.0 1.2 1.0 0.7 1.0 1.0
Oven temperature (°C) RT RT RT 45 22 RT
UV-detection wavelength (nm) 254 and 280 N.A. 260 254 254 260
Eluens
70% 0.1 mol/L KH2PO4 (pH 5.5) 
/ 8 mmol/L TBAS; 30% MeOH
0.015 mol/L KH2PO4; 0.5 
mol/L KH2PO4 (pH 3.45)
4% MeOH in water 
H3PO4 pH 1.8
4% MeOH in 96% 50 mmol/L KH2PO4 
+ 7 mmol/L TBAS (pH 5.50)
5.5 mmol/L MgSO4 + 100 mmol/L 
H3PO4 + TEA (pH 6.40)
4% MeOH in water H3PO4 pH 1.8
Runtime (min) 21 33 > 25 35 54 20
Activity unit pmol / h / mg protein pmol / min / 106 cells nmol / min / ml WB(C) nmol / h / mg protein pmol / min / 106 cells pmol / min / 106 cells
N.A., not available; TBAS, tetrabutylammonium hydrogen sulphate; TEA, triethylamine; RT, room temperature; WB(C), whole blood (cells).
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IMPDH mrNA GeNe exPreSSIoN
An alternative method to monitor the IMPDH activity could be measuring IMPDH mRNA, 
using the relative easier to use quantitative real-time polymerase chain reaction (RT-
PCR) method. The regulation of expression of the two IMPDH genes differs between 
the two isoforms. IMPDH type I mRNA is expressed in a complex manner with three 
transcripts arising from three alternate promoters.113,114 IMPDH type II is strongly up-
regulated at the transcriptional level by a promoter region that responds directly to 
growth stimuli.115-117 The gene expression of these two IMPDH isoforms has a negative 
Table 1. Comparison of the different currently used non-radioactive IMPDH activity assays
Author Montero, 1995102 Griesmacher, 1997103 Albrecht, 2000104 Glander, 2001106 Daxecker, 2002107 vethe, 2006105
Compartment erythrocytes
Lymphocytes, 
lymphoblasts
whole blood PBMC PBMC CD4+ cells
Sample blood volume (mL) 10 N.A. 7.5 5 30 4
Reaction mixture
IMP (mmol/L) 1 1 0.25 1 0.273 1.79
NAD (mmol/L) 0.5 0.5 0.25 0.5 0.273 0.38
KCl (mmol/L) 100 200 - 100 200 -
EDTA (mmol) - - 3.0 - - 3.0
Allopurinol (mmol/L) - - 0.058 - - 0.058
Buffer; concentration (mmol/L) Phosphate; 40 Phosphate; 80 Tris; 0.1 Phosphate; 40 Phosphate; 80 Tris; 0.1
pH 7.4 7.5 8.0 7.4 7.4 8.0
IMPDH assay
Incubation time (h) 2 2.5 or 1.5 0.5 and 1 2.5 2 2
Incubation temperature (°C) 37 37 37 37 37 37
Incubation termination 40% trichloroacetic acid perchloric acid 4 mol/L perchloric acid 4 mol/L perchloric acid 2.5 mol/L perchloric acid 4 mol/L perchloric acid
Neutralization of sample
Extracted, water-saturated 
diethyl ether pH > 5.0
potassium carbonate
1h heated 100°C, 4M 
KOH pH 2-3
5M potassium carbonate 3M K2HPO4 pH > 7.2 1h heated 100°C, 4M KOH pH 2-3
HPLC specifications
Injection volume (μL) 50 100 200 15 20 100
Column
125x4.6mm 3μm ODS2 
Hypersil
CNU-010
2x 150x4.6mm 5μm ID 
C18 Nucleosil
250x3.1mm 5μm ODS AQ Prontosil 
120
250x4.0mm ID RP-18 LiChroCART 
Superspher 100
100x4.6mm Chromolith + 
150x4.6mm 5 μm C18 Nucleosil
Type of HPLC Ion exchange Reversed phase Reversed phase Ion exchange Ion exchange Reversed phase
Flow rate (mL/min) 1.0 1.2 1.0 0.7 1.0 1.0
Oven temperature (°C) RT RT RT 45 22 RT
UV-detection wavelength (nm) 254 and 280 N.A. 260 254 254 260
Eluens
70% 0.1 mol/L KH2PO4 (pH 5.5) 
/ 8 mmol/L TBAS; 30% MeOH
0.015 mol/L KH2PO4; 0.5 
mol/L KH2PO4 (pH 3.45)
4% MeOH in water 
H3PO4 pH 1.8
4% MeOH in 96% 50 mmol/L KH2PO4 
+ 7 mmol/L TBAS (pH 5.50)
5.5 mmol/L MgSO4 + 100 mmol/L 
H3PO4 + TEA (pH 6.40)
4% MeOH in water H3PO4 pH 1.8
Runtime (min) 21 33 > 25 35 54 20
Activity unit pmol / h / mg protein pmol / min / 106 cells nmol / min / ml WB(C) nmol / h / mg protein pmol / min / 106 cells pmol / min / 106 cells
N.A., not available; TBAS, tetrabutylammonium hydrogen sulphate; TEA, triethylamine; RT, room temperature; WB(C), whole blood (cells).
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feedback regulation by intra- and extracellular guanine nucleotides.118-120 An increased 
expression of IMPDH type I and II genes leads to an increased IMPDH activity.77,111 It is 
known that an increased IMPDH activity has been correlated with an increased cellular 
proliferation and transformation.121,122
Recent studies have evaluated the expression of the IMPDH type I and II gene after 
kidney transplantation. The expression of the IMPDH type I gene was up-regulated 0.5-
fold for CD4+ and 20-fold for PBMC under MMF therapy compared with values before 
transplantation without MMF therapy. IMPDH type II mRNA was increased after trans-
plantation 15% for CD4+ and 121% for PBMC.113,118,123,124 Induction of IMPDH activity after 
prolonged exposure to MPA may be partially explained by the up-regulation of IMPDH 
type I and II mRNA in PBMCs.124 Although, a significant difference was seen in IMPDH 
type II gene expression in CD4+ cells between patients with and without a BPAR, this dif-
ference was probably related to the high-dose glucocorticoids, according the authors.123
It is not yet comprehensible that measuring IMPDH mRNA is a useable alternative 
to monitoring IMPDH activity. A correlation between mRNA and IMPDH activity is 
necessary to adopt mRNA measurements an alternative approach for IMPDH activity 
measurement.
clINIcAl PHArMAcoDyNAMIc StuDIeS
Even though IMPDH activity assays are complex analyses, they are more and more used 
in research studies. Pharmacodynamic monitoring is a novel approach for individualiza-
tion of the MPA therapy. It may better reflect biological response to the drug.30,67
Early studies already showed an inverse correlation between MPA concentration and 
IMPDH activity. In general, the maximum inhibition of IMPDH was achieved 1 to 2 hours 
after dosing.97,125-127 The concentration-effect correlation was evaluated by Langman et 
al in 22 healthy persons and showed an IC50 (the concentration of MPA where 50% of 
the maximum IMPDH activity is measured) of 2.0 to 5.0mg/L. Complete inhibition of 
IMPDH was not observed but modeled at MPA concentrations of 20mg/L.128 Besides 
using whole blood, the correlation was evaluated when lymphocyte membranes were 
disrupted and an in vitro setting of unbound MPA was created. The unbound MPA IC50 
was 0.5 to 1.0mg/L.128 In a number of studies, large inter-patient variability was observed 
in IMPDH activity, with a relative small intra-patient variability in respectively healthy 
persons, patients on dialysis and kidney transplant recipients. The inter-patient variabil-
ity of more than 10-fold followed a Gaussian distribution, while the intra-patient vari-
ability measured over one month varied 14%.106,127-130 The large inter-patient variation 
in healthy volunteers could not be attributed to age or gender. Genetic differences may 
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account for some of this variablility.129 The causes of this large inter-patient variability in 
pre- and post-transplant IMPDH activity need to be investigated.28
A few studies have investigated the effect of time on the inhibition of IMPDH. In 
a population of five patients treated with MMF for more than two years, the inhibi-
tion of IMPDH activity was dramatically reduced when the length of the MPA therapy 
increased.81 In a cohort of 29 patients the IMPDH activity was 5-fold higher than at 
baseline and occurred at a median of 40 days post-transplantation.109 However, these 
studies were preformed in whole blood and therefore the results are difficult to inter-
pret. Pharmacodynamic studies of IMPDH activity performed in PBMCs are few. In a 
study of 8 long-term MMF treated patients the IMPDH activity measured in PBMCs did 
not cause induction, despite a 2-fold higher MPA exposure after two years.129 All these 
findings suggest IMPDH activity changes over time, which stresses that IMPDH activity 
measurement could help to optimize the individually MPA treatment.
One of the most interesting studies on the pharmacodymanics of MPA found a cor-
relation between pre-transplant IMPDH activity and post-transplant dose adjustments, 
MPA related side effects and episodes of acute rejections. A cohort of 48 kidney trans-
plant recipients treated with 1000 mg MMF twice a day was followed the first year after 
transplantation. Patients with high pre-transplant IMPDH activity had a 3.6-fold higher 
risk for acute rejection compared with patients with low pre-transplant IMPDH activity 
(P = 0.009). The risk for MMF dose reduction – due to MMF related clinical side-effects 
– was even 4.6-fold higher in patients with a high pre-transplant IMPDH activity (P = 
0.005).130 This study emphasizes that patient-specific measurements of IMPDH activity 
may optimize the MMF efficacy and toxicity.
It is not yet known whether IMPDH activity increases prior to rejection or if other 
promoters of lymphocyte activation, such as infection, also induce IMPDH activity. Only 
an increase in IMPDH activity appearing a few days before rejection has been described 
in a rabbit heart transplant model.98 More research is needed to investigate whether dif-
ferences in IMPDH activity can predict efficacy and dose requirements of MPA, and how 
differences in unbound MPA concentration may affect IMPDH activity. The observed 
high inter-patient variability in MPA exposure and pre- and post-transplant IMPDH 
activity strengthen the idea that therapeutic drug monitoring could optimize the use of 
MMF and improve the rejection outcome. Post-transplant IMPDH activity while on MPA 
therapy needs to be related to clinical outcome.28,129 Further investigations with a large 
number of patients are needed to fully explore the pharmacodynamic – pharmacokinetic 
relationship between MPA and IMPDH activity. The measurement of pharmacodynamic 
drug effects by determination of IMPDH activity may provide a more direct insight of 
the functional activity of MMF therapy in vivo and may help to increase the efficacy and 
safety of MMF therapy.131
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ScoPe AND AIMS oF tHIS tHeSIS
Since the introduction of MMF in clinical practice, research has taken place to optimize 
and individualize MMF therapy in transplanted patients to improve the clinical outcome. 
The high observed inter-patient variability in MPA exposure and the small therapeutic 
window of MPA plead for good therapeutic drug monitoring regimens. Many studies 
monitored the pharmacokinetics of MPA concentrations for this purpose, sometimes 
with different outcomes. Pharmacodynamic monitoring of the response to MPA could 
be an attractive approach to individualization, because it integrates pharmacokinetic 
and pharmacodynamic variability.
Therefore, the overall aim of this thesis was to explore the usefulness of pharma-
codynamic monitoring of IMPDH activity in MPA treated transplant recipients to opti-
mize and individualize the MPA therapy. The obtained findings are supposed to make 
a foundation for clinical research strategies aiming at individualized MPA therapy in 
transplant recipients. More specifically, separate objectives were also formulated and 
were as follows:
1. To improve the robustness and reproducibility of the method for the determina-
tion of IMPDH activity in order to allow for the method to be used in multicenter 
longitudinal studies and in different patient groups (chapter 2).
2. To investigate the pharmacodynamic correlation between IMPDH activity and 
unbound and total MPA concentration (chapter 3).
3. To investigate the inter- and intra-patient variability in IMPDH activity in correla-
tion to genetic polymorphisms, demographic characteristics and clinical laboratory 
parameters (chapters 3 and 4.1).
4. To determine the predictive performance of IMPDH activity for the incidence of 
acute rejection and adverse effects (chapters 3.1 and 4).
5. To study the correlation between IMPDH activity and IMPDH mRNA gene expression 
(chapter 4.2).
6. To explore IMPDH activity in haemotopoietic stem cell transplant recipients (chapter 
5.1).

Chapter 2
IMPDH activity method

Chapter 2.1
Improved assay for the non-radioactive 
determination of IMPDH activity in 
peripheral blood mononuclear cells
 
Ferdi Sombogaard1,*, Petra Glander2,*, Klemens Budde2, Teun van Gelder1, 
Pia Hambach2, Lutz Liefeldt2, Christine Lorkowski2, Marco Mai2, 
Hans H. Neumayer2, Arnold G. Vulto1, Ron A.A. Mathot1
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2 Department of Internal Medicine, Nephrology, Campus Mitte, Charité–Universitätsmedizin Berlin, 
Berlin, Germany
* The first two authors share first authorship; both authors have contributed equally to this paper
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AbStrAct
Mycophenolic acid (MPA) inhibits the enzyme inosine monophosphate dehydrogenase 
(IMPDH). Thus, the measurement of IMPDH activity could serve as a specific pharma-
codynamic (PD) tool for monitoring MPA therapy. At present, however, monitoring of 
pharmacokinetic (PK) parameters is preferred over that of PD parameters because in 
general, PD assays are labor-intensive and poorly reproducible. Currently, cell count or 
protein concentration is widely accepted as methods to normalize enzyme activity. In 
the present study we have attempted to further improve a method for the determination 
of IMPDH activity to increase the robustness and reproducibility of the IMPDH activity 
assay itself, without making the assay more labor-intensive. Therefore, several aspects of 
the IMPDH method were investigated regarding their influence on the reproducibility 
and also modified to increase the feasibility and consistency of the assay. The isolation 
of peripheral blood mononuclear cells (PBMC) of whole blood samples was found to be 
the most variable step. Normalization on cell count is labor-intensive and at the same 
time has a poor reproducibility. Determination of the protein content in cell extracts is 
impaired by contamination with extra-cellular proteins and non-PBMC. Alternatively, the 
intracellular substance adenosine monophosphate (AMP) was investigated to normal-
ize the newly generated xanthosine monophosphate. Among various subject groups, 
no significant differences in mean AMP concentration were found. To simplify the 
procedure, PBMCs were diluted to a fixed volume after isolation from sample of whole 
blood, and the IMPDH activity was normalized to the AMP concentration quantified in 
the same high-performance liquid chromatography run as xanthosine monophosphate 
was quantified. The within-run and total imprecision (coefficient of variation) ranged 
from 4.2 to 10.6% and from 6.6% to 11.9%, respectively. In conclusion, the modified 
method described here for the measurement of IMPDH activity can be used reliably in 
multicenter trials and in longitudinal studies to evaluate the additional value of any PD 
monitoring among a diversity of patients treated with MPA.
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INtroDuctIoN
The immunosuppressive drugs mycophenolate mofetil (MMF, CellCept) and enteric-
coated mycophenolic sodium (Myfortic) have been registered for the prevention of 
acute rejection after solid organ transplantation. The active compound mycophenolic 
acid (MPA) is responsible for the reversible inhibition of inosine 5’-monophosphate 
dehydrogenase (IMPDH, EC 1.1.1.205). IMPDH is an nicotinamide adenine dinucleotide 
(NAD+)-dependent dehydrogenase that converts inosine monophosphate (IMP) into 
xanthosine monophosphate (XMP).1 MMF and enteric-coated mycophenolic sodium 
were each developed originally as fixed-dose drugs.2 Reasons to consider individualiza-
tion of dosage rather than using fixed-dose therapy include the large inter-individual 
variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of this drug.3-5 A 
recently published randomized trial showed that dose adjustment based on therapeutic 
drug monitoring using MPA levels reduced acute rejections in comparison with that 
using fixed-dose MMF therapy. In this study, a Bayesian estimation based on 3-point 
sampling was used to calculate the MPA exposure.6
On pure mechanistic grounds, measurement of PD parameters might correlate more 
closely with clinical outcome than would the measurement of PK parameters.7 Recently 
we presented the first study showing a relationship between pretransplant IMPDH activ-
ity and posttransplant outcome.8 At present, however, monitoring of PK parameters is 
preferred over PD parameters because, in general, PD assays are deemed to be labor-
intensive and to have poor reproducibility. For measurement of the activity of IMPDH in 
tissue or blood samples, either the chromatographic or the radiometric quantification 
of enzyme-catalyzed product formation are used. Advantages and disadvantages of the 
different methods are summarized in a recently published review.9 Because the target 
for MPA therapy is the lymphocyte, measuring IMPDH activity in isolated peripheral 
blood mononuclear cells (PBMCs) seems to be more appropriate.10-12 A few years ago, 
Glander et al13 introduced a method for the determination of IMPDH activity in PBMC 
extracts obtained after an accelerated cell isolation technique and using a nonradioac-
tive procedure based on chromatographic determination of the XMP produced. This 
assay has been used in several clinical trials.8,14-18
To express an enzyme activity, the enzyme product measured has to be normalized. 
Currently, 2 potential methods are widely accepted, namely cell count and protein con-
centration. In the present study, the method of Glander et al13 was modified to increase 
the robustness and reproducibility of the IMPDH activity assay, without rendering the 
assay more labor-intensive. We investigated how the different steps of the assay influ-
ence the variability and to what extent any contamination of the extract may influence 
the IMPDH activity derived. Modifications of the isolation of PBMCs, the preparation of 
lysate, and the normalization of the XMP improved the consistency and reproducibility 
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of the IMPDH activity assay. Moreover, it was evaluated whether the adenosine mono-
phosphate (AMP) concentration in the PBMC extract could be used as normalization 
factor for IMPDH activity.
MAterIAlS AND MetHoDS
Experiments were performed at 2 research centers: the Department of Internal Medi-
cine, Nephrology of the University Medical Center Charité, Berlin, and the Department 
of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam. Where necessary, 
referral will be made here to research center B (Berlin, Germany) or center R (Rotterdam, 
The Netherlands). 
Patients and samples
Blood was obtained from healthy volunteers (n = 12), dialysis patients (n = 11), de novo 
renal transplant patients (n = 25) and stable renal transplant patients (n = 31) treated 
with calcineurin inhibitors and MMF with or without corticosteroids. The local ethics 
committees of Charité – Universitätsmedizin, Berlin, Germany and Erasmus University 
Medical Center, Rotterdam, The Netherlands have approved the blood sampling for 
this purpose. All subjects gave their informed consent. Before dosing, blood samples 
were collected in lithium heparin tubes stored at room temperature (15°C–25°C) and 
processed within 12 hours after collection.
Reagents and chemicals
IMP, XMP, AMP, NAD+ and bovine serum albumin were obtained from Sigma-Aldrich 
Chemicals (Deisenhofen, Germany; Zwijndrecht, The Netherlands). Phosphate-buffered 
saline (PBS, pH 7.4) was purchased from PAA Laboratories GmbH (Linz, Austria). All 
other chemicals were obtained from Merck (Darmstadt, Germany; Zwijndrecht, The 
Netherlands) and were of analytical grade; the ion-pair reagent tetra-n-butylammonium 
hydrogen sulfate (TBAS) and methanol were of high-performance liquid chromatogra-
phy (HPLC) quality (LiChropur, LiChrosolv). Leucosep tubes with Ficoll-Paque solution 
were obtained from Greiner Bio-One (Frickenhausen, Germany; Alphen a/d Rijn, The 
Netherlands).
Isolation of human PBMCs 
PBMCs were isolated from lithium heparin-anticoagulated whole blood using Leucosep 
tubes with Ficoll-Paque according to the manufacturer’s protocol with slight modifica-
tions. A biologically inert barrier on top of the separation medium Ficoll-Paque allowed 
a direct dilution of the 2.5 mL blood with an equal volume of PBS within the tube. Tubes 
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were centrifuged at 1200g at room temperature for 20 minutes. PBMCs were harvested 
and diluted with 5 ml of PBS. After centrifugation of the suspension for 10 minutes at 
1200g at 4°C, the cell pellet was resuspended in 250 µL of water (HPLC grade, 4°C) and 
frozen at -80°C. Insoluble fragments of disrupted cells were removed by centrifugation 
at 1000g for 2 minutes after thawing. This supernatant lysate was used for the enzyme 
assay and protein determination. Protein concentrations were determined with BCA 
(bicinchoninic acid) Protein Assay Reagent (Pierce Chemical Co., Rockford, IL) according 
to the instructions of the manufacturer. In some experiments, cells were counted in an 
aliquot using a Neubauer counting chamber or a CASY cell counter (Casy Technology, 
Reutlingen, Germany) and resuspended to yield a final cell concentration of 1 x 107 cell 
per milliliter with cold HPLC water.
IMPDH activity assay
The incubation buffer consisted of 1 mmol/L IMP, 0.5 mmol/L NAD+, 40 mmol/L sodium 
dihydrogen phosphate, and 100 mmol/L potassium chloride with a pH of 7.4, similar to 
that used in the previous method.13 The incubation was initiated by the addition of 50 
µL of lysate to 130 µL of incubation buffer in a 1.5-mL microtube maintained at 37°C and 
moderately shaken at 800 rpm (Thermomixer, Eppendorf, Hamburg, Germany). After 
150 min, the enzymatic reaction was terminated by adding 20 µL of 4 mol/L perchloric 
acid, mixing, and placing the samples on ice. Precipitated proteins were removed by 
centrifugation for 5 minutes. The supernatant (170 µL) was transferred to a second 1.5-
mL microtube containing 10 µL of 5 mol/L potassium carbonate and then mixed. Subse-
quently, samples were stored for at least 30 minutes at -80°C or for 2 hours at -20°C. After 
thawing and centrifugation, the supernatant was transferred into HPLC injection vials.
HPLC analysis 
At research center B, AMP and XMP were quantified using a Shimadzu LC-2010 system 
(Shimadzu, Kyoto, Japan) with a built-in UV-VIS detector set to a wavelength of 256 nm. 
For chromatographic separations, a ProntoSIL AQ C18 column (particle size 3 µm, 3 mm 
inner diameter x 150 mm (Bischoff chromatography, Leonberg, Germany) was employed, 
and for data acquisition and reprocessing, Class VP software (Shimadzu) was used. The 
isocratic eluent consisted of a 6:94 (v/v) mixture of methanol and buffer containing 50 
mmol/L KH2PO4 and 7 mmol/L TBAS (pH 5.50).
In center R, the HPLC system included a continuous mobile-phase degasser, an HPLC 
pump, an auto injector and an UV-VIS spectrophotometric detector with the wavelength 
set to 254 nm (Surveyer, Thermo Finnigan, Breda, The Netherlands). Data was captured 
and processed by ChromQuest software (Thermo Electron, Waltham, MA). Separation 
was achieved by using a ChromSpher C18, 5 μm particle size, 150 x 4.6 mm column (Var-
ian Inc, Lake Forest, CA). For elution, a 50 mmol/L potassium dihydrophosphate buffer 
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(pH 5.6) with 7 mmol/L TBAS in 100% methanol was employed as a gradient. Over 0–4 
minutes, the eluant consisted of 90% ion-pair buffer and 10% methanol, after 4 minutes 
methanol was increased linearly from 10% to 50% over 1 minutes, was then kept con-
stant at 50% for 6 minutes, returned to 10% over 1 minute and then finally equilibrated 
for 5 minutes prior to the next injection.
In both centers, a 5-µL sample was injected onto the column, which was maintained 
at 40°C. Using a flow rate of 1.0 mL/min the cycle time amounted to 25 minutes for the 
isocratic mode, and 17 minutes for the gradient mode.
Calibrators and quality control samples
Quantification was performed using external standard calibrators and XMP and AMP 
with four calibration levels of 1, 5, 10 and 25 µmol/L for both components. Two calibra-
tors (0.75 and 50 µmol/L) were added for the validation of the method. Because of the 
natural occurrence of AMP and XMP in PBMCs, no spiked blank samples could be used as 
calibrators. Therefore, calibrators were prepared by dissolving XMP and AMP in incuba-
tion buffer (without IMP and NAD+) which contained 1 mg/mL of bovine serum albumin. 
The calibrators were treated with perchloric acid, neutralized and analyzed in the same 
manner as the incubation samples were.
For the final HPLC method, calibration curves and linearity, imprecision according to 
the NCCLS EP5-T guidelines19, analytical specificity, recovery, and the lower limits of de-
tection and quantification were determined for AMP and XMP. Quality control samples 
(QCSs) for the IMPDH assay were prepared by pooling several cell extracts of healthy 
volunteers, dialysis patients, or patients under MMF treatment. Both centers made QCSs 
of their own pool of subjects. The average activity and its standard deviation of the QCSs 
were determined in duplicate on 5 different days. The coefficient of variation accepted 
had to be less than 10%. Aliquots of this pool were stored at -80°C until analysis.
Sample stability
Investigations with regard to the stability of IMPDH activity in stored samples were 
carried out with the following components: whole blood at room temperature over 24 
hours, lysate samples stored at -20°C and -80°C over 6 months, and samples that had 
been incubated to completion at room temperature and then stored at -20°C and -80°C 
over 6 months.
Data analysis
The results shown here are expressed as mean ± SD. Correlations between variables 
were assessed using univariate linear regression analysis for continuous data or Χ2 test 
for categorical data. Paired 2-tailed Student t tests or Mann-Whitney U tests were pre-
formed for the comparison of two means and 1-way analysis of variance when dealing 
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with more than 2 means. Statistics were processed by SPSS 12.0.1 for Windows (SPSS Inc, 
Chicago, IL). Results were considered significant if P < 0.05.
reSultS
PBMC isolation variability
Sample aliquots after different intermediate steps of PBMC isolation were used to assess 
the variability for the different steps of the assay. The coefficient of variation for XMP 
production in samples isolated from the same volumes of identical blood was 29% (n = 
6). The variation of XMP production in PBMC aliquots after harvesting from the interface 
was 19% (n = 6). Coefficients of variation for multiple cell counts (n = 6) of one and the 
same PBMC suspension ranged between 6%–28% (median 8%) for the CASY cell counter 
and 6%–19% (median 16%), and 8%–17% (median 11%) for 2 experienced researchers 
utilizing manual counting with the hemacytometer. Multiple incubations of the same 
lysate after removing undisrupted and insoluble cell fragments revealed a variation of 
4.8% (n = 8). XMP determination by HPLC in identically incubated samples showed a 
variation of 0.3% (n = 8).
MPA concentrations in lysates and the corresponding total MPA plasma levels were 
measured in 25 randomly chosen samples from renal transplant recipients. All patients 
had been receiving MMF treatment with 1000 mg twice a day. The MPA concentration in 
the lysates was correlated with the total MPA concentration in plasma (Fig. 1; r2 = 0 .94; P 
< 0.0001). It is thought that the unbound fraction is responsible for immunosuppressive 
activity.20 Accordingly, an unbound fraction of MPA in plasma of 1.38% ± 0.045% (the 
slope of curve) will represent the total MPA concentration in the lysate, equating to the 
unbound MPA concentration in plasma.
Contamination of cell extracts
It is possible that after only 1 step of washing, residual supernatant may still introduce 
extracellular protein to the sample. A nearly plasma free cell extract was prepared from 
an extensively washed cell pellet and resuspended in different volumes of water (50, 250 
and 1000 μL). To this suspension, variable volumes of supernatant (10–150 μL) contain-
ing a mixture of plasma and PBS were added. Although XMP production was the same in 
all measured samples, calculated enzyme activity based on normalization with protein 
concentration was dramatically reduced when protein concentration was increased, and 
the volume of water for preparation of cell extracts was decreased (Fig. 2).
An erythrocyte suspension was used as an artificial contamination of the PBMC ex-
tract via an increasing number of erythrocytes (0.05 x 107 to 30 x 107 erythrocytes per 1 x 
107 PBMC). Figure 3 illustrates the relative trueness of the IMPDH activity when compared 
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to that of samples measured without any additional contamination using erythrocytes. 
Calculated IMPDH activity decreased more than 10% with increasing contamination by 
erythrocytes due to increasing AMP and protein content. But in contrast to normaliza-
tion using protein concentrations, the influence of increasing AMP on trueness seems to 
be significant only when contamination is observable.
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Figure 1. The correlation between the MPA level in lysate sample and its corresponding total MPA plasma levels was found to be significant af-
ter the isolation of PBMCs described in this paper (r2 = 0.94; P < 0.0001). Accordingly, an unbound faction of MPA in plasma of 1.38% ± 0.045%–
corresponding to the slope of the curve–will yield a total MPA concentration in lysate equal to the unbound MPA concentration in plasma.
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Figure 2. Influence of extracellular protein contamination on the calculated IMPDH activity. Different volumes of plasma-PBS dilution were 
added to cell pellets, and these were then resuspended in 50 µL (squares), 250 µL (triangles), or 1000 µL (circles) HPLC water for lysis. Although 
XMP production (diamonds) is the same in all samples, calculated enzyme activities based on normalization with protein concentration are 
influenced significantly. The relative trueness of the activity was at least 62% after adding 1000 μL (circles) or 21% after adding 50 μL (squares) 
of water to resuspend the cell extracts.
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Sample stability
Storage of lithium heparin blood samples at room temperature for 24 hours before to 
PBMC isolation did not lead to any significant changes in the IMPDH activity measured, 
when the activity was normalized to the AMP concentration. Samples of 5 patients 
(1 healthy volunteer, 2 renal transplant recipients and 2 dialysis patients) were used. 
Comparison of the results during the first 5 hours with those after 22 hours showed 
that only random fluctuations occurred. AMP and XMP were altered in the same manner 
reflecting only the variability in the yield of cells, whereas protein concentrations were 
additionally influenced to varying degrees by contamination and via performance of the 
protein assay. AMP concentrations followed XMP fluctuations more closely than protein 
concentrations. No activity was lost when cell extracts were kept at -20°C or -80°C for up 
to 6 months (data not shown).
Samples obtained from 1 healthy volunteer, 2 dialysis patients and 3 renal transplant 
recipients were used for to investigate the influence of incubation time on AMP stabil-
ity and XMP production. Figure 4A shows a small increase of AMP in all investigated 
samples over time, but it still appears to be quite small when compared to the variability 
between the samples. The XMP production of the enzymes increased linearly over the 
time of incubation (Fig. 4B; r2 = 0.96 ± 0.04; P < 0.001) similar to the ratio of XMP/AMP 
(Fig. 4C; r² = 0.83–0.99; P < 0.001).
When the patients’ samples were incubated to completion, neutralized, and then 
stored at room temperature, the AMP signal was found to remain stable only over the 
first 24 hours. Thereafter, AMP concentrations increased, whereas the XMP concentra-
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Figure 3. Influence of erythrocytes’ contamination on the calculated IMPDH activity. Relative trueness of the calculated activity was compared 
in samples with increasing erythrocyte contamination based on normalization of XMP production after utilizing cell counts (squares), AMP con-
centrations (circles), and protein concentrations (triangles). Protein concentration is most sensitive to contamination with erythrocytes. In the 
usual working range (<3.0 x 107 erythrocytes per 107 PBMC) IMPDH activity, which was related to the protein concentration, was decreased to 
71% (triangles). In contrast, IMPDH activity normalized to cell count (squares) and AMP concentration (circles) were only decreased to 93% and 
95%, respectively.
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tions remained constant. There were no significant differences observed in the content 
of AMP or XMP in completely incubated and neutralized patient samples when they 
were stored at -20 °C or -80 °C for up to 6 months; when compared to initial values, 
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Figure 4. Time profiles of (A) AMP, (B) XMP, and (C) the ratio of XMP/AMP in different patients. Samples of 2 dialysis patients (open squares), 3 
renal transplant recipients (solid circles), and pooled lysate samples from healthy volunteers (crosses) are displayed. AMP shows a small increase 
in all samples investigated over time, but remains very small when compared to the variability between the samples. The XMP production of the 
enzymes increased linearly with the time of incubation (r2 = 0.96 ± 0.04; P < 0.001) similar to the ratio of XMP/AMP (r2 = 0.83–0.99; P < 0.001).
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these 2 temperature conditions represented values of 106 and 102% respectively. Thus, 
samples should be analyzed within 24 hours or kept frozen until analysis.
Linearity with sample dilution
Lysate samples from 2 healthy volunteers were diluted stepwise in order to obtain 5 
different enzyme concentrations. These samples were incubated in duplicate and XMP 
and AMP activities were then determined. The correlation was linear with a regression 
coefficient of 1.00 (P < 0.001) and 0.996 (P < 0.001). The enzyme activities of the original 
nondiluted lysate were 117.9 and 69.39 μmol·s-1·mol-1 AMP in the 2 healthy subjects. The 
activities of all of the measured samples (n = 10) from the same two subjects were 117.7 
± 8.89 and 72.35 ± 4.31 μmol·s-1·mol-1 AMP. The coefficients of variation were 7.6 and 
6.0%, and the accuracies 99.8 % and 104.3% (Fig. 5).
AMP in PBMC of patients and healthy subjects
Samples of 3 different subject groups were isolated, and then, AMP and protein concen-
trations were determined (Fig. 6). No significant differences were noticed in regard to 
the AMP concentration among the patient groups (P = 0.63), but a significant difference 
in protein concentration (P < 0.001) in the patient groups was observed.
HPLC Determination of AMP and XMP
The chromatograms of incubation buffer without the addition of cell extracts did not re-
veal any interfering peaks at the retention times seen for AMP or XMP (Fig. 7A). Cell extracts 
incubated in incubation buffer but without IMP and NAD+ were apparently free of XMP 
(Fig. 7B). No interfering peaks in the vicinity of the retention time of AMP were found in 10 
different batches of patient plasma. Isocratic elution (in research center B) resulted in reten-
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Figure 5. Linearity between XMP produced and AMP present in the sample after diluting 2 different patient samples. Both lines showed 
linearly [r2 = 1.00; P < 0.001 (square) and r2 = 0.996; P < 0.001 (triangle)] with a calculated activity out of the each 10 diluted samples of 117.7 
± 8.89 and 72.35 ± 4.31 μmol·s-1·mol-1 AMP respectively.
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tion times for AMP and XMP of 5.9 and 7.6 minutes respectively (Fig. 7C). With gradient elu-
tion (in center R), retention times for AMP and XMP were found to be 3.5 and 5.6 minutes, 
respectively (Fig. 7D). The resolutions of the peaks were 1.5 ± 0.06 (range 1.44–1.63) and 3.6 
± 1.5 (range 1.40–6.05), respectively. These values were all assessed in 24 patient samples.
Calibration curves of XMP and AMP were constructed by relating peak area to the 
concentration of the calibrators. For XMP, the calibration curve was linear in the con-
centration range of 0.75–50.0 μmol/L. The correlation coefficient (r2) ranged from 0.996 
to 1.000. The imprecision and accuracy for XMP determination of 4 levels measured 
separately is summarized in Table 1. The accuracy of determination (as percentage of 
the theoretical value) ranged from 99.2% to 103.3%. The lower limit of quantification 
and determination was 0.031 μmol/L and 0.010 μmol/L, respectively. The recovery of 
XMP ranged from 76% ± 1.9% to 108% ± 3.9%.
For AMP, the calibration curve was linear in the concentration range of 0.75–50.0 
μmol/L. The correlation coefficient (r2) ranged from 0.986 to 1.000. The imprecision and 
accuracy for AMP determination measured at 4 different levels is summarized in Table 1. 
The accuracy of determination (as percentage of the theoretical value) ranged from 99.7% 
to 103.3%. The lower limit of quantification and detection was 0.067 μmol/L and 0.040 
μmol/L, respectively. The recovery of AMP ranged from 102% ± 1.1% up to 118% ± 3.9%.
Imprecision of IMPDH activity measurement
There is not yet a gold standard for the measurement of IMPDH activity. To compare 
imprecision of 3 alternative procedures for the normalization of IMPDH activity, PBMCs 
were isolated, 10-fold, from whole blood samples taken from 2 normal healthy controls. 
In these 20 samples, cells were counted during isolation, protein concentrations were 
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Figure 6. Box-Whisker plots of protein concentrations (filled) and AMP concentration (empty) within and between 3 different subject groups. 
No differences in AMP concentrations were found between the groups (P = 0.63), whereas there was a difference in protein concentration 
(P < 0.001). There was no difference in XMP production between the groups which were not undergoing MMF treatment (data not shown). 
Normalizing the activity of AMP concentrations makes it possible to compare the calculated IMPDH activity between different patient groups.
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determined, and subsequently the lysates were incubated. Finally, the concentrations 
of AMP and XMP were determined. The IMPDH activity was normalized according to the 
following 3 procedures. Cell counts, protein concentration and AMP concentration. The 
coefficients of variation ranged between 11.2% and 39.8%, 11.8% and 12.4%, and 6.6% 
and 8.5%, respectively.
Multiple aliquots of cell extracts with 3 different activity levels were measured over 
20 days (10 days for the high level) whereby 4 samples a day were used for each estima-
tion of within-run, within-day, between-runs, between-days, and total standard devia-
tion. Results are summarized in Table 2. Lysate samples of 3 patients treated with MMF 
were incubated and measured six-fold to calculate the IMPDH activity. The coefficient of 
variation differed between 0.6% and 3.4% (Table 3). The total within-run imprecision for 
the complete assay including PBMC cell isolation and incubation was 109.7%, 106.4%, 
and 104.0% (n = 6) for 3 different activity levels (114.1, 78.5 and 18.9 μmol·s-1·mol-1 AMP). 
The limited stability of whole blood unfortunately did not permit any estimation of 
between-runs imprecision of the complete assay including the PBMC isolation step.
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Figure 7. Chromatograms of different samples involving (A) incubation buffer used for the in vitro IMPDH enzyme reaction; (B) cell extract 
incubated in reaction buffer without IMP and NAD+; and (C) patient sample incubated according to the new method used in research center B. The 
retention times of AMP and XMP are 5.9 and 7.6 minutes, respectively, and (D) patient sample incubated according to the new method used in 
center R. The retention times here of AMP and XMP are 3.5 and 5.6 minutes, respectively.
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table 1. Imprecision among determinations of AMP and XMP using 4 different SCSs
ScS (1.0 µmol/l) ScS (5.0 µmol/l) ScS (10.0 µmol/l) ScS (25.0 µmol/l)
XMP
 Mean (µmol/L) 0.99 5.05 10.33 25.67
 Accuracy (%) 99.2 100.9 103.3 102.7
 SD within-run 0.16 (16.6) 0.49 (9.6) 0.78 (7.6) 0.71 (2.8)
 SD between-runs <0.01 <0.01 <0.01 0.59 (2.3)
 SD total imprecision run 0.16 (16.6) 0.49 (9.6) 0.78 (7.6) 0.93 (3.6)
 SD within-day 0.15 (15.3) 0.46 (9.0) 0.77 (7.4) 0.73 (2.9)
 SD between-days <0.01 <0.01 0.064 (0.6) 0.58 (2.3)
 SD total imprecision day 0.15 (15.3) 0.46 (9.0) 0.77 (7.4) 0.93 (3.6)
AMP
 Mean (µmol/L) 1.02 4.99 10.23 25.82
 Accuracy (%) 102.0 99.7 102.3 103.3
 SD within-run 0.11 (11.2) 0.40 (8.0) 0.69 (6.8) 0.39 (1.5)
 SD between-runs 0.015 (1.5) <0.01 0.30 (2.9) 0.67 (2.6)
 SD total imprecision run 0.12 (11.3) 0.40 (8.0) 0.75 (7.4) 0.78 (3.0)
 SD within-day 0.11 (10.9) 0.39 (7.9) 0.70 (6.8) 0.41 (1.6)
 SD between-days 0.034 (3.3) <0.01 0.29 (2.9) 0.67 (2.6)
 SD total imprecision day 0.12 (11.3) 0.39 (7.9) 0.76 (7.4) 0.79 (3.0)
Imprecision was evaluated according to NCCLS EP5-T.19 For each concentration, 80 samples were determined: 2 samples per run, 2 runs per day for 
20 days. Imprecision data are presented as follows: standard deviation [relative standard deviation (%)]. 
SCS, spiked control sample.
table 2. Imprecision of IMPDH activity determined in I-QCS at 3 different IMPDH activity levels
I-QcS (low level) I-QcS (Medium level) I-QcS (High level)
Mean (µmol·s-1·mol-1 AMP) 31.5 89.2 124.5
SD within-run 3.35 (10.6%) 3.79 (4.2%) 6.98 (5.6%)
SD between-runs 1.65 (5.3%) 4.44 (5.0%) 4.62 (3.7%)
SD total imprecision run 3.75 (11.9%) 5.84 (6.6%) 8.37 (6.7%)
SD within-day 3.42 (10.8%) 4.60 (5.2%) 7.80 (6.3%)
SD between-days 1.55 (4.9%) 3.62 (4.1%) 3.08 (2.5%)
SD total imprecision day 3.76 (11.9%) 5.86 (6.6%) 8.38 (6.7%)
Imprecision was evaluated according to NCCLS EP5-T.19 For the low and medium levels, 80 samples were determined, and for the high level, 40 
samples: 2 samples per run, 2 runs per day for 20 days (10 days for the high level). Imprecision data are presented as follows: standard deviation 
[relative standard deviation (%)].
I-QCS, incubation quality control samples.
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DIScuSSIoN
Following publication of the HPLC-based measurements by the German group,13 other 
laboratories also set up this assay. Continued experience with the assay has shown that 
a number of steps require further assay improvement. In a mutual project, 2 laboratories 
actively involved in monitoring kidney transplant patients with this assay have modified 
the method. In Table 4, all modifications described in this article–in comparison with 
those of the first publication–are summarized. The modifications have led to an IMPDH 
assay which is less labor-intensive, more robust in general, and capable of yielding a 
better reproducibility.
table 3. Imprecision of the IMPDH activity determination using 3 different patient samples
Parameters analyzed Patient 1 (n = 6) Patient 2 (n = 6) Patient 3 (n = 6)
MPA mean (mg/mL) 1.95 0.94 1.29
AMP mean (μmol/L) 17.14 ± 0.59 19.52 ± 0.38 17.98 ± 0.16
CV (%) 3.4 1.9 0.9
XMP mean (μmol/L) 8.77 ± 0.09 4.06 ± 0.04 30.97 ± 0.24
CV (%) 1.0 1.0 0.8
IMPDH activity mean (μmol·s-1·mol-1 AMP) 56.9 ± 1.9 23.1 ± 0.4 191.4 ± 1.1
CV (%) 3.4 1.6 0.6
CV, coefficient of variation (SD/mean * 100%).
table 4. Summary of all modifications of the assay in comparison with the previous publication
Parameters analyzed Glander et al 200113 Glander et Sombogaard 2009
Sample preparation
 Volume of whole blood (mL) 5 2.5
 Aliquot resuspension
To a cell concentration of about 1 x 
107 cells/mL
In 250 μL ice-cold HPLC water
HPLC method
 Column temperature 45°C 40°C
 Eluent Isocratic
Isocratic (research center B)
Gradient (center R)
 Flow rate (mL/min) 0.7 1.0
 Injected sample volume (μL) 15 5
 Run time (min) 35
25 (center B)
17 (center R)
Normalization
Expression of concentration in 
calibrators 
pmol/incubation sample μmol/L
Normalization of XMP production Protein concentration AMP concentration
Expression of IMPDH activity nmol·h-1·mg-1 protein μmol·s-1·mol-1 AMP
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Currently, there are 2 widely accepted ways to normalize enzyme activity, namely 
cell count and protein concentration. We here introduce a third method, that of measur-
ing the AMP concentration. When comparing these 3 methods, the following advan-
tages and disadvantages can now be envisaged. At first glance, the counting of cells 
after harvesting from the interface seems to be an easy and reproducible method, but it 
also accounts for the variability of yield and number of cells in the whole blood sample. 
Even experienced technicians are faced with high intraobserver and interobserver vari-
ability when using automatic and manual methods for counting PBMCs harvested from 
the interface. In a recent article concerned with PD monitoring of calcineurin inhibitor 
therapy, it was shown that leukocyte subset cell count variation could also affect the 
calcineurin activity measured. Variability in sample composition could also affect other 
PD monitoring strategies for immunosuppressive drugs.21 An additional source of error 
in the proposed IMPDH activity method is found in the process of cell disruption by 
osmosis after adding water. During this process, the cytoplasm–including the IMPDH 
enzymes–will be released into the lysis medium while nondisrupted cells are removed 
after centrifugation. The rate of the cell disruption will be less when samples contain 
more cells. Measuring the cell count prior to cell disruption however does not indicate 
the actual number of cells that really do disrupt. The poor reproducibility of cell count-
ing, combined with the uncertainty of any further steps for the final preparation of cell 
extracts, may thus explain why laborious cell counting has no advantage in regard to 
optimizing reproducibility of the composition of PBMC extracts.
In yet a different IMPDH method, the cell pellet is resuspended in the original patient 
plasma.22 This method will result in an MPA concentration in the lysate, which is identical 
to the total MPA concentration in plasma. However we found that the MPA concentration 
in the lysate is much lower in comparison with the total MPA concentration in plasma. 
The MPA concentration in lysates correlates with the total MPA plasma concentration 
and is similar to the theoretical unbound MPA plasma concentration, which is thought 
to be responsible for its immunosuppressive activity.20 Therefore, our method reflects 
much better the in vivo situation and results in a more accurate determination of the 
IMPDH inhibition by MPA. 
Traditionally, enzyme activity has been related to protein content. For the calculation 
of enzyme activity per amount of protein, intracellular as well as extracellular proteins 
from the sample matrix have been included. Despite a careful isolation of the PBMCs, it 
is in our opinion still impossible to obtain a supernatant-free PBMC pellet just before the 
lysis step. The remaining supernatant on the pellet always contains a variable amount of 
dissolved (extracellular) proteins. These proteins will also be present in the final sample, 
and therefore, they too will be measured in the protein determination. Contamination 
with erythrocytes during the isolation of PBMCs will further increase the total protein 
concentration measured in the final samples, thereby decreasing the calculated IMPDH 
57
Im
pr
ov
ed
 IM
PD
H
 a
ct
iv
ity
 m
et
ho
d
Ch
ap
te
r 2
.1
activity. The storage time of whole blood before isolation has some influence on the 
yield of cells. Although the yield of mononuclear cells often decreases, the contamina-
tion with erythrocytes increases due to aggregation of erythrocytes and lymphocytes. 
The magnitude of this variability differs between samples and is a random occurrence.
The solution which we have chosen for the normalization of the enzymes’ products 
makes use of an intracellular compound instead of cell count or protein concentration. 
By using an intracellular compound, a correction is made for the number of cells that are 
actually lysed and have released their contents including the enzymes into the solution. 
AMP is a nucleotide of the cell matrix and derives from the same cells from which IMPDH 
enzymes originate. When enzyme activity is normalized to AMP content, this should 
better reflect the enzyme activity of disrupted cells. AMP concentrations can easily be 
determined in the same run as newly synthesized XMP. The IMPDH activity is expressed 
as the number of moles of XMP produced per second per mole of detected AMP, in short 
mol·s-1·mol-1 AMP or katal/mol AMP. The activity can be calculated from the measured 
concentrations of AMP and XMP according to the following equation:
  produced XMP (μmol · L-1) · 106
IMPDH activity (μmol · s-1 · mol-1 AMP) = 
 incubation time (s) · measured AMP (μmol·L-1)
We consider that the variation in precision and accuracy of the AMP and XMP determina-
tion in the present work is on an excellent level, with coefficients of variation residing 
below 15%. The amount of AMP present in the final sample of an assay seems to be 
influenced neither by the supernatant above PBMCs during the isolation nor by con-
tamination with erythrocytes in the usual working range. One disadvantage of using 
AMP concentrations is the amount of time it takes before a stable level of AMP is reached 
in the incubation step. An incubation time of at least 120 minutes is necessary in order 
to obtain a stable concentration of AMP.
The factor for normalization must also be comparable in different subject groups. 
In contrast to the usage of protein concentrations, it has been shown here that AMP 
concentrations did not differ between normal healthy volunteers, dialysis patients and 
renal transplant patient treated with MMF. The large variation for AMP in renal transplant 
recipients is possibly due to a substantial variability in harvested PBMCs from patients 
who received antithymocyte globulin induction therapy. Even patients after a trans-
plantation who were treated early with an antithymocyte globulin induction therapy 
exhibited similar IMPDH activities.
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coNcluSIoNS
We present here a method capable of reducing the variability and at the same time 
improving the practicability of the enzymatic assay for the measurement of IMPDH ac-
tivity in PBMCs. The protocol requires only 2.5 mL of fresh blood and the usual standard 
laboratory equipment. Using AMP concentrations for normalization of the newly gener-
ated XMP results in a smaller variability when compared with that of other normalization 
factors used previously, such as protein concentrations and cell counts. The within-run 
and within-day reproducibilities of the IMPDH activity values as gained by our modified 
HPLC method are, in our opinion, for such a complex method really within acceptable 
limits (<11%).
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AbStrAct
Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), exerts 
its immunosuppressive effect by inhibiting inosine 5´-monophosphate dehydrogenase 
(IMPDH). A cohort of 101 de novo kidney transplant patients was followed prospectively 
for 12 months. MPA concentrations were related to IMPDH activity at day 6, 21, 49 and 
140 post-transplantation using NONMEM. An inhibitory Emax model described the rela-
tionship between MPA concentration and IMPDH activity. At day 6 the area under the 
12-hour time profile (AUC0-12h) of MPA concentration of patients with a biopsy proven 
acute rejection (BPAR) (n=23) was comparable to non-BPAR patients (n=69) (p=0.73), 
whereas the AUC0-12h of IMPDH activity was higher with median values of 241 and 201 
h·µmol/s/mol AMP (p=0.086), respectively. An a posteriori analysis indicated that BPAR 
patients exhibited a significantly higher E0 and IC50 at day 6 than non-BPAR patients; cor-
responding increases were 23% (p=0.025) and 75% (p=0.011). Our data suggest that the 
inhibition of IMPDH activity during the first week of MMF treatment is associated with 
the rate of rejection. Combined monitoring of MPA concentration and IMPDH activity 
may optimize MMF therapy.
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INtroDuctIoN
Mycophenolate mofetil (MMF) is an immunosuppressant used to prevent allograft rejec-
tions in solid organ transplant patients.1 MMF is a prodrug of mycophenolic acid (MPA) 
– a noncompetitive reversible inhibitor of inosine 5´-monophosphate dehydrogenase 
(IMPDH). IMPDH is the rate-limiting enzyme in the de novo pathway of guanine nucleo-
tide synthesis. Inhibition of IMPDH retards the proliferation of T- and B-lymphocytes, 
which are dependent on the guanine nucleotide synthesis pathway.2 There are two 
isoforms of IMPDH that are encoded by two distinct genes: type I and type II.3
After oral administration MMF is rapidly hydrolyzed to MPA, which is metabolized in 
the liver by UDP-glucuronosyltranferases to three metabolites 7-O-mycophenolic acid 
glucuronide (MPAG), MPA-acyl-glucuronide and MPA-phenyl-glucuronide.4 The glucuro-
nides are excreted in urine and bile. Biliary excretion of metabolites in the gut lumen 
contributes to enterohepatic recirculation.5
The existence of a therapeutic window and the highly variable pharmacokinetics 
of MPA have led investigators to evaluate the potential benefit of therapeutic drug 
monitoring using MPA plasma concentrations.6 In a prospective randomized study it 
was demonstrated that therapeutic monitoring using a limited sampling strategy to 
determine the area under the 12 hour MPA plasma concentration versus time curve 
(MPA AUC0-12h) reduced the risk of treatment failure and acute rejection in the first year 
after renal transplantation.7
So far, individualization of MMF therapy has been focused primarily on the pharma-
cokinetics of MPA. However, since IMPDH is the molecular target of MPA, IMPDH activity 
may serve as a surrogate pharmacodynamic marker for immunosuppression and clinical 
outcome. By monitoring of MPA-induced IMPDH inhibition it is conceivable that a more 
accurate prediction of therapeutic response will be obtained than by monitoring of MPA 
plasma concentrations alone.8
In the present study a prospective cohort of 101 de novo renal transplant recipients 
on MMF therapy was followed for 12 months after transplantation. Time profiles of 
plasma MPA concentration and IMPDH activity in peripheral blood mononuclear cells 
(PBMC) were assessed at 4 occasions (days 6, 21, 49 and 140 post-transplant) in order to 
develop an integrated pharmacokinetic-pharmacodynamic model. Population pharma-
cokinetic and pharmacodynamic parameters was assessed as well as their relationship 
with clinical outcome.
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reSultS
Patients and clinical outcome
The patient characteristics are summarized in Table 1. At day 140 post-transplant 37 
patients had discontinued the study due to primary non-function of graft or transplan-
tectomy (n=4), problems with repetitive blood sampling (n=6), withdrawal of informed 
consent (n=13), missed clinical visits (n=9) and other reasons (n=5).
table 1. Demographic, baseline biochemical and molecular patient characteristics
visit 1 
(Day 6)
visit 2 
(Day 21)
visit 3 
(Day 49)
visit 4 
(Day 140)
Days post transplant (days) 6 (3-16) 21 (15-42) 49 (40-76) 140 (133-168)
Number of patients (n) 101 82 72 64
Gender male/female (n) 73/28 62/20 53/19 47/17
Race Caucasian/Black/Asian/Hispanic (n) 83/13/3/2 69/8/3/2 59/9/3/1 51/9/3/1
Patients with pre-Tx diabetes (n) 14 9 9 8
IMPDH type II 3757T>C WT/het/hom (n) 89/10/2 71/9/2 63/7/2 54/8/2
Age (years) 54 (19-76) 54 (19-76) 55 (19-76) 54 (20-77)
Weight (kg) 80 (44-145) 79 (40-131) 80 (42-126) 82 (44-134)
IMPDH act pre-Tx (µmol/s/mol AMP) 44 (6-178) 43 (6-178) 43 (6-178) 45 (6-178)
Serum creatinine (µmol/L) 213 (61-1190) 149 (74-1013) 134 (78-525) 132 (81-816)
Creatinine clearance (mL/min) 28 (4-90) 43 (5-90) 49 (10-90) 47 (6-82)
Plasma albumin (g/L) 34 (21-43) 39 (10-46) 42 (24-50) 43 (26-48)
Serum AST (U/L) 34 (9-236) 17 (9-58) 17 (8-66) 23 (12-73
Serum ALT (U/L) 44 (2-534) 26 (7-162) 17 (5-114) 19 (1-83)
Haemoglobin (mmol/L) 6.2 (3.3-9.4) 6.1 (4.2-8.8) 6.8 (4.5-9.5) 7.6 (4.9-9.5)
Thrombocytes (109/L) 194 (32-407) 254 (40-568) 232 (131-455) 245 (7-338)
Leukocytes (109/L) 8.1 (0.3-29.0) 8.4 (3.1-18.3) 7.7 (3.3-24.0) 6.2 (0.4-12.3)
Patients with first Tx (n) 90 72 65 57
Donor living/deceased (n) 64/37 55/27 51/21 46/18
HLA mismatch 0 / 1-3 / 4-6 (n) 6/50/45 5/41/36 3/38/31 3/33/28
PRA 0 / 1-10 / 11-50 / 50-100 / n.a. (n) 66/12/5/4/14 55/10/4/3/10 49/10/3/3/7 46/8/3/3/4
Delayed graft function (n) 31 23 17 13
Dose MMF (mg) 1000 (500-1500) 500 (500-1500) 500 (250-1500) 500 (250-1000)
Daily dose tacrolimus (mg) 11 (4-20) 9 (2-20) 8 (2-20) 4 (1-20)
Tacrolimus trough level (µg/L) 11 (2-30) 11 (5-28) 10 (4-21) 9 (4-16)
ATG induction therapy (n) 29 21 15 14
Values are expressed as median (range) except for (n).
ALT, alanine transaminase; AMP adenosine monophosphate; AST, aspartate transaminase; ATG, anti-thymocyte globulin; het, heterozygote; HLA, 
human leukocyte antigen; hom, homozygote; IMPDH, inosine monophosphate dehydrogenase; MMF, mycophenolate mofetil; n.a., not available; 
PRA, panel-reactive antibodies; Tx, transplantation; wt, wild type; XMP, xanthine monophosphate.
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Twenty three patients exhibited a biopsy proven acute rejection (BPAR) within 12 
months post-transplant. Acute rejection was presumed for 4 patients and a primary non-
function of the graft was observed in 5 patients. BPAR occurred at a median of 11 days 
(range 6 – 210) post-transplant. Incidence rates of abdominal cramps, diarrhoea, nausea 
and vomiting were less than 21%, 15%, 16% and 8%, respectively. Anemia decreased 
from 68% on day 6 to 16% on day 140, whereas thrombocytopenia decreased from 32% 
to 8%. The incidence of leukopenia was less than 13%.
Pharmacokinetics
Figure 1 depicts the time profiles of MPA plasma concentrations at day 6, 21, 49 and 
140. A two-compartment pharmacokinetic model with first-order absorption and 
elimination adequately described the data. Time dependency was detected for both the 
central volume of distribution (V1/F) and apparent oral clearance (CL/F) (Table 2). CL/F 
was 62% and 25% higher on day 6 and 21 compared to day 49 and 140; corresponding 
values for V1/F were 273% and 73%. Diagnostic plots (e.g predicted versus observed 
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Figure 1. Time profiles of mycophenolic acid (MPA) plasma concentration (circles) and inosine monophosphate dehydrogenase (IMPDH) activ-
ity (squares) following an oral administration of mycophenolate mofetil (MMF). Data are expressed as median plus 25% and 75% percentiles. 
Data were obtained in 101 (day 6), 82 (day 21), 72 (day 49) and 64 (day 140) patients.
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concentrations, weighted residuals versus time) confirmed the adequacy of the popula-
tion pharmacokinetic model (plots not shown). Furthermore, the population estimates 
of the model were well within the 95% confidence interval as produced by the bootstrap 
procedure (Table 2).
table 2. Population pharmacokinetic parameter estimates for mycophenolic acid
Population parameters
estimated value
(%cv)
1000 bootstrap replicates
Median (95% interval)
Typical parameter
Tlag (h) 0.36 (7%) 0.35 (0.32-0.39)
Ka (h
-1) 31 31
V1 visits 3 and 4 (L) 65 (13%) 66 (47-90)
 ΘV1-visit 1 3.7 (16%) 3.6 (2.5-4.0)
 ΘV1-visit 2 1.7 (16%) 1.7 (1.1-2.3)
CL visits 3 and 4 (L/h) 15 (6%) 15 (13-18)
 ΘCL-visit 1 1.6 (7%) 1.5 (1.3-1.8)
 ΘCL-visit 2 1.3 (6%) 1.3 (1.1-1.6)
V2 (L) 1200 (125%) 1300 (570-2350)
Q (L/h) 38 (11%) 37 (29-49)
Between-patient variability
Tlag (%) 45 (86%) 52 (23-102)
Ka (%) 102 (108%) 98 (66-150)
V1 (%) 59 (53%) 65 (34-89)
CL (%) 32 (23%) 33 (21-51)
Correlation
CL – V1 1
2 12
CL – Ka 0.14 0.18 (0.05-0.35)
CL – Tlag 0.25 0.25 (0.12-0.46)
V1 - Ka 0.14 0.11 (0.03-0.21)
V1- Tlag 0.25 0.26 (0.12-0.35)
Ka – Tlag 0.88 0.81 (0.46-0.95)
Within-patient variability
Ka (%) 143 (23%) 150 (86-200)
V1 (%) 56 (59%) 52 (35-88)
CL (%) 35 (16%) 35 (24-49)
Residual error
Additive (mg/L) 0.44 (4%) 0.44 (0.40-0.50)
1 Ka was fixed to 3 h
-1; 2 Correlation between CL and V1 was high and fixed to 1.
CL/F day 49 and 140, apparent oral clearance on days 49 and 140; Ka, absorption rate constant; Q/F, intercompartmental clearance; Tlag, lag time; 
V1/F day 49 and 140, central volume of distribution on days 49 and 140; V2/F, peripheral volume of distribution; ΘCL/F-day 6, fractional increase of 
CL/F on day 6 compared to days 49 and 140; ΘV1/F-day 6, fractional increase of V1/F on day 6 compared to days 49 and 140.
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On the basis of the individually derived pharmacokinetic parameters MPA exposure 
was calculated. Median (range) MPA AUC0-12h was 29 (9 – 70), 28 (11 – 85), 27 (11-103) 
and 27 (10 – 63) h·mg/L on day 6, 21, 49 and 140, respectively (n=101, 82, 72 and 64). 
No significant differences were detected between the exposures on the different days.
Pharmacodynamics
The median pretransplant IMPDH activity in PBMC was 44 µmol/s/mol AMP (range 6-178 
µmol/s/mol AMP). The predose IMPDH activity at the first sampling day was significantly 
lower than the pre-transplant activity with a median value of 20 µmol/s/mol AMP (range 
7-119 µmol/s/mol AMP) (p<0.01). As depicted in Figure 1 IMPDH activity decreased 
from the predose value of 20 µmol/s/mol AMP to 13 µmol/s/mol AMP at 1 hour after 
dose ingestion. With decreasing MPA concentrations IMPDH activity restored to pre-
administration values.
The relationship between IMPDH activity and MPA plasma concentration was 
adequately modeled with an inhibitory Emax model (Equation 3, Table 3, Figure 2). The 
baseline IMPDH activity (E0) increased from 55 µmol/s/mol AMP at day 6 to 76 µmol/s/
mol AMP at day 21 and to 92 µmol/s/mol AMP at days 49 and 140 (p<0.01). The MPA 
concentration at half maximal inhibition of IMPDH activity (IC50) was 0.76 mg/L at day 
6 and 0.17 mg/L at the subsequent days (p<0.01). The maximum reduction of IMPDH 
activity was 88%. 
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Figure 2. Inosine monophosphate dehydrogenase (IMPDH) activity versus mycophenolic acid (MPA) plasma concentration. The data points 
represent the observed IMPDH activity at bayesian predicted MPA concentrations for day 6 (closed circles), day 21 (open circles) and day 49 and 
140 (open squares). The respective solid, dashed and dotted line represent the relationship on basis of the population parameters presented in 
Table 3 for day 6, day 21 and day 49/140. The baseline IMPDH activity (E0) increases from 55 µmol/s/mol AMP at day 6 to 76 µmol/s/mol AMP at 
day 21 and to 92 µmol/s/mol AMP at days 49 and 140 (p<0.01), whereas the MPA concentration at half maximum inhibition (IC50) decreases from 
0.76 mg/L at day 6 to 0.17 mg/L at the subsequent days (p<0.01).
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E0 of black patients was 12% lower than for Caucasian, Asian and Hispanic patients 
(p<0.05; Figure 3). Patients homozygous for the IMPDH type II 3757T>C genotype ex-
hibited an E0 55% higher than heterozygous and wild type patients (p<0.05; Figure 3). 
No difference was detected between the latter two genotypes. A significant correlation 
was observed for E0 and the number of leukocytes (p<0.01). Compared to the median 
leukocyte count of 8.1·109 cell, E0 decreased with 34% when leukocytes dropped to 1·10
9 
cells and E0 increased with 20% with a leukocyte count increased to 20·10
9. IC50 cor-
related with albumin (p<0.05). An increase of albumin from 34 (median value) to 40 g/L 
table 3. Population pharmacodynamic parameter estimates
basic model 
estimate (%cv)
Final model
estimate (%cv)
1000 bootstrap replicates
median 95% interval
Typical parameter
E0 (µmol/s/mol AMP) 60 (13%) - -
E0 visit 3 and 4 (µmol/s/mol AMP) - 92 (21%) 89 (65-112)
 Θvisit 1 - 0.61 (10%) 0.54 (0.42-0.85)
 Θvisit 2 - 0.83 (9%) 0.84 (0.68-0.96)
 Θblack - 0.88 (6%) 0.90 (0.77-0.98)
 Θhomozygous - 1.55 (13%) 1.43 (1.12-2.01)
 Θleukocytes - 0.20 (35%) 0.18 (0.11-0.42)
IC50 (mg/L) 0.44 (26%) - -
IC50 visit 2, 3 and 4 (mg/L) - 0.17 (32%) 0.18 (0.09-0.31)
 Θvisit 1 - 4.4 (45%) 4.3 (1.4-7.9)
 Θalbumin - 1.14 (36%) 1.18 (0.36-1.98)
Emax 0.85 (3%) 0.88 (4%) 0.87 (0.80-0.99)
Between-patient variability
E0 (%) 8 (89%) 9 (91%) 10 (0 - 28)
IC50 (%) 102 (41%) 99 (52%) 95 (45 – 176)
Correlation
E0-IC50 -1
1 -11
Within-patient variability
Baseline activity (%) 41 (45%) 39 (41%) 42 (22-85)
Residual error
Additive error 0.48 (3%) 0.48 (3%) 0.48 (0.41-0.52)
MVOF -72.5 -110.4
1 Correlation between E0 and IC50 was high and fixed to -1.
AMP adenosine monophosphate; E0 day 49 and 140, baseline inosine monophosphate dehydrogenase (IMPDH) activity at day 49 and 140; IC50 day 
21, 49 and 140, MPA plasma concentration at half maximum inhibition at day 21, 49 and 140; ΘE0-black, fractional decrease of E0 in black patients 
compared to Caucasian, Asian and Hispanic patients; ΘE0-day 6, fractional decrease of E0 on day 6 compared to days 49 and 140; ΘE0-homozygous, 
fractional increase of E0 in patients homozygous for IMPDH type II 3757T>C compared to wild type and heterozygous patients; ΘE0-leukocytes, 
exponent in relationship between E0 and number of leukocytes (E0 = 92 x (leukocytes/8.1 10
9)0.20); ΘIC50-albumin, exponent in relationship betwe-
en IC50 and albumin (IC50 = 0.17 x (albumin/34)
1.14); ΘIC50-day 6, fractional increase of IC50 on day 6 compared to days 21, 49 and 140.
73
Re
la
tio
ns
hi
p 
be
tw
ee
n 
PK
 a
nd
 IM
PD
H
Ch
ap
te
r 3
.1produced a 20% higher IC50 value, whereas a reduction to 20 g/L produced a 45% lower 
IC50 value.
Between-patient variability in IC50 was high (99%) whereas between-patient vari-
ability in E0 was low (8%). Within-patient variability in E0 was however considerable 
(39%).
The diagnostic plots confirmed the adequacy of the population pharmacodynamic 
model (plots not shown). The population estimates of the final model were well within 
the 95% confidence interval as produced by the bootstrap procedure (Table 3).
The area under the 12 hour time curve of IMPDH activity (IMPDH activity AUC0-12h) 
was calculated using the individual pharmacokinetic and pharmacodynamic parameters. 
Median (range) values were 210 (80 – 710), 187 (64 – 690), 195 (96-837) and 217 (76 – 908) 
h·μmol/s/mol AMP for day 6, 21, 49 and 140, respectively (n=101, 82, 72 and 64). IMPDH 
activity AUC0-12h on day 21 was significantly lower than on the other days (p<0.01).
Relationships with clinical outcome and adverse effects
An a posteriori analysis indicated that BPAR patients exhibited a significantly higher E0 
and IC50 at day 6 than non-BPAR patients; corresponding increases were 23% (p=0.025) 
and 75% (p=0.011). No differences were detected for the other days. At day 6 the IMPDH 
activity AUC0-12h of BPAR patients was higher than in non-BPAR patients with respec-
tive median (range) values of 241 (103-710, n=23) and 201 (80-618, n=69) h·µmol/s/
mol AMP (Figure 4). This difference almost reached statistical significance (p=0.086). No 
relationships were found between clinical outcome and pharmacokinetic parameters 
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Figure 3. Bayesian predicted E0 versus race and IMPDH type II 3757T>C genotype. E0 of Black patients was 12% lower than for Caucasian, Asian 
and Hispanic patients (p<0.05). E0 was 55% higher in homozygous (hom) patients compared to heterozygous (het) and wild type (wt) patients 
(p<0.05). Data (n=319) are presented for all patients and for all visits. The solid lines represent the median baseline inosine monophosphate 
dehydrogenase (IMPDH) activity (E0).
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like CL/F and MPA AUC0-12h. At day 6 MPA AUC0-12h of BPAR patients was comparable to 
the AUC of non-BPAR patients with respective median values of 29 (13- 59) h·mg/L and 
29 (9- 70) h·mg/L (p=0.73) (Figure 4). Pre-transplant IMPDH activity was not associated 
with clinical outcome. Pre-transplant IMPDH activity in BPAR and non-BPAR patients was 
38 (10-105) and 45 (6-178) µmol/s/mol AMP, respectively (p=0.54).
IMPDH activity AUC0-12h was significantly lower in case of leukopenia grade 1 to 4 
compared to grade 0; corresponding median values were 163 and 212 h·µmol/s/mol 
AMP (n=18 and n=293, p<0.01). IMPDH activity AUC0-12h was significantly lower in case 
of anemia grade 2 to 4 compared to grade 0 and 1 with median values of 176 and 210 
h·µmol/s/mol AMP, respectively (n=65 and n=250, p<0.05). No significant relationships 
were detected between the incidence rates of thrombocytopenia, abdominal cramps, 
diarrhoea, nausea and vomiting and IMPDH activity AUC0-12h or MPA AUC0-12h.
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Figure 4. Area under the inosine monophosphate dehydrogenase (IMPDH) activity versus time profile curve during 12 hours (IMPDH activity 
AUC0-12h) at day 6 and area under the mycophenolic acid (MPA) plasma concentration versus time profile during 12 hours (MPA AUC0-12h) for 
patients with no acute rejection (no BPAR), a biopsy proven acute rejection (BPAR), a presumed AR and a primary non-functioning graft. Median 
IMPDH activity AUC0-12h of no BPAR and BPAR patients was 201 and 241 h·µmol/s/mol AMP, respectively (p=0.086). Median MPA AUC0-12h of no 
BPAR and BPAR patients was similar 29 h·mg/L (p=0.73). The solid line represents the median.
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DIScuSSIoN
IMPDH activity may serve as a surrogate pharmacodynamic marker for immunosuppression 
and clinical outcome. The combination of pharmacokinetics and pharmacodynamics could 
be used to optimize the dosing regimen of MMF, as well as to monitor therapy and allow for 
dosage adjustments to maximize immunosuppression and to minimize side effects. In the 
present study the relationship between MPA plasma concentrations, inhibition of IMPDH 
activity and clinical outcome was quantified in 101 de novo renal transplant patients.
The pharmacokinetics of MPA were adequately described with a two-compartment 
model. The estimated apparent oral clearance in the first week (24 L/h, Table 2) corre-
sponds well with the value of 29 L/h reported earlier by Staatz.9 The time-dependency of 
the pharmacokinetics of MPA as observed in the present study has been studied earlier 
by Van Hest10 who reported that following renal transplantation clearance was reduced 
from 34 L/h in the first week to 20 L/h in week 20 (41% reduction). In the referred study 
the decrease of clearance was explained by the improvement of both the renal func-
tion and albumin in time over time. The inverse correlation between MPA clearance 
and both creatinine clearance and albumin may be explained by their influence on 
protein binding of MPA. Impaired renal function may reduce protein binding of MPA by 
uremia as well as MPAG accumulation.11 Consequently, impaired renal function and low 
plasma albumin may produce an increased free fraction of MPA, which in turn may lead 
to increased metabolism of MPA, since MPA is believed to have a low to intermediate 
extraction ratio.12
The relationship between the IMPDH activity in PBMC and MPA plasma concentra-
tion was successfully described with an inhibitory Emax model (Figures 2 and 3). Vethe
13 
used a similar pharmacodynamic model to relate IMPDH activity in CD4+ cells to MPA 
plasma concentrations of healthy volunteers receiving single doses of MMF. In the 
referred study an Emax value of approximately 85% was observed, which corresponds 
well with the value estimated in the present study (88%, Table 3). In our renal transplant 
patients baseline IMPDH activity increased from 55 (day 6) to 92 µmol/s/mol AMP at 
day 49 and 140 (Table 3). The increase of baseline activity may reflect the induction 
of enzyme activity. Long-term MPA therapy has been associated with an induction of 
IMPDH activity which is suggested to be mediated through feedback regulation by 
guanine nucleotides.14 Induction of enzyme activity has been described to occur in 
renal transplant patients taking MMF for a prolonged period of time.15,16 Interestingly, a 
parallel increase was observed for both IMPDH type I and type II mRNA in the patients 
of the present study.17
The presence of considerable predose inhibition of IMPDH activity has also been 
reported by Vethe.13 In healthy volunteers taking single doses of 500 and 1000 mg MMF 
IMPDH activity in CD4+ cells at 12 hours after ingestion was still reduced with 32% and 
76
40%, respectively, compared to pre-administration levels.13 In the referred study a value 
of 2.3 mg/L was reported for the IC50 which was higher than the value estimated in the 
present study (Table 3). In in vitro experiments the MPA concentration required for 50% 
inhibition of IMPDH activity was approximately 2.0-5.0 mg/L for both whole blood and 
isolated lymphocytes.18 It is difficult to compare the reported IC50 values with our results 
since the inhibitory potency may be dependent on the studied cell type (whole blood 
cells, lymphocytes, monocytes), the applied IMPDH assay (single or multiple washing 
steps), single versus multiple MMF dosing (enzyme induction) and the applied immuno-
suppressive drug regimen.16,18-20
The covariate analysis demonstrated that patients homozygous for the IMPDH type 
II 3757T>C single-nucleotide polymorphism exhibited a baseline activity that was 55% 
higher than heterozygous and wild type patients. For the two homozygous patients 
IMPDH activity AUC0-12h was 522 and 710 h·µmol/s/mol AMP at visit 1 which was in the 
upper 10 percentile of the whole population [median 210 h·µmol/s/mol AMP (n=101)]. 
One of the two homozygous patients experienced an acute rejection. Increased rejec-
tion rates have been reported for patients with a variant allele.21 The decreased baseline 
activity in black patients may be explained by a genetic polymorphism as well. However, 
so far no information is available in the literature with respect to ethnic differences in 
IMPDH activity. 
It is difficult to explain the observed association between the leukocyte count and 
the baseline IMPDH activity, since both are influenced by multiple factors like the clinical 
status of the patient and the administered immunosuppressive drugs. The positive cor-
relation between IC50 and albumin may be explained by a decreased MPA free fraction in 
case of high albumin. With less unbound MPA available for inhibiting the IMPDH enzyme, 
the whole IMPDH activity versus total MPA plasma concentration curve will be shifted to 
the right producing an increased IC50. On the basis of the observed association between 
IC50 and albumin it may be speculated that the inhibition of IMPDH activity is primarily 
determined by unbound MPA concentration instead of total MPA concentrations. With 
an assumed free fraction of MPA of 3%, the observed IC50 of 0.17 mg/L corresponds to 
a unbound IC50 of 5.1 µg/L or 16 nM, which is in the same order of magnitude as the 
reported Ki for IMPDH type I and II with respective values of 37 nM and 9.5 nM.
3
Since estimates of between- and within-patient variability of pharmacokinetic and 
pharmacodynamic parameters are available (Tables 2 and 3), one may speculate on the 
feasibility to adjust the individual MMF dose in order to obtain a specific targeted inhibi-
tion of IMPDH activity. Bayesian adaptive dosing may be used to reduce the influence of 
between-patient variability whereas within-patient variability cannot be reduced. The 
observed within-patient variability of 39% for E0 in the present study indicates that a pa-
tient with a typical baseline IMPDH activity of 55 µmol/s/mol AMP may actually exhibit 
an E0 value in the range from 12 to 98 µmol/s/mol AMP (95% CI = mean ± t0.95*σ/√n = 55 
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± 2·0.39·55) at a specific visit. The 8-fold within-patient variability in E0 will presumably 
produce major variability in the observed IMPDH activity AUC0-12h. As a result it is difficult 
at this point to predict whether it will be possible to target IMPDH activity AUC0-12h at a 
certain value.
By monitoring of MPA-induced IMPDH inhibition it is conceivable that a more ac-
curate prediction of therapeutic response will be obtained than by monitoring of MPA 
plasma concentrations alone. In the present study at day 6 post-transplant no difference 
in pharmacokinetic exposure was detected between patients with or without BPAR; 
both median values were 29 h·mg/L (n=23 and n=69, respectively). It has been reported 
earlier that targeting AUC0-12h in the range of 30 – 60 h·mg/L reduces the risk of acute 
rejection.6 In our study however, MPA exposure did not predict clinical outcome. A BPAR 
was observed in 12 of 51 patients (24%) with an AUC0-12h less than 30 h·mg/L, whereas in 
the 41 patients with an AUC0-12h greater than 30 h·mg/L 11 patients (27%) experienced 
a BPAR (p=0.54). Glander has reported that high pre-transplant activity and MMF dose 
reductions were associated with high rejection rates.22 We can not confirm this in the 
present study as pre-transplant IMPDH activity was comparable in patients with and 
without BPAR. Interestingly, IMPDH activity AUC0-12h at day 6 was greater [although not 
statistical significant (p=0.086)] in patients that experienced a BPAR when compared 
to patients without a BPAR, with respective values of 241 (103-710, n=23) and 201 (80-
618, n=69) h·µmol/s/mol AMP [median (range)]. Since IMPDH activity AUC0-12h ranges 
are overlapping (Figure 4) it is not possible to define a target value for IMPDH activity. 
Nevertheless, it can be concluded that IMPDH activity in PBMC may be a more sensitive 
parameter to predict transplantation outcome than MPA plasma concentration. Conse-
quently, combined monitoring of MPA plasma concentration and IMPDH activity during 
MMF therapy may more accurately predict the therapeutic response than monitoring of 
MPA plasma concentrations alone. This needs however to be confirmed in a prospective 
study.
In summary, an integrated pharmacokinetic-pharmacodynamic model was devel-
oped which described the relationship between MMF dose, MPA plasma concentrations 
and IMPDH activity in PBMC in renal transplant patients. Our data suggest that the 
inhibition of IMPDH activity during the first week of MMF treatment is associated with 
the rate of rejection. As a result, combined monitoring of MPA plasma concentration and 
IMPDH activity may allow the optimization of MMF therapy.
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PAtIeNtS AND MetHoDS
Patients
A prospective cohort of 101 de novo renal transplant recipients was followed for 12 
months after transplantation. Before transplantation a blood sample was obtained for 
the determination of pre-transplant IMPDH activity and pharmacogenetic analysis. On 
days 6, 21, 49 and 140 days after transplantation blood samples were drawn for assess-
ment of MPA concentrations and IMPDH activity. On day 6 samples were taken pre-dose, 
0.5, 1, 2, 6, and 12 hours after oral intake of MMF. On the other days samples were taken 
at pre-dose, 0.5 and 2 hours after oral intake of MMF. The study was approved by the 
local ethics committee of Erasmus MC, Rotterdam, The Netherlands and complied with 
the Declaration of Helsinki. All patients gave written informed consent.
Immunosuppressive therapy
Immunosuppressive therapy was started directly after the transplant surgery. Patients 
started with MMF 1000 mg twice daily. MMF dose adjustments were dependent on the 
clinical status of the patient and at the physician’s own discretion. Tacrolimus was dosed 
to obtain the following trough levels: 10-15 μg/L (first month), 8-12 μg/L (second month), 
6-10 μg/L (months 3, 4 and 5) and 5 - 8µg/L (month 6 and further). The start dose of 
prednisone was 20 mg once daily after two days of 50 mg prednisone i.v. twice daily; the 
dose was tapered at the physician’s own discretion. Patients that received a kidney from 
a deceased donor were considered for anti-thymocyte globulin (ATG) induction therapy.
Clinical outcome
The efficacy of the immunosuppressive therapy was evaluated by monitoring the occur-
rence of biopsy proven acute rejections (BPAR) within 12 months post-transplant using 
the Banff classification.23 Kidney biopsies were taken on clinical grounds of suspicion of 
a rejection episode. No routine kidney biopsies were taken. Adverse events were graded 
according to the standard response and toxicity criteria.24 Delayed graft function was 
defined as more than 3 days depending on dialysis starting in the first two weeks after 
transplantation.
Assays
IMPDH activity in peripheral blood mononuclear cells (PBMC) was assessed by using a 
non-radioactive HPLC method reported earlier.25 The total and within-day imprecision of 
the IMPDH activity assay was less than 8.4% and 7.8%, respectively, in the IMPDH activity 
range of 32 to 125 μmol/s/mol AMP. MPA plasma concentrations were measured with a 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.26 The total and 
within-day imprecision of the method was less than 5% and 3%, respectively, for plasma 
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MPA concentrations in the range from 0.1 to 50 mg/L. Genotyping of the IMPDH type II 
3557T>C eight polymorphism was performed as described by Sombogaard.26
Population pharmacokinetic-pharmacodynamic modeling
All data were analyzed simultaneously using the nonlinear mixed effects modeling 
software program NONMEM (double precision, Version VI, level 2.0, GloboMax LLC, Ha-
nover, USA). The concentration data were logarithmically transformed. Parameters were 
estimated using the first order (FO) estimation method, since the first order conditional 
estimate method (FOCE) did converge successfully. The pharmacokinetics of MPA were 
described with a two-compartmental model with first-order absorption (Ka) with a lag 
time (Tlag). The following parameters were estimated: apparent oral clearance (CL/F), 
intercompartmental clearance (Q/F) and central and peripheral volumes of distribu-
tion (V1/F and V2/F). Between- and within-patient variability was characterized using 
exponential models. For example, CL/F for the ith individual on the jth visit (CL/Fij) was 
estimated using equation 1:
 CL/Fij (L/h) = θpop * exp(ηi + κj)    (Eq. 1)
where θpop represents the population value for CL/F. ηi and κj represent the between- and 
within-patient random effect, respectively, with mean 0 and variance ω2 and π2. In case 
of two or more random effects covariance was estimated as well. Within-patient vari-
ability corresponded to the variability of a pharmacokinetic parameter within a patient 
between the sampling days.
The difference between the kth observed concentration of the ith individual (Cobs,ik) and the 
corresponding model predicted value (Cpred,ik) was modeled using an additive error model:
 ln Cobs,ik = ln Cpred,ik + εik     (Eq. 2)
where ε is the residual random error with mean 0 and variance σ2.
In population pharmacodynamic analysis effect IMPDH activity data were loga-
rithmically transformed. The FOCE method was used in combination with NONMEM´s 
INTERACTION option to allow for interaction between random effects. In analysis 
individual pharmacokinetic parameters were fixed at posthoc values. The relationship 
between MPA concentration (C) and IMPDH activity in PBMC (E) was described with an 
inhibitory Emax model:
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where E0 is the baseline IMPDH activity [i.e. with no MPA present (C=0)], Emax is the maxi-
mal fractional inhibitory effect and IC50 is the MPA concentration at half Emax. Between- 
and within-subject variability was modeled using exponential models (equation 1) and 
residual variability was modeled using an additive error model (equation 2).
Relationships between both demographic and pathophysiological factors and 
pharmacodynamic parameters were evaluated. The tested covariates included age, gen-
der, ethnicity, IMPDH type II 3557T>C genotype, weight, pretransplant diabetic status, 
plasma albumin concentration, plasma protein concentration, liver enzymes aspartate 
transaminase (AST) and alanine transaminase (ALT), bilirubin, alkaline phosphatase, 
gamma-glutamyltransferase (GGT), urea, creatinine clearance (CrCl), calculated using the 
4-variable MDRD formula, C-reactive protein (CRP), hemoglobin, hematocrite, thrombo-
cytes, leukocytes, pretransplant IMPDH activity, delayed graft function, tacrolimus daily 
dose, tacrolimus concentration, corticosteroid dose and anti-thymocyte globulin (ATG) 
induction therapy (Table 1).
Continuous covariates, for instance leukocytes, were modeled in an exponential 
manner:
 E0,ij = θpop * (leukocytes/8.1 10
9)θleuko    (Eq. 4)
in which θpop is the baseline IMPDH activity in an individual with 8.1 10
9 leukocytes 
(median of the population) and θleuko is an exponent determining the shape of the rela-
tionship. Categorical variables, like for example IMPDH type II 3557T>C genotype, were 
modeled as shown in equation 6:
 E0,ij = θpop * θ1
θheterzygote * θ2
θhomozygote    (Eq. 5)
where θpop is the population value for E0 in wildtype patients (θheterozygote = 0 and θhomozygote 
= 0), θ1 is the fractional change of E0 in heterozygous patients (θheterozygote = 1 and θhomozygote 
= 0) and θ2 is the fractional change of E0 in homozygous patient (θheterozygote = 0 and 
θhomozygote = 1).
The log-likelihood test was used to assess the statistical signifcancy of the relation-
ship between the covariate and the pharmacodynamic parameters.27 In an univariate 
analysis a decrease of the minimum value of objective function (MVOF) of >3.8 units 
indicated p<0.05 (1 degree of freedom). Furthermore, a reduction in between- or within-
patient variability was used as a criterion for covariate selection, as well as the biological 
plausibility of a relationship. All covariates selected during the univariate analysis were 
included in an intermediate model. Subsequently, covariates were excluded separately 
in a backward elimination procedure. An increase of MVOF (>3.8 units) was necessary to 
remain the parameter in the population model.
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The stability and the performance of the final model were checked with an internal 
validation of the final model, using the bootstrap resample technique.28
The area under the concentration versus time curve (MPA AUC0-12h) and IMPDH activ-
ity versus time curve (IMPDH activity AUC0-12h) were calculated over a period of 12 hours 
on basis of individual Bayesian parameter estimates.
Statistical analysis
Statistical tests were performed using SPSS software version 15.0 (SPSS, Chicago IL, USA) 
and a p-value less than 0.05 was considered significant. Normally distributed data were 
analyzed by a t-test or ANOVA, and non-normally distributed data by a Mann-Whitney U 
test or Kruskal-Wallis test.
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AbStrAct
The active moiety of the immunosuppressivum mycophenolate mofetil – mycophenolic 
acid (MPA) – is extensively bound to plasma albumin. It is thought that the unbound 
concentration of mycophenolic acid is responsible for the inhibition of inosine mono-
phosphate dehydrogenase (IMPDH). From 99 kidney transplant patients blood samples 
were drawn 6 days after transplantation. IMPDH activity was correlated with total and 
unbound MPA concentrations and albumin in causing the biological effect of MPA.
Significant poor correlations were found between total and unbound MPA con-
centration pre-dose and IMPDH activity pre-dose using an Emax model. The calculated 
E0 and IC50 parameters showed a large confidence interval. The therapeutic window of 
total MPA AUC (30 to 60 h•mg/L) was not significant correlated to IMPDHact AUC, but 
unbound MPA AUC (2.1 to 4.2 h•mg/L; 7.0% unbound fraction) was. IMPDH activity was 
significantly lower in patients with low serum albumin compared to patients with higher 
levels. Nevertheless, no significantly differences were found between patients with low 
and high albumin for unbound MPA AUC, but a significantly difference was found in 
total MPA AUC.
We conclude that patients with decreased albumin levels have lower total MPA AUC 
and decreased IMPDH activity despite having similar unbound MPA concentrations.
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INtroDuctIoN
Mycophenolic acid (MPA) has become a frequently used drug to prevent acute rejec-
tion in de novo kidney transplant recipients. Although this success has been largely 
accomplished with standard dose therapy, there is now increasing evidence that other 
strategies than the standard fixed dosing recommendation may further improve the 
efficacy of MPA therapy.1
Based on the large between-patient variability in pharmacokinetics and on the re-
peatedly shown relationship between MPA plasma concentrations early after transplan-
tation and incidence of acute rejection, therapeutic drug monitoring (TDM) strategies 
have been developed.2 The APOMYGRE-study showed that by using a limited sampling 
strategy to adjust the dose of mycophenolate mofetil the risk of treatment failure could 
be significantly reduced, without an increase in adverse events.3
The pharmacokinetics of MPA are characterized by an extensive binding to plasma 
albumin with a non-protein bound fraction reported to be less than 3%.4 It is the 
unbound fraction that is thought to be responsible for immunosuppressive activity.5 
One would expect that observational studies would show a better correlation between 
efficacy and non-protein bound MPA plasma concentrations compared to total MPA 
concentrations.6
MPA is believed to undergo restrictive clearance. Only the unbound MPA fraction is 
presumed to be available for elimination from the body through metabolism to the 7-O-
MPA-glucuronide metabolite (MPAG) in liver, kidney, and intestinal mucosa.7,8 Especially 
during renal insufficiency the unbound MPA fraction would increase, due to the uremic 
state and to displacement of MPA from its albumin binding sites by high concentrations 
of MPAG that is cleared by the kidneys.9,10
In patients with poor renal function, due to increased MPA clearance, total MPA 
concentrations are low, but at the same time the non-protein bound fraction is high 
(fractions up to 18.3% are reported11) and free MPA concentrations may be unaltered or 
even elevated.12,13 If one would believe in the concept that free MPA is the biologically 
active moiety, then dose increases would not be indicated and the low total MPA levels 
should be ignored.14
In order to investigate the relevance of non-protein bound MPA plasma concentra-
tions in causing the biological effect of MPA we decided to monitor MPA therapy by 
measurement of the activity of the target enzyme inosine monophosphate dehydroge-
nase (IMPDH).15 We correlated total as well as unbound MPA concentrations to IMPDH 
activity and serum albumin levels in order to evaluate the relevance of the unbound 
MPA concentration in generating the biological effect of MMF.
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MetHoDS AND PAtIeNtS
Patients
A prospective cohort of de novo kidney transplant patients (n=101) was followed for 12 
months after transplantation. At 6 days after transplantation blood samples were drawn 
for pharmacokinetics (PK) and pharmadynamics (PD). A full area under the curve (AUC, 
0-12 hr) was obtained with samples taken at pre-dose, 0.5, 1, 2, 6, and 12 hours after oral 
intake of MMF. Patients with a de novo adult kidney transplant with an uncomplicated 
post-operative recovery on the first day following transplantation and who were being 
treated with MMF were asked to participate in this study. Patients with seriously com-
promised peripheral venous vasculature (for example due to repetitive dialysis access 
surgery), complicating venous blood sampling, were not approached. The study was ap-
proved by the local ethics committee of Erasmus MC, Rotterdam, The Netherlands and 
complied with the Declaration of Helsinki. All patients gave written informed consent.
Immunosuppressive therapy
All patients received triple immunosuppressive therapy, consisting of tacrolimus (FK, 
Prograf®, Astellas Pharma, Leiderdorp, The Netherlands), mycophenolate mofetil (Cell-
Cept®, Roche, Welwyn Garden City, United Kingdom) and prednisone according to the 
local protocol. Medication was started directly after the transplant surgery. Patients were 
treated with 1000 mg MMF twice a day. Dose adjustments could take place depending 
on the clinical status of the patient. Tacrolimus was dosed to achieve target trough 
levels, while the target levels decreased over time after transplantation. Prednisone was 
given once daily, started with 20 mg and was discontinued after 4 months. Patients who 
had received a kidney from a deceased donor could be considered for anti-thymocyte 
globulin (ATG) induction therapy. In total, 29 of all patients (29%) received ATG induction 
therapy.
Measurement of MPA plasma concentrations and IMPDH activity
To sample of 50μL plasma, 200 μL zinksulfate 0.1 mol/L and 500 μL acetonitril with 3 mg/
mL MPAC was added for determine the total plasma concentrations of MPA. For the de-
termination of the unbound plasma concentration of MPA, plasma was first ultrafiltrated 
using 30 KDa centrigugal filter devices (Microcon Ultracel YM-30, Millipore, Amsterdam, 
The Netherlands). To 50 μL ultrafiltrate 50 μL acetonitril with 60 mg/mL MPAC was added. 
The UPLC-MS/MS system consisted of a Waters Acquity UPLC instrument coupled to a 
Quattro Premier XE tandem-quadrupole mass spectrometer (Waters Corp., Milford, MA). 
The analytical column was an Acquity UPLC BEH C18 2.1-mm by 50-mm column with a 
1.7-μm particle size (Waters Ltd., Dublin, Ireland). The mobile phase was a gradient of 
solution A (2.0 mmol/L ammonium acetate and 0.1% formic acid in water) and solution 
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B (2.0 mmol/L ammonium acetate and 0.1% formic acid in methanol), with an initial 
composition of 25% solution B. The mobile phase composition changed linearly from 
initial 25% B to 80% B at 2.0 min and onward to 100% B at 3.0 min. The composition was 
switched back to 25% B at 4.0 min and maintained until 5.5 min. The flow rate was 0.5 
ml/min, with a column temperature of 50°C. From each sample, 5 μL was injected onto 
the column. Analytes were detected via MS with an electrospray ionization interface in 
positive multiple reaction monitoring mode. Optimized multiple reaction monitoring 
settings were for MPA: parent-daughter ion mass 338.10>206.90 m/z; cone voltage, 15.0 
V; collision energy, 22.0 eV; and for MPAC: parent-daughter ion mass 438.10>206.90 m/z; 
cone voltage, 10.0 V; collision energy, 30.0 eV. The acquisition settings were as follows: 
capillary voltage, 3.0 kV; source temperature, 130°C; desolvation temperature, 300°C; 
desolvation gas flow, 600 L/h; cone gas flow, 1 L/h; and dwell time, 50 ms. The coefficient 
of variation of the inter- and intraday precision of the used method was less than 5% and 
3% respectively for the total plasma MPA (range 0.1 – 50 mg/L). For the unbound plasma 
concentration these values were less than 13% and 7% (range 0.001 – 1.0 mg/L). 
The procedure for determination of the IMPDH activity in PBMC has been described 
in detail elsewhere.16 Enzyme activity was expressed as produced xanthosine mono-
phosphate (XMP) (μmol) per time unit (s) per present adenosine monophosphate (AMP) 
(mol) for normalizing the activity to the destructed cells. AMP and XMP concentrations 
were validated in the range from 0.75 to 50.0 µmol/L. The precision of the IMPDH activity 
assay was 6.6 to 11.9% and the coefficient of variation ranged from 0.6 to 3.4%. 
Data analyses
A linear trapezoidal model was used to calculate the area under the concentration – 
time curve of MPA (MPA AUC) and the effect – time curve of IMPDH activity (IMPDHact 
AUC). Data was only used from patients that had complete AUC curves, containing at 
least 6 samples.
The relation between IMPDH activity and MPA plasma concentrations was evalu-
ated using an inhibitory Emax-model according to the following equation:
 



+
−•= CIC
EEE
500
1  
where E0 is the baseline IMPDH activity with no MPA present, C is the concentration of 
MPA and IC50 is the concentration of MPA where 50% of the maximal inhibition of IMPDH 
activity is measured. Emax presents the maximal decrease in IMPDH activity and was set 
equal to E0.
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Statistical analysis
All statistical tests were performed using SPSS software version 16.0 (SPSS, Chicago, 
IL) and a P-value < 0.05 was considered significant. Correlations coefficients between 
normally distributed data were analyzed with by Pearson’s correlation, non-normally 
distributed data by Spearman’s rang. All normally distributed data were analyzed by 
an independed-samples t test and non-normally distributed data by a Mann-Whitney 
U test. A one-way ANOVA test was used to analyze data with more than two variables. 
Values are reported as mean ± standard deviation, unless otherwise stated.
reSultS
Baseline characteristics
From April 2006 to September 2007, a total of 101 patients were recruited for the study. 
On day 6.1 ± 1.7 post transplantation blood samples were drawn. From 99/101 patients 
blood samples were collected for the first two hours and from 82/101 patients a full 
twelve hours AUC consisting of six blood samples was collected. Patient baseline char-
acteristics are summarized in Table 1 for the 99 patients of whom full data in the first two 
hours were available. The laboratory results and the daily dose of tacrolimus and MMF 
on the day of sampling are shown in Table 2.
table 1. Patient characteristics of included patients
characteristics n=99
Age (years) 51.2 ± 14.4
Weight (kg) 80.9 ± 18.2
Gender Male 72 (73%)
Ethnicity
 Caucasian 82 (83%)
 Black 13 (13%)
 Asian 2 (2%)
 Hispanic 2 (2%)
Donor Living / Deceased 62 / 37
Delayed graft function 30 (30%)
ATG induction therapy 29 (29%)
Patients with previous Tx 11 (11%)
Diabetes Melitus present pre-Tx 14 (14%)
HLA – mismatch 0 / 1-3 / 4-6 6 / 50 / 43
PRA 0 / 1-10 / 11-50 / 50-100 / N.A. (%) 64 / 12 / 4 / 5 / 14
BPAR / presumed AR / primary non-function 23 / 4 / 5
ATG, anti-thymocyte globulin; (BP)AR, (biopsy proven) acute rejection; HLA, human leukocyte antigen; N.A., not available; PRA, panel-reactive 
antibodies; Tx, transplantation.
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IMPDH activity and MPA levels
Figure 1 shows the IMPDH activity time profiles of total MPA (A) and unbound MPA (B) 
on day 6. IMPDH activity decreased after MMF intake and reached its nadir after 2 hours. 
After this a full recovery of the activity to pre-dose levels was established. Both MPA 
curves reach a maximal concentration 1 hour post-dose.
MPA plasma concentrations and pharmacodynamic parameters of the patients are 
summarized in Table 3.
A significant correlation was found between total and unbound pre-dose MPA con-
centrations and IMPDH activity pre-dose (Figures 2A and 2B respectively). Though the 
correlations are significant, the correlation coefficients are poor (r = 0.33; P < 0.001 and 
r = 0.20; P < 0.001 for total and unbound MPA respectively). The calculated E0 was 47.2 
μmol/s/mol AMP (95% CI: 29.2 – 65.3 μmol/s/mol AMP) using the total MPA concentra-
table 2. Laboratory results and immunosuppressive treatment on day of sampling
clinical laboratory n=99
Albumin (g/L) 34.0 ± 4.0
Urea (mmol/L) 19.5 ± 10.8
Creatinine (μmol/L)
 median (range)
338 ± 281
213 (61 – 1190)
Creatinine clearance1 (mL/min)
 median (range)
33.2 ± 25.2
28.0 (4.1 – 122.0)
Hemoglobine (mmol/L) 6.3 ± 1.0
Trombocytes (·109/L) 195.4 ± 74.1
Leukocytes (·109/L) 9.0 ± 4.6
Tacrolimus daily dose (mg) 10.8 ± 3.7
Tacrolimus trough level (μg/L) 12.5 ± 6.7
MMF daily dose (mg) 1970 ± 224
1 Estimated using 4-variable MDRD equation.
table 3. Pharmacokinetic en pharmacodynamic parameters of MPA on day 6 after transplantation
Parameter t=0h (n=99) t=2h (n=99)
Total MPA (mg/L) 1.86 (0.233-10.6) 4.02 (0.769-16.8)
Unbound MPA (mg/L) 0.039 (0.002-0.846) 0.098 (0.003-1.32)
IMPDH activity (µmuol/s/mol AMP) 19.7 (7.2-119.3) 13.0 (2.2 – 57.5)
       0-12h (n=82)
Total MPA AUC (h·mg/L) 34.0 (8.93-127)
Unbound MPA AUC (h·mg/L) 1.88 (0.038-9.09)
Free fraction MPA (%) 7.0 (0.25-24)
IMPDHact AUC (h·µmol/s/mol AMP) 226 (58-868)
Values are presented as median (range).
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tion and 32.3 μmol/s/mol AMP (95% CI: 25.7 – 38.8 μmol/s/mol AMP) using the unbound 
MPA concentration. The IC50 was calculated at 2.6 mg/L (95% CI: 0 – 5.4 mg/L) and 0.7 
mg/L (95% CI: 0 – 1.7 mg/L) for total and unbound MPA concentrations respectively.
Figures 2C and 2D show the correlation between the AUC0-12 of total and unbound 
MPA and IMPDH activity pre-dose. Both correlations are significant, but MPA AUC is not 
better correlated compared to MPA trough levels (r = 0.20; P < 0.001 and r = 0.22, P 
< 0.001 respectively). The calculated E0 was 41.6 μmol/s/mol AMP (95% CI: 18.0 – 65.2 
μmol/s/mol AMP) for the total MPA concentration and 36.7 μmol/s/mol AMP (95% CI: 
27.0 – 46.5 μmol/s/mol AMP) for the unbound MPA concentration. The IC50 was calcu-
lated at 75 h·mg/L (95% CI: 0 – 215 mg/L) and 7 h·mg/L (95% CI: 0 – 15 mg/L) for total 
and unbound MPA concentrations respectively. No significant correlations were found 
between total or unbound MPA AUC and IMPDH activity AUC (data not shown).
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Figure 1. IMPDH activity (square) on day 6 as a function of time after oral MMF intake (A and B). The total MPA plasma concentration (circle) 
is shown in plot A and the unbound MPA plasma concentration (triangle) is shown in plot B. Values are means; the error bars reflect the standard 
deviations of the means.
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The presumed therapeutic window for the exposure to total MPA (total MPA AUC) is 
set at 30 to 60 h·mg/L.17,18. Figure 3 shows the exposure to IMPDH activity (IMPDHact AUC) 
for patients with a total MPA AUC below 30, between 30 and 60 and above 60 h·mg/L. 
In this cohort, on day 6 post-transplant 31 patients (40%) had a total MPA AUC below 
the lower threshold of the therapeutic window and 9 patients (12%) had a total MPA 
AUC above 60 h·mg/L. There was no significant difference in the IMPDHact AUC between 
the three groups (P = 0.76). For unbound MPA we have also divided the patients into 
three groups and correlated the unbound MPA AUC to IMPDHact AUC. The lower limit 
for unbound MPA AUC was set at 2.1 h·mg/L and the upper limit at 4.2 h·mg/L. These 
limits of unbound MPA AUC were calculated by multiplying the limits of the total MPA 
AUC with the median unbound fraction in this cohort (7.0%). For unbound MPA AUC, 
41 patients (53%) were below the lower threshold and 17 patients (22%) above the up-
per threshold. In contrast to the data shown for total MPA AUC there was a significant 
difference in the IMPDHact AUC for the three unbound MPA AUC groups (P = 0.038). The 
difference in IMPDHact AUC between patient below and patients above the therapeutic 
window defined for the unbound MPA AUC was also significantly (P = 0.025).
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Figure 2. A and B show the IMPDH activity pre-dose correlated to the corresponding total and unbound MPA concentration respectively. While 
both correlations are significant, the correlation coefficients were poor (r = 0.33; P < 0.001 and r = 0.20; P < 0.001 for total and unbound MPA 
concentrations respectively). The IMPDH activity pre-dose versus the AUC of total and unbound MPA over 12 hours are shown in plot C and D (r 
= 0.20; P < 0.001 and r = 0.23; P < 0.001 for total and unbound MPA AUC respectively). The correlation coefficient for total MPA AUC was lower 
compared to the MPA trough level, and a slightly higher correlation coefficient was found for the unbound MPA.
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Influence of serum albumin on unbound MPA concentration and on IMPDH activity
Because MPA is highly bound to serum albumin, patients with low serum albumin levels 
may have higher unbound MPA concentrations and more inhibition of IMPDH activity5 
Figure 4 shows that patients with albumin levels below 32 g/L have lower total MPA 
concentrations (P = 0.011), but unbound MPA concentrations are not different (P = 
0.34). Figure 5 shows the pre-dose IMPDH activity for patients with a serum albumin 
concentration below 32 g/L or a serum albumin equal and above 32 g/L. IMPDH activity 
is significantly lower in patients with low serum albumin compared to patients with high 
serum albumin (20.4 ± 16.3 vs. 30.6 ± 25.0 μmol/s/mol AMP; P = 0.030).
DIScuSSIoN
For more than a decade MMF is used to prevent acute rejection after solid organ trans-
plantation. Despite extensive clinical experience with this drug there is uncertainty 
about the importance of the non-protein bound MPA concentration. Theoretically, and 
in line with other drugs, the unbound fraction of MPA would be responsible for the im-
munosuppressive activity.
The inhibitory effect of unbound MPA on IMPDH activity was investigated in vitro,19 
but there have been no reports on the relevance of the unbound MPA concentration on 
IMPDH inhibition in vivo in renal transplant patients using MMF. We here present the first 
prospective pharmacodynamic study in 99 renal transplant recipients correlating the in 
vivo inhibition of IMPDH to both total and unbound MPA concentrations.
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Figure 3. The distribution of the exposure to IMPDH activity (IMPDHact AUC) for patients below, within or above the therapeutic window of 
total (circles) or unbound (squares) MPA AUC0-12. There was no significant difference between the total MPA AUC groups for IMPDHact AUC (P 
= 0.76), but a significant difference in IMPDHact AUC was found for the unbound MPA AUC (P = 0.038). The difference in IMPDHact AUC between 
patients below and above the therapeutic window for unbound MPA was also significant (P = 0.025). The figures below the plots represent the 
number of patients. The lines are geometric means; the error bars reflect the 95% confidence interval of the geometric mean.
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We confirm the inverse relationship between IMPDH activity and MPA plasma levels, with 
maximal inhibition of the IMPDH activity almost coinciding with the MPA peak levels.20 
The changes in IMPDH activity follow the pharmacodynamics of total and unbound MPA 
concentrations closely, and there is a striking recovery of IMPDH activity to pre-dose 
levels over the 12 hour dosing interval.
To investigate the pharmacodynamic – pharmacokinetic relationship of IMPDH, 
we used an inhibitory Emax-model. Previously Glander et al have shown a 10-fold inter-
patient variability in IMPDH activity and a relatively small intra-individual variability 
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Figure 4. Patients with a serum albumin below 32 g/L had significantly lower total MPA AUC (circles) compared to patients with a serum 
albumin level equal and above 32 g/L (P = 0.011). A difference between patients with albumin levels below or equal and above 32 g/L was 
not found for unbound MPA AUC (squares; P = 0.34). The lines are geometric means; the error bars reflect the 95% confidence interval of the 
geometric mean.
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Figure 5. Patients with a low serum albumin (<32 g/L) have a significantly lower IMPDH activity compared to patients with a serum albumin 
level of 32 g/L or higher (P = 0.030).
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of 14% over a one month interval.19,21 In this study the large inter-patient variability is 
confirmed; patients with equal MPA AUC showed different IMPDH activities, as displayed 
in figure 2. For example, a total MPA concentration of 1.48 mg/L resulted in one patient 
in an IMPDH activity of 8.15 µmol/s/mol AMP, but another patient who had a total MPA 
concentration of 1.43 mg/L showed an IMPDH activity of 119.3 µmol/s/mol AMP, almost 
15-fold higher IMPDH activity with comparable MPA concentrations. Although there 
were significant correlations between the IMPDH activity and the total and unbound 
MPA concentration and exposure, the correlations were weak (ranged from 0.20 to 0.33). 
Langman et al showed in in vitro tests an IC50 for total MPA of 2.0-5.0 mg/L and 0.5-
1.0 mg/L for unbound MPA.22 The IC50 calculated in this study were 2.64 mg/L for total 
MPA concentration and 0.73 mg/L for the unbound MPA concentration, but with large 
confidence intervals. Nevertheless, the calculated IC50 values corresponded to earlier 
finding. Values of E0 could not be compared to previously reported values, as there are 
no known publications reporting E0 values using the same IMPDH activity assay. Using 
an Emax model, the calculated 95% confidence interval values of E0 were largely ranged 
between 18.0 and 65.3 µmol/s/mol AMP.
Considering the wide range in the 95% confidence intervals of the estimated 
pharmacodynamic values, it is reasonable these analyses were unable to describe the 
pooled data of the whole cohort in a correct way. Given the large inter-patient variabil-
ity, a separate estimation for the individual pharmadynamic parameters could improve 
the estimation of these population parameters. A possible reason could be the large 
inter-patient variability in the concentration – effect relation. Introducing more patient 
characteristics in the pharmacokinetic-pharmacodynamic model could improve the 
explanation of the variability in IMPDH activity under MMF therapy. Some factors which 
partly explaining the inter-patient variability in pharmacokinetics of MMF could also be 
used to explain the inter-patient variability in IMPDH activity. It is likely different races 
difference in IMPDH gene polymorphisms and expression of the IMPDH enzyme. It also 
could be that co-morbidity influences the IMPDH activity in the same way. Time after 
transplantation could have any influence on the sensitivity or recovery of the inhibition 
of MPA on IMPDH, and perhaps co-medication has an inhibitory or inductive influence 
on the activity of IMPDH. It is not entirely unreasonable to expect that these factors 
affect IMPDH enzymes and IMPDH activity. Presumable, also other factors affect the 
individual pharmacodynamic of IMPDH. This could be pre-transplant IMPDH activity; 
hence the higher IMPDH has to be inhibited after transplantation. Glander et al have 
also shown a correlation between pre-transplant IMPDH activity and clinical outcome 
after transplantation.21 Genetic polymorphisms in the IMPDH genes could directly or 
indirectly influence the stability or functionality of the IMPDH enzymes. Alterations in 
leukocytes differentiation could give a different distribution of the cells and thereby the 
number and type of IMPDH enzymes. The mentioned factors are only suggestions; it is 
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also possible that other factors and patient characteristics have any influence on the 
IMPDH activity.
Based on a number of observational studies the presumed therapeutic window for total 
MPA AUC was set at 30 to 60 h·mg/L.17,18 The upper and lower limit of the therapeutic 
window for unbound MPA AUC are unknown. To compare the effects of total and un-
bound MPA exposure on IMPDH activity, we defined an arbitrary window for unbound 
MPA AUC by multiplying the window of 30 to 60 h·mg/L of total MPA with the median 
of the unbound fraction of MPA (7%). As shown in Figure 3, a significant difference in 
IMPDH activity for the three groups was found for unbound MPA, but not for total MPA. 
We also found that patients with a low serum albumin level had a significantly lower 
IMPDH activity compared to patients with a normal serum albumin. In this study we 
used the cut-off value for albumin levels of 32 g/L that was previously reported to be 
clinically relevant.12 Surprisingly however, despite the lower IMPDH activity in patients 
with a low serum albumin we did not find high unbound MPA concentrations in these 
patients. It remains unclear how the stronger inhibition of IMPDH activity in patients 
with low albumin levels is explained. Possibly patients with low albumin levels are 
in a poor general clinical condition and perhaps this poor condition induces a state 
of reduced immunoreactivity that is reflected in reduced IMPDH activity. It would be 
interesting to study the IMPDH activity in transplant patients not treated with MPA and 
see if IMPDH activity is a reflection of immune status. The lower total MPA AUC values in 
patients with a low albumin are not surprising. Our group has previously described that 
low plasma albumin levels are associated with decreased total MPA AUC.23 A population 
pharmacokinetic study found that decreased albumin levels have a minimal to no effect 
on the unbound MPA AUC, while a significantly increased unbound fraction was seen.24 
The concept is that in patients with low albumin levels the unbound MPA will imme-
diately be cleared by metabolism in the lever or may be transferred into intra-cellular 
compartments. Due to the increased clearance the bound MPA concentrations decrease 
and the unbound MPA concentrations do not alter which results in decrease total MPA.
We conclude that compared to patients with a normal albumin level, patients with 
decreased albumin levels have lower total MPA AUC and decreased IMPDH activity 
despite having similar unbound MPA concentrations. For clinical practice we would 
recommend that patients with low albumin levels in whom low total MPA AUC values 
are found, no MMF dose increments are performed, as in those patients IMPDH activity 
is already at a low level. Measurement of unbound MPA concentrations is not likely to 
further contribute to patient management, as we show that in patients with low albumin 
levels the unbound concentrations are not significantly increased.
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AbStrAct
Objectives
The active metabolite of mycophenolate mofetil (MMF), mycophenolic acid, inhibits the 
activity of the target enzyme inosine monophosphate dehydrogenese (IMPDH). The aim 
of this study was to correlate eight different single nucleotide polymorphisms of the 
IMPDH type II gene to the activity of the IMPDH enzyme to explain between-patient 
differences in IMPDH activity.
Methods and results
In a prospective study we measured IMPDH activity, mycophenolic acid plasma con-
centrations and eight polymorphisms of IMPDH type II in de novo kidney transplant 
recipients, 6 days post-transplantation while on MMF treatment. Polymorphisms in the 
IMPDH type II gene were only observed for the IMPDH type II 3757T>C (rs11706052) single 
nucleotide polymorphism. Ten of 101 patients (10%) were heterozygous and two of 101 
patients (2%) homozygous for IMPDH type II 3757T>C. The allele frequency was 6.9%. 
The IMPDH activity over 12 hours (AUCact) was 49% higher for patients with an IMPDH 
type II 3757C variant [n=12 vs. n=68; 336 (95% confidence interval: 216 – 512) vs. 227 
(95% confidence interval: 198 – 260) hμmol/s/mol adenosine monophosphate; P=0.04]. 
The IMPDH activity measured before transplantation (Actpre-Tx) was not significantly dif-
ferent between IMPDH type II 3757TT wild type and variant carrier patients (p=0.99).
Conclusion
We report that the IMPDH type II 3757T>C polymorphism is associated with an increased 
IMPDH activity in MMF-treated renal transplant patients. This polymorphism explains 
8.0% of the interpatient variability in IMPDH activity.
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INtroDuctIoN
Mycophenolate mofetil (MMF), mostly combined with calcineurin inhibitors and 
corticosteroids, is the most frequently used immunosuppressive drug in newly trans-
planted kidney recipients.1 The official dose recommendation for patients after kidney 
transplantation is 1000 mg MMF twice daily (b.i.d.). Although MMF has been on the 
market for more than 10 years and is mostly used as a fixed dose drug, there is ongoing 
debate whether or not fixed-dose therapy is the optimal strategy to treat patients.2 One 
possibility to individualize therapy would be to adjust the MMF dose based on plasma 
concentrations of mycophenolic acid (MPA), the active metabolite of MMF. The interindi-
vidual variability in exposure to MPA, and the correlations between drug concentrations 
and outcome are strong arguments in favor of MPA monitoring.3 A recently published 
randomized trial showed that concentration-controlled renal transplant patients indeed 
had lower rates of acute rejection compared to patients on fixed-dose MMF therapy.4
Another possibility would be to monitor the pharmacodynamic effect of MPA, by 
measuring the activity of the target enzyme inosine monophosphate dehydrogenase 
(IMPDH).5 The advantage of using pharmacodynamic measures is that, in contrast to 
drug concentrations, they do take into account inter-individual differences in suscepti-
bility for the drug.6,7 IMPDH is the key enzyme in the de-novo synthesis of nucleotides 
and induces the rate-limiting step in this synthesis.8 The proliferation of lymphocytes 
depends on the synthesis of nucleotides by IMPDH, while other types of cells have a 
salvage pathway for the synthesis of nucleotides. This makes MPA a drug that specifi-
cally inhibits the proliferation of the lymphocytes. MPA is a noncompetitive inhibitor of 
IMPDH and it will react on the MPA/nicotinamide adenine dinucleotide (NAD)-binding 
pocket.9
Two isoforms of IMPDH exist, derived from different genes.10 In mature resting lym-
phocytes, IMDPH type I is the dominant species. In activated lymphocytes IMPDH type 
II predominates over type I. This difference in expression suggests different regulatory 
mechanisms for IMPDH type I and type II.8,11,12 The selective inhibition of IMPDH type II is 
thought to explain the relatively mild side effects of MMF in clinical trials.13,14
Human IMPDH type I and type II cDNAs encode the same size proteins of 514 
amino acids with 84% sequence identity. Both isoforms show similar affinities for the 
substrates, with Km values for NAD and inosine 5′-monophosphate (IMP) and Ki values for 
the reduced form of NAD (NADH) and xanthosine monophosphate (XMP) that are also 
similar.14,15 MPA was found to inhibit both IMPDH isoforms by the same mechanism.12 
However, IMPDH type II (Ki = 9.5 nmol/l) was 3.9-fold more sensitive to MPA than the 
type I isoform (Ki = 37 nmol/l).
14
Assays of IMPDH activity have produced conflicting results.5 Assays using whole 
blood typically showed increasing IMPDH activity and increased guanosine triphos-
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phate (GTP) levels under prolonged MMF therapy.16,17 The target cells for MMF therapy 
are in the white blood cell compartment, and not in erythrocytes. Therefore, measuring 
IMPDH activity in isolated peripheral blood mononuclear cells (PBMCs) seems more ap-
propriate.12,18,19 This is enforced by data showing that MMF causes a significant reduction 
in GTP in PBMCs, with a paradoxical simultaneous elevation of GTP in erythrocytes.16,20 
Another potentially useful approach would be to measure IMPDH activity in the CD4+ 
cell population.21,22
Glander et al23 have used a validated high-performance liquid chromatography 
(HPLC) method that measures the rate of XMP production by PBMCs under controlled 
in-vitro conditions. With this assay, the combined IMPDH activity of type I and II is 
measured. After oral administration of MMF, IMPDH activity is decreased by 65–100 %, 
persisting for 4–8 h, and returned to the level of activity before the intake of MMF after 
12 h.24 They also showed that equimolar doses of MMF and enteric-coated mycophe-
nolate sodium resulted in similar inhibition of IMPDH activity.25 In a preliminary study 
using this pharmacodynamic assay, correlations between preoperative IMPDH results 
and posttransplantation outcome were shown.26
All studies have found considerable interpatient variability in IMPDH activity, with 
relatively small intraindividual variability. This has generated speculations that single-
nucleotide polymorphisms (SNPs) in the gene encoding for IMPDH could explain part of 
the variability in IMPDH activity. Potentially, such pharmacogenetic variability could be 
linked to the occurrence of adverse drug events or to reduced efficacy, and transplant 
patients would then benefit from individualization of immunosuppression, guided by 
pharmacogenetic data.27 Several studies have shown pathogenicity correlated with poly-
morphisms of the IMPDH type I gene in patients with retinitis pigmentosa.28-31 One study 
conducted in renal transplant patients proved an association between two IMPDH type I 
SNPs and acute rejection.32 The IMPDH type II 787C>T polymorphism reduces the IMPDH 
activity in variant carrier group to 10% of the wild type, but had an allele frequency of 
only 1.0%.33 In this study, we correlate, for the first time, eight currently known IMPDH 
type II SNPs directly to IMPDH activity pre transplantation and posttransplantation with 
the aim to explain the between-patient differences in IMPDH activity.
MetHoDS AND PAtIeNtS
Patients
For the purpose of this study in a prospective cohort of kidney transplant patients, we 
performed an MPA pharmacokinetic assessment 6 days after transplantation. From April 
2006 to September 2007, a total of 101 patients were recruited for this study. All patients 
were transplanted in Erasmus University Medical Center, Rotterdam, The Netherlands. 
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All samples obtained were measured for IMPDH activity at the laboratory of the Depart-
ment of Hospital Pharmacy and genotyped at the Pharmacogenetics laboratory of the 
Department of Clinical Chemistry, both in Erasmus MC. A full area under the curve (AUC, 
0-12 h) was obtained, with samples taken at predose, 0.5, 1, 2, 6, and 12 h after oral 
intake of MMF. The pharmacodynamic effect of MPA was assessed on the same day and 
at the same sample times by measuring the IMPDH activity. Patients with a de novo adult 
kidney transplant with an uncomplicated postoperative recovery on the first day after 
transplantation and who were being treated with MMF were informed to participate in 
this study. Patients with seriously compromised peripheral venous vasculature (e.g. be-
cause of repetitive dialysis access surgery), complicating venous blood sampling, were 
not approached. The study was approved by the Local Ethics Committee of Erasmus MC, 
Rotterdam, The Netherlands, and complied with the Declaration of Helsinki. All patients 
gave written informed consent.
Immunosuppressive therapy
All patients received triple immunosuppressive therapy, consisting of tacrolimus (FK, 
Prograf, Astellas, Leiderdorp, The Netherlands), mycophenolate mofetil (MMF, CellCept, 
Roche, Woerden, The Netherlands) and prednisone. Medication was started directly 
after the transplant surgery. All patients were treated with 1000 mg MMF b.i.d., except 
two patients in the wild type group who received 500 mg MMF b.i.d. at the time of sam-
pling. Doses and trough levels of tacrolimus are listed in Table 1. All patients received a 
fixed dose prednisone of 20 mg once daily. In 23 patients, anti-thymocyte globulin (ATG) 
induction therapy was given (Table 1).
Measurement of mycophenolic acid plasma concentrations
For the purpose of this study, the active compound MPA was measured with a validated 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.34 The LC-MS/
MS system consisted of a Waters Acquity Ultra Performance LC coupled to a Quattro 
Premier XE tandem quadrupole mass spectrometer. Data were acquired using Masslynx 
V4.1 and processed using Quanlynx V4.1 software (Waters Inc., Etten-Leur, The Nether-
lands). The analytical column was an Acquity UPLC BEH C18 2.1 x 50 mm with 1.7 μm 
particle size (Waters Inc.). Of each sample, 5 μL was injected onto the column. Detection 
was performed via MS with an ESI interface in positive MRM mode. Optimized MRM-
settings for MPA and its metabolites and carboxy butoxy ether of MPA are according 
the setting Brandhorst et al,35 reported earlier, and were optimized for our equipment. 
The coefficient of variation of the interday and intraday precision of the used method 
was less than 5 and 3% respectively. A linear trapezoidal model was used to calculate 
manually the area under the time-concentration curve of MPA (AUCMPA), for those curves 
that contains 6 points.
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Measurement of IMPDH activity
A validated nonradioactive HPLC method by Glander et al36 was used to measure the 
IMPDH activity. The rate of XMP production by IMPDH from PBMCs was measured and 
was normalized to the measured intracellular adenosine monophosphate (AMP).
In summary, PBMCs were isolated from lithium heparin-anticoagulated whole blood 
using Leucosep tubes with Ficoll-Paque (Greiner Bio-One, Alphen a/d Rijn, The Neth-
erlands) according to the manufacturer’s protocol with slight modifications. After one 
washing step, the aliquot was resuspended in 250μl ice-cold water and stored at –20°C 
to lysate. To 50μl mononuclear cells lysate 130μl reaction buffer with IMP and β-NAD+ 
was added to start the incubation of enzyme reaction. The reaction tubes were placed 
in a Thermomixer (Eppendorf Ltd., Cambridge, UK) and were incubated at 37°C and 800 
rpm for 2.5 h. The reaction was stopped by adding 20μl 4 mol/l ice-cold perchloric acid. 
After centrifugation, 10μl of 5 mol/l potassium carbonate was added to 170μl superna-
table 1. Patient baseline characteristics and demographics
characteristics
IMPDH type II 3757t>c
P valueWild type (n = 68) variant carrier (n = 12)
Age (years) 49.8 ± 14.4 53.5 ± 12.8 0.412
Weight (kg) 80.2 ± 16.2 81.5 ± 11.4 0.792
Height (cm) 174 ± 10 174 ± 6 0.902
Male sex, n (%) 50 (74%) 11 (92%) 0.173
Ethnicity, n (%)
 Caucasian 57 (84%) 11 (92%)
0.733 Black 9 (13%) 1 (8%)
 Oriental 2 (3%) 0
Donor characteristics, n (%)
 Living donor 44 (64%) 8 (67%)
0.903
 Deceased donor 25 (36%) 4 (33%)
Patients previously transplanted 7 (10%) 2 (17%) 0.523
Delayed graft function 19 (28%) 4 (33%) 0.703
ATG induction therapy 20 (29%) 3 (25%) 0.763
Mycophenolate mofetil daily dose (mg) 1971 ± 170 2000 ± 0 0.552
Tacrolimus daily dose (mg) 11.2 ± 3.4 10.4 ± 4.1 0.482
 Range (mg) 4-20 4-18
 Trough level (μg/l) 13.2 ± 6.9 12.5 ± 8.2 0.782
Albumin (g/l) 34 ± 3.6 33 ± 4.0 0.392
Creatinine clearance1 (ml/min) 31 ± 21 39 ± 30 0.412
Leukocytes (109/l) 9.0 ± 4.6 9.0 ± 5.1 0.992
Data are expressed as mean ± SD.
1 Estimated using MDRD equation; 2 t-test; 3 Pearson’s χ2 test.
ATG, antithymocyte globulin; IMPDH, inosine monophosphate dehydrogenase. 
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tant to neutralize the solution. The supernatant was transferred into HPLC injection vials 
for the determination of AMP and of produced XMP. Enzyme activity was expressed as 
produced XMP (μmol) per time unit (s) per amount of AMP (mol). The precision of the 
IMPDH activity assay was 6.6-11.9% and the coefficient of variation ranged from 0.6 to 
3.4%. A linear trapezoidal model was used to calculate manually the area under the time 
effect curve for the activity (AUCact), for those curves that contained 6 points.
IMPDH type II genotyping
For all the patients, 4 ml EDTA blood was drawn within 3 weeks after transplantation 
for analysis of polymorphisms in the IMPDH gene. Genotyping of eight different 
polymorphisms (Table 2) was performed using a TaqMan allelic discrimination assay 
(assay ID C1842928-10; Applied Biosystems, Foster City, California, USA) on an ABI Prism 
7000 sequence detection system (Applied Biosystems, Nieuwerkerk aan den IJssel, The 
Netherlands). PCR were performed in a reaction volume of 12.5 μl containing assay-
specific primers, allele-specific TaqMan MGB probes (either FAM or VIC labeled), TaqMan 
Universal PCR Master Mix No AmpErase UNG (2X), and 10 ng genomic DNA. The thermal 
profile consisted of an initial incubation at 50°C for 2 min, denaturation at 95°C for 10 
min, followed by 40 cycles of denaturation at 92°C for 15 s, and annealing and extension 
at 60°C for 1 min. Genotypes were scored by measuring allelic-specific fluorescence us-
ing the SDS 1.2.3 software for allelic discrimination (Applied Biosystems). The assay was 
validated by sequencing a wild type, a heterozygote and a homozygote variant sample. 
Wild type, heterozygote and homozygote variant quality control samples validated by 
direct sequencing were added in each run.
table 2. Genetic variants of IMPDH type II in renal transplant patients detected by bidirectional DNA se-
quencing
variant Position Flanking sequence
Amino Acid 
change
Minor allele 
frequency (%)
reference
-95T>G
Promoter /
5’UTR
CGCAGCGCAG[T/G]GACGAAATCG
192A>G Exon 3 TTAAGACCCC[A/G]CTGGTTTCCT Phe64Phe N.A. rs11557547
460T>C Exon 5 GGGGAGCCGC[T/C]TGGTGGGCAT Leu154Leu N.A. rs11557542
720C>T Exon 7 CCAAAGATGC[C/T]AAGAAACAGC Ala240Ala N.A. rs11557544
787C>T Exon 7 GCTGGACTTG[C/T]TCGCCCAGGC Leu263Phe 1.0 33
915C>G Exon 9 CCATAGTGGT[C/G]ACTGCTGCCC Val305Val N.A. rs11557546
1253A>G Exon 11 GGTTCTCTCG[A/G]TGCCATGGAC Asp418Gly N.A. rs11557540
3757T>C Intron 7 GGTGGACACA[T/C]CGTCGAGTGG
10.41
6.8
rs11706052
37
1 HapMap-CUE: European Caucasian population.
IMPDH, inosine monophosphate dehydrogenase; N.A., not available; UTR, untranslated region.
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Statistical analysis
All statistical tests were performed using SPSS software Version 16.0.1 (SPSS, Chicago, 
Illinois, USA) and a P value of less than 0.05 was considered significant. IMPDH activ-
ity data and AUCMPA were log-transformed and were reported back-transformed. Data 
was tested for normal distribution by one-sample Kolmogorov-Smirnov test. Data were 
analyzed by an independent-samples t-test (t-test; normal distributed) or by a Mann-
Whitney U test (MW-test; effect data). Related data was tested with a Wilcoxon signed-
ranks test. Categorical data and genotype and allele distribution as well as the presence 
of Hardy–Weinberg equilibrium were analyzed by a Pearson χ2 test. Values are reported 
as mean ± standard deviation or as mean (95% confidence interval), unless otherwise 
stated.
reSultS
Baseline characteristics
From April 2006 to September 2007, 177 adult patients have received a single blood 
group ABO-compatible kidney transplantation in our center; 101 patients were recruited 
for the study. Seventy-six patients were not included in the study because of (i) patient 
refusal (38), (ii) seriously compromised peripheral venous vasculature complicating 
frequent blood sampling (23), and (iii) other reasons (15). From 80 of 101 patients (79%), 
a full 12 hours curve consisting of six blood samples on day 6.0±1.3 was available for 
measurement of both MPA plasma concentrations and IMPDH activity. From the other 
21 patients, incomplete 12 h curve samples had been collected. For calculating the 
area under the effect (IMPDH activity) – time curve (AUCact) and the area under the MPA 
plasma concentration – time curve (AUCMPA) from 0 to 12 h, these patients were with-
drawn from the analyses. Polymorphisms in the IMPDH type II gene were only observed 
for the IMPDH type II 3757T>C polymorphism (Table 2). In 12 patients, at least one IMPDH 
type II 3757C allele was found: 10 of 101 patients (10%) were heterozygous and two of 
101 patients (2%) homozygous for this allele. The allele frequency of the IMPDH type II 
3757T>C for this patient group was 6.9%. The IMPDH type II 3757T>C polymorphism was 
approaching the limit of Hardy Weinberg disequilibrium (P=0.07). Patients with at least 
one IMPDH type II 3757C allele were pooled together (n=12) and compared with patients 
with the wild type SNP (n=68). Patient baseline characteristics for the 80 patients of 
whom full data (full MPA-AUC and genotype) were available are summarized in Table 
1. None of the characteristics showed significant differences between the two groups.
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IMPDH activity pre-transplantation
The IMPDH activity measured from samples taken just before the transplantation (Actpre-
Tx) showed no difference between the two groups [40.7 (95% CI: 33.0–50.1) vs. 42.8 (95% 
CI: 26.6–68.9) μmol/s/mol AMP; P=0.99, MW-test; Table 3).
IMPDH activity and MPA levels post-transplantation
Figures 1 and 2 show the IMPDH activity and the MPA levels on day 6 posttransplantation 
for the IMPDH type II 3757TT wild type and the IMPDH type II 3757C carriers, respectively. 
The IMPDH activity 12 h after MMF intake was significantly higher in the variant carrier 
group compared to the IMPDH type II 3757TT wild type group [40.8 (95% CI: 23.8–69.8) 
vs. 24.5 (95% CI: 20.8–29.0) μmol/s/mol AMP; P = 0.02, MW-test; Table 3]. The area under 
the time–effect curve for the IMPDH activity over 12 h was significantly higher in the 12 
patients with an IMPDH type II 3757C variant compared to the 68 patients with the IMPDH 
type II 3757TT wild type [336 (95% CI: 216–521) vs. 227 (95% CI: 198–260) h∙μmol/s/
mol AMP; P = 0.04, MW-test; Table 3]. The MPA exposure (AUCMPA) was not significantly 
different between these groups (P = 0.18, MW-test; Table 3). Patients with a variant SNP 
table 3. Comparisons of Act and C parameters between IMPDH type II 3757 T>C wild type and variant car-
rier groups
Parameter
IMPDH type II 3757t>c
P value3
Wild type (n = 68) variant carrier (n = 12)
Actbas(pre-Tx) (μmol/s/mol AMP)
1 40.7 (33.0–50.1) 42.8 (26.6 – 68.9) 0.99
AUCact (h∙μmol/s/mol AMP)
1 227 (198–260) 336 (216 – 521) 0.042
IMPDH activity (μmol/s/mol AMP)1
 Act0 19.8 (16.4–24.0) 26.5 (15.6–45.0) 0.31
 Act0.5 18.9 (16.0–22.4) 17.4 (10.3–29.6) 0.62
 Act1 14.3 (12.3–16.6) 15.4 (10.3–23.0) 0.67
 Act2 13.0 (11.2–15.1) 16.7 (9.1–30.5) 0.56
 Act6 16.5 (13.8–19.8) 22.0 (12.0–40.3) 0.51
 Act12 24.5 (20.8–29.0) 40.8 (23.8–69.8) 0.021
AUCMPA (h∙mg/L)
1 31.0 (27.2–35.3) 38.9 (30.2–50.2) 0.18
MPA levels (mg/L)2
 C0 2.39 ± 1.92 2.54 ± 1.30 0.22
 C0.5 3.84 ± 4.79 4.42 ± 3.49 0.32
 C1 4.94 ± 4.08 4.55 ± 3.10 0.92
 C2 4.21 ± 2.38 5.08 ± 4.27 0.80
 C6 2.14 ± 1.29 3.07 ± 1.57 0.038
 C12 2.23 ± 1.67 2.23 ± 1.19 0.62
1 Data are expressed as mean (95% confidence interval); 2 Data are expressed as mean ± SD; 3 Mann–Whitney U test.
Act, IMPDH activity; Actpre-Tx, IMPDH activity measured before transplantation; AMP, adenosine monophosphate; AUCMPA, area under the time–con-
centration curve of mycophenolic acid; C, mycophenolic acid concentration; IMPDH, inosine monophosphate dehydrogenase.
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were randomly distributed among the overall population (Fig. 3). The mean AUCMPA 
values are in close proximity in a highly variable range of MPA exposure. Excluding the 
two patients who received 500 mg MMF b.i.d. did not alter the results. Therefore, those 
two patients are included in all presented results. A bivariate correlation coefficient r 
of 0.29 (P = 0.01) was found between AUCact and the analyzed SNP. The square of the 
correlation coefficient is 0.080 (8.0%) and displays the variation in AUCact explained by 
the analyzed SNP. Restricting the patient group to only Caucasian patients resulted in a 
similar coefficient of correlation. In 68 Caucasian patients, 57 patients with the IMPDH 
type II 3757TT wild type and 11 patients with at least one C-allele were found. The AUCact 
in the IMPDH type II 3757C variant carrier group was also significantly higher compared 
to the wild type patients [347 (95% CI: 215–561) vs. 229 (95% CI: 197–266) hμmol/s/mol 
AMP; P = 0.04, MW-test].
One of the two patients who were homozygous for the variant allele had the highest 
IMPDH activity of the entire patient cohort (AUCact of 1218 hμmol/s/mol AMP; Fig. 4). The 
two patients with the IMPDH type II 3757CC homozygote variant genotype had a slightly 
higher IMPDH activity in comparison with the 10 IMPDH type II 3757TC heterozygote 
variant patients [495 and 1218 vs. 284 (95% CI: 186–435) hμmol/s/mol AMP].
The IMPDH activity expressed as AUCact is lower when the AUCMPA is higher. The 
decreasing AUCact over the three AUCMPA subgroups (< 30, 30-60 and > 60 hmg/l respec-
tively38,39) was, however, not significantly different: 264 (95% CI: 207–336) versus 227 
(95% CI: 193–268) versus 204 (95% CI: 121–345) μmol/s/mol AMP (P = 0.35, MW-test).
In 16 of the 80 of the patients (20%), a biopsy proven acute rejection (BPAR) was reported 
within 1 year after transplantation. Of these patients, 15 had a wild type IMPDH genotype 
and one was homozygous for the variant allele. This implies that 22% of the IMPDH type 
      

























Figure 1. Inosine monophosphate dehydrogenase (IMPDH) activity versus time curve. Triangles represent the IMPDH type II 3757T>C wild 
type group (n=68), and the squares the variant carrier group (n=12). The marked activity after 12 h is significantly higher in the variant carrier 
group compared with the wild type group (*P = 0.02, Mann–Whitney U test).
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II 3757TT wild type patients and 8% of the variant genotype patients had a BPAR, which 
was not significantly different (P = 0.27, MW-test). The interesting homozygous variant allele 
patient with the highest measured AUCact (1218 hμmol/s/mol AMP) was the patient suffering 
from a BPAR (Banff classification I-b) 4.5 months after transplantation. Figure 5 shows the 
IMPDH activity and MPA plasma levels over 12 h after MMF oral dosing, of all 80 patients on 
day 6 posttransplantation. An inverse relationship between IMPDH activity and MPA plasma 
levels is observed, with maximal inhibition of IMPDH activity coinciding with the MPA peak 
levels.40 The inhibition of the IMPDH activity is significantly lower up to 6 h after intake of 
MMF compared to the predose activity. The MPA plasma levels increase after MMF intake 
and are also significantly higher compared to predose until 6 h after MMF intake (Table 4).
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Figure 2. Mycophenolic acid (MPA) plasma concentration versus time curve. Triangles represent the IMPDH type II 3757T>C wild type group 
(n=68), and the squares the variant carrier group (n=12). The marked MPA concentration after 6 h is significantly higher in the variant carrier 
group compared with the wild type group (*P = 0.04, Mann–Whitney U test).
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Figure 3. Patients with a variant single nucleotide polymorphism (SNP; solid triangles) were distributed equally throughout the patients 
with a wild type SNP (open circles). The error bars present the 95% confidence interval of the area under the time-effect curve for the activity 
(AUCact) and area under the time-concentration curve of mycophenolic acid (AUCMPA) for both patient groups.
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Anti-thymocyte globulin induction therapy
Induction therapy with ATG was given to 20 of 68 patients (28%) in the IMPDH type II 
3757TT wild type and to three of 12 patients (25%) in the IMPDH type II 3757TT variant 
genotype group. The AUCact of all patients who received ATG induction therapy was not 
significantly different compared with patients who did not receive ATG [210 (95% CI: 
155–283) vs. 254 (95% CI: 220–294) hμmol/s/mol AMP; P = 0.15, MW-test]. Lymphocyte 
counts were significantly different in patients who did and did not receive ATG (0.17±0.19 
vs. 1.15±0.87 109/l; P < 0.0001, MW-test). No significant correlation between AUCact and 
lymphocytes counts was found (r = 0.34; P = 0.32).
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Figure 4. Histogram of the area under the time-effect curve for the activity (AUCact) of the inosine monophosphate dehydrogenase (IMPDH) 
activity of the IMPDH type II 3757T>C polymorphism. Gray filled bars presenting the IMPDH type II 3757TT wild type patients, dark filled bars 
IMPDH type II 3757TC variant carrier patients, and the blank filled bars IMPDH type II 3757CC variant carrier patients.
table 4. Mean values of IMPDH activity and MPA concentrations at sample time points.
time (h)
Activity
(μmol/s/mol AMP)
P value1
(compare to t = 0h)
MPA concentration
(mg/l)
P value1
(compare to t = 0h)
0 20.72 (17.39 – 24.70) 2.41 ± 1.84
0.5 18.72 (15.99 – 21.92) 0.053 3.92 ± 4.61 < 0.001
1 14.46 (12.58 – 16.61) < 0.001 4.88 ± 3.93 < 0.001
2 13.53 (11.63 – 15.74) < 0.001 4.34 ± 2.73 < 0.001
6 17.25 (14.48 – 20.56) 0.013 2.28 ± 1.37 0.88
12 26.44 (22.46 – 31.12) 0.009 2.23 ± 1.60 0.22
P values are calculated for each sample point compared to the sample point on 0 h. Data are expressed as mean (95% confidence interval) or 
mean ± SD. 
1 Wilcoxon signed-ranks test.
AMP, adenosine monophosphate; IMPDH, inosine monophosphate dehydrogenase; MPA, mycophenolic acid.
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DIScuSSIoN
We here report that the IMPDH type II 3757T>C polymorphism is associated with an 
increased IMPDH activity in MMF-treated renal transplant patients. Patients with at least 
one variant IMPDH type II 3757C allele had a mean IMPDH activity that was 48% higher 
compared with IMPDH type II 3757TT wild type patients [336 (95% CI: 216–521) vs. 227 
(95% CI: 198–260) h∙μmol/s/mol AMP, respectively]. This polymorphism explains 8.0% 
of the variation in IMPDH activity between patients. Remarkably, the patient with the 
highest IMPDH activity in this cohort of 80 patients was one of the two patients homo-
zygous for the variant C-allele. The allele frequency of this polymorphism was 6.9%. The 
IMPDH type II 3757T>C polymorphism in the IMPDH type II gene was not associated with 
IMPDH activity pretransplantation. This may be explained by the constitutive expression 
of mainly IMPDH type I in nonactivated lymphocytes, and induction of expression of 
IMPDH type II following allo-recognition. IMPDH activity in pretransplantation samples 
mainly reflects type I activity, and as a result the type II polymorphism does not lead to 
substantial change in overall IMPDH activity pretransplantation. Despite the significant 
difference in lymphocyte counts between patients who did and did not receive ATG 
induction therapy, a difference in IMPDH activity was not found. This can be explained 
by the method used to measure IMPDH activity that expresses XMP production per the 
amount of AMP present, and thus corrects for the number of cells from which IMPDH 
was isolated.
As shown in Fig. 4, and despite the statistically significant difference, there is ex-
tensive overlap between the ranges of IMPDH activity results from patients with the 
IMPDH type II 3757TT versus the IMPDH type II 3757CT/CC genotype. All IMPDH activity 
measurements were made while the patient was on MMF therapy. Though the pharma-
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Figure 5. Inosine monophosphate dehydrogenase (IMPDH activity; squares) and mycophenolic acid (MPA plasma levels; triangles) of the 
whole study population on day 6 posttransplantation. Sample points that are significantly different compared with the sample point at 0 h *P < 
0.01, Wilcoxon signed-ranks test or a †P=0.01, Wilcoxon signed-ranks test.
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cokinetics of MPA is not stabilized until several months after transplantation, all activity 
measurements have taken place at the same time (6±1.3 days post transplantation). MPA 
exposure, that is, both predose plasma concentrations as well as the AUCMPA, was not 
different between the two IMPDH type II 3757T>C genotype groups. Although the mean 
AUCMPA was 20% higher in patients with a variant allele, the mean AUCMPA in patients 
with a variant allele was not significantly different from wild type patients. Individual 
data points of patients with a variant SNP were randomly distributed among the overall 
population. In view of the inhibitory effect of MPA on IMPDH, the IMPDH activity would 
have been higher in the absence of MPA, but as all patients were on MMF therapy we 
cannot show untreated posttransplant IMPDH activities from our patients. In line with 
the aim of this study, the similarity of AUCMPA between the two groups strengthens our 
conclusion that the IMPDH type II 3757T>C polymorphism is primarily responsible for 
less inhibition of IMPDH activity with comparable MPA exposure.
We did find an inverse relationship between MPA concentrations and IMPDH activ-
ity. First, IMPDH activity was significantly higher in samples drawn pre-MMF dosing (Act0) 
compared with samples drawn at a half (Act0.5), 1 (Act1), 2 (Act2) and 6 (Act6) h postdose 
(20.72 μmol/s/mol AMP vs. 18.72, 14.46, 13.53 and 17.25 μmol/s/mol AMP, respectively). 
MPA levels were significantly higher compared to pre-MMF dosing at half (C0.5), 1 (C1) 
and 2 (C2) h postdose. We found no significant differences in IMPDH activity between 
patients with low versus high AUCMPA on day 6 after transplantation. It is remarkable that, 
despite the influence of MPA on IMDPH activity, we still found a correlation between the 
IMPDH type II 3757T>C polymorphism and IMPDH activity. Along these correlations, the 
ultimate effect on the IMPDH enzyme of this intronic polymorphism of the IMPDH type 
II gene is still not clarified. In general, intronic polymorphisms would be associated with 
the susceptibility and stability of the mRNA. The consequences are presumably a shorter 
peptide or a decreased amount of encoded protein.41,42
In this study, there was no increased incidence of BPAR in the patients with at least 
one C-allele. Given the fact that these patients have a higher IMPDH activity, one would 
expect them to be more allo-reactive and have more rejections. In the Caesar study, 
a statistically significant association between rejection incidence and the IMPDH type 
II 3757T>C polymorphism was found in a cohort of 237 genotyped patients.37 With a 
patient population of 80 patients and only 12 patients with at least one IMPDH type II 
3757C allelle, our study was underpowered to show a significant difference in rejection 
incidence in the different genotype groups. Given the low numbers of BPARs for each 
genotype, this finding cannot directly be interpolated to a clinically relevant conclusion. 
Grinyo et al37 suggested that further studies are needed to determine a possible cor-
relation between IMPDH2 type II 3757T>C polymorphism and IMPDH enzyme activity. 
In our study, we have support this correlation. The previously reported IMPDH type II 
787C>T polymorphism was not present in our patient group. The authors reported an 
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allele frequency of 1.0 %.33 This low allele frequency could explain the absence of this 
polymorphism and its association with a lower IMPDH activity in our patient population 
of 80 patients. All performed tests were univariate tests. A multivariate test would be 
superior, but with the small sample size of 12 patients with at least IMPDH type II 3757C 
allelle the results were underpowered.
The main finding of this study is that between-patient variability in IMPDH activity 
measured in blood samples drawn from renal transplant patients treated with MMF is ex-
plained for 8.0% by the IMPDH type II 3757T>C polymorphism. This effect of genotype on 
posttransplantation phenotype cannot be identified before transplantation by measur-
ing IMPDH activity, because of the differences in expression of IMPDH type I and type II.
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Chapter 4.2
IMPDH mRNA expression is correlated 
to clinical outcomes in MMF 
treated kidney transplant patients 
whereas IMPDH activity is not
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AbStrAct
Measurement of the pharmacodynamic biomarker inosine monophosphate dehydro-
genase (IMPDH) activity in renal transplant recipients has been proposed to reflect the 
biological effect better than using pharmacokinetic parameters to monitor mycopheno-
late mofetil therapy. The IMPDH assays are however labor intensive and this complicates 
implementation into patient care. Quantification of IMPDH messenger RNA (mRNA) 
could form an attractive alternative. This study was designed to correlate IMPDH mRNA 
levels with IMPDH activity and clinical outcome in renal transplant recipients.
From a cohort of 101 renal transplant patients, blood samples were drawn pre trans-
plantation and at 4 times after transplantation. IMPDH activity, IMPDH type I and type II 
mRNA levels, and mycophenolic acid concentrations were measured and correlated to 
clinical outcomes.
No correlation was found between IMPDH type I and type II mRNA levels and IMPDH 
activity in pre- and posttransplant samples. A significant increase in IMPDH mRNA levels 
was found between day 6 and day 140 after transplantation. IMPDH type I and type II 
mRNA levels before transplant showed a trend towards statistical significantly higher 
levels in patients with an acute rejection (P = 0.052 and P = 0.058). After transplant, the 
IMPDH type I and type II mRNA levels were significantly lower in patients with an acute 
rejection (P = 0.026 and P = 0.007).
We conclude that IMPDH mRNA levels do not correlate with IMPDH activity but are 
nevertheless correlated with acute rejections. Furthermore, although the regulation of 
the expression of the 2 isoforms is presumed to be different, in this study, the changes in 
the expression of type I mRNA closely paralleled those of type II.
125
IM
PD
H
 m
RN
A
 c
or
re
la
te
d 
to
 c
lin
ic
al
 o
ut
co
m
e
Ch
ap
te
r 4
.2
INtroDuctIoN
Inosine monophosphate dehydrogenase (IMPDH) is the rate-limiting enzyme in the de 
novo synthesis of guanine nucleotides. It catalyzes the conversion of inosine monophos-
phate to xanthosine monophosphate (XMP) at the purine metabolic branch point. There 
are 2 isoforms of IMPDH, type I and type II, and each consists of 514 amino acids with 
84% sequence identity.1 Type I and type II are encoded by 2 distinct genes, located at 2 
different chromosomes.2,3 IMPDH type I is constitutively present in the majority of cells, 
including resting lymphocytes.4,5 Proliferation of cells is related to upregulation of the 
type II isoform, whereas lymphocyte activation under normal physiological conditions 
is associated with increased expression of both isoforms. The regulation of expression 
of the 2 IMPDH genes differs according to the 2 isoforms. IMPDH type I messenger RNA 
(mRNA) is expressed in a complex manner with 3 transcripts arising from 3 alternate 
promoters.6,7 The IMPDH type II gene is strongly upregulated at the transcriptional level 
by a promoter region that responds directly to growth stimuli.8-10 The gene expression 
of the 2 IMPDH isoforms has a negative feedback regulation by intra- and extracellular 
guanine nucleotides.11-13 The increased expression of IMPDH genes leads to increased 
IMPDH activity,14,15 and an increased IMPDH activity has been correlated with an in-
creased cellular proliferation and transformation.16,17
Inhibition of IMPDH leads to depletion of guanine nucleotide pools and retards 
the proliferation of T en B lymphocytes, which are dependent on this de novo syn-
thesis pathway of the nucleotides.18 Mycophenolic acid (MPA), the active metabolite 
of mycophenolate mofetil (MMF), is a clinically used inhibitor of IMPDH as part of im-
munosuppressive therapy after solid organ transplantation and hematopoietic stem 
cell transplantation and varied autoimmune diseases. MPA is a 3.9-fold more potent 
inhibitor of IMPDH type II compared to IMPDH type I.19 The activity of IMPDH shows 
a large inter-patient variability.20 The sensitivity for MPA to inhibit IMPDH also differs 
between individuals, even when MPA levels are equal. Pharmacokinetic (PK) monitoring 
of MPA concentrations does not take this interpatient variability into account, whereas 
the pharmacodynamic (PD) approach (ie, measurement of IMPDH activity) does. For 
this reason, a number of different IMPDH activity assays have been developed, each 
having its own advantages and disadvantages.21,22 The major disadvantage of all IMPDH 
assays is the time-consuming and labor-intensive procedure. An alternative method to 
monitoring the IMPDH activity could be the measurement of IMPDH mRNA using a rela-
tively easy-to-use quantitative real-time polymerase chain reaction (RT-PCR) method.23 
Preferably, for the use of IMPDH mRNA as a biomarker for the IMPDH activity and MPA 
treatment, IMPDH mRNA must be correlated with the IMPDH activity.
Recent studies have evaluated the expression of the IMPDH type I and type II gene 
after kidney transplantation. Transplantation and the initiation of immunosuppressive 
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therapy were associated in peripheral blood mononuclear cells (PBMCs) with a signifi-
cantly increased IMPDH type I mRNA expression of 50%–88% and with a significantly 
decreased IMPDH type II mRNA expression of 42%–56% within 2 weeks after transplan-
tation. In CD4+ T cells, however, IMPDH type II increased significantly by 15%.24 It has 
been demonstrated in in vitro experiments that IMPDH type II mRNA is correlated with 
the IMPDH activity in transplanted tissue.25 Patients suffering from acute rejection 
during follow-up demonstrated significantly higher IMPDH type II mRNA expression 
in CD4+ T cells pre transplant than nonrejectors.24 The authors concluded that IMPDH 
type II mRNA expression could be an indicator of immune activation.24 Another study 
showed a 2- to 3-fold elevation of IMPDH type I mRNA during the first 3 months follow-
ing transplantation.25 IMPDH type I mRNA expression reached its maximal level during 
acute rejection episodes, whereas IMPDH type II mRNA was stable in PBMCs. A 20-fold 
increase of IMPDH type I mRNA was observed in the 2 patients who experienced acute 
rejection. In vitro experiments confirmed that IMPDH type I is inducible but more in 
monocytes than in lymphocytes. This finding suggests that the measurement of IMPDH 
mRNAs may provide reliable information to predict acute rejection.25
The aim of this prospective longitudinal study was to correlate IMPDH type I and 
type II mRNA levels to MPA concentrations, IMPDH activity, and clinical outcomes after 
kidney transplantation. Potentially, IMPDH mRNA levels could be an interesting bio-
marker to monitor and optimize MMF treatment after kidney transplantation.
PAtIeNtS AND MetHoDS
Patients
A prospective cohort of de novo kidney transplant patients (n = 101) was longitudinally 
followed for 12 months after transplantation. Before transplantation and on day 6, 21, 49 
and 140 after transplantation, blood samples were drawn for PK (MPA concentrations) 
and PD (IMPDH activity) monitoring to follow IMPDH activity over time. A full area under 
the curve (AUC, 0-12 hours) was obtained on day 6, when samples were taken pre dose, 
0.5, 1, 2, 6, and 12 hours after oral intake of MMF. An abbreviated AUC was taken on 
the second (day 21), third (day 49) and fourth (day 140) visit, when samples were taken 
pre-dose, 0.5 and 2 hours after oral intake of MMF. At all visits, a sample was drawn pre 
dose for determination of IMPDH mRNA levels. Patients were included into the study 
from April 2006 to September 2007. Due to logistic problems with the mRNA samples, 
no post-transplant mRNA data were available from the period of April 2006 to August 
2006. Adult patients receiving a kidney transplant with an uncomplicated postoperative 
recovery in the first days after transplantation and who were being treated with MMF 
were informed to participate in this study. Patients with seriously compromised periph-
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eral venous vasculature, complicating venous blood sampling, were not approached. 
The study was approved by the local Ethics Committee of Erasmus University Medical 
Center, Rotterdam, The Netherlands, and complied with the Declaration of Helsinki. All 
patients gave written informed consent.
Immunosuppressive therapy
All patients received triple-drug immunosuppressive therapy, consisting of tacrolimus 
(FK, Prograf; Astellas Pharma, Leiderdorp, The Netherlands), mycophenolate mofetil 
(MMF, CellCept; Roche, Welwyn Garden City, United Kingdom) and prednisone according 
to protocol. Therapy was started directly after transplant surgery. Patients were treated 
with MMF twice a day, starting with 2000 mg daily. Dose adjustments were performed 
depending on the clinical status of the patient and at physician’s own discretion. MPA 
plasma concentrations were available but were not used for MMF dose adjustment. Ta-
crolimus was dosed on trough levels, although the trough target levels decreased over 
time after transplantation (first month after transplantation, 10-15 μg/L; second month, 
8-12 μg/L; 6-10 μg/L after month 3; and 5-8 μg/L after month 6). Methylprednisolone 
was given intravenous for the first 3 postoperative days, in a dose of 100 mg daily. There-
after, prednisone was given orally once daily, starting with 20 mg and was tapered at 
physician’s own discretion and to be discontinued at month 3. In total, 22 recipients of a 
kidney from a deceased donor and 1 recipient of a kidney from a living unrelated donor 
received antithymocyte globulin (ATG) induction therapy [23 patients of all included 
patients (30%)].
Quantitative mRNA expression analysis
Total RNA was isolated using the High Pure RNA Isolation kit (Roche Applied Science, 
Almere, The Netherlands), according to the manufacturer’s instructions. RNA concen-
trations were measured by using the Nanadrop ND-8000 Spectrophotometer (Isogen 
Life Science, De Meern, The Netherlands). Samples containing at least 500 ng RNA per 
sample were used. The purity of the used samples was examined using UV spectral 
ratios. For RNA purity, a cutoff value of the 260/280nm ratio of 1.8 was used, and for the 
organic purity of the samples, a cutoff value of the 260/230nm ratio of 1.0 was used. 
Impure samples with a ratio below the cutoff value were rejected. RNA was denatured 
for 5 minutes at 80°C and then chilled on ice. First-strand complementary DNA (cDNA) 
reaction was performed from 500 ng of the isolated RNA at 42°C for 90 minutes in a 
volume of 50 μL. The reaction mixture contained 10 μL of 5x first-strand buffer, 500 
U of Moloney murine leukemia virus reverse transcriptase (M-MLV RT), 0.5 nmol/L of 
dithiothreitol (Life Technologies, Gaitherburg, MD), 25 pmol of each dNTP (Amersham 
Pharmacia Biotech Benelux, Roosendaal, The Netherlands), 0.25 μg of random primers, 
and 20 U of RNAse inhibitor (Promega Benelux, Leiden, The Netherlands). After the cDNA 
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reaction, the M-MLV reverse transcriptase was inactivated by a 5-minute incubation at 
95°C.
A quantitative RT-PCR was used to quantify the amount of IMPDH type I and type II 
expression in the samples. Assay-on-demand products for the detection and quantifica-
tion of IMPDH type I (hs00992210_m1) and IMPDH type II (hs01021353_ma) mRNA were 
designed by Applied Biosystems (Foster City, CA).
A 5 μL sample of cDNA was added to 20 μL PCR mixture containing 12.5 μL Universal 
PCR Master Mix (Applied Biosystems), 0.625 μL of each specific primer and probe assay-
on-demand mix, and 6.875 μL water. The RT-PCR reaction was performed after a first 
step of 2 minutes 50°C and 10 minutes 90°C followed by cycles of 15 seconds at 95°C and 
1 minute at 60°C using the ABI Prism 7700 sequence detector (Applied Biosystems). Each 
run contained several negative controls (no template), and 2 positive reference samples. 
The amount of each target molecule was quantified by measuring the threshold cycles 
(Ct) on a TaqMan Real-Time PCR system (Applied Biosystems) and was transformed to the 
number of cDNA copies [2(40-Ct)] as described by Bustin et al26 The absolute values of the 
number of IMPDH mRNA copies were log transformed.
IMPDH activity assay
The validated nonradioactive high-performance liquid chromatography method 
by Glander et al22 was used to measure the IMPDH activity. In summary, PBMCs were 
isolated from lithium heparin-anticoagulated whole blood using Leucosep tubes with 
Ficoll-Paque (Greiner Bio-One, Alphen a/d Rijn, The Netherlands). After one washing 
step, the aliquot was resuspended in 250 μL ice-cold water and stored at –20°C to lysate. 
To 50 μL PBMC lysate 130 μL reaction buffer with inosine monophosphate and β-NAD+ 
was added to start the incubation of enzyme reaction at 37°C and moderately shaken at 
800 rpm (Thermomixer; Eppendorf, Hamburg, Germany) for 2.5 hours. The reaction was 
stopped by adding ice-cold perchloric acid. After centrifugation, potassium carbonate 
was added to the supernatant to neutralize the solution. The supernatant was trans-
ferred into high-performance liquid chromatography injection vials for determination 
of produced XMP and present adenosine monophosphate (AMP). Enzyme activity was 
expressed as produced XMP (micromoles) per time unit (s) per present AMP (moles) for 
normalizing the activity to the destructed cells. The precision of the IMPDH activity assay 
was 6.6% to 11.9%, and the coefficient of variation ranged from 0.6 to 3.4%.
Measurement of MPA concentrations
For the purpose of this study, the active compound MPA was measured using a validated 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) method27 optimized for 
our equipment. To a sample of 50 μL plasma, 200 μL zinc sulfate (0.1 mol/L) and 500 μL 
acetonitrile with 3 mg/mL of the internal standard carboxy butoxy ether of MPA was 
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added for determination of the total plasma concentrations of MPA. For the determina-
tion of the unbound free plasma concentration of MPA, plasma was first ultrafiltrated 
using 30 KDa centrifugal filter devices (Microcon Ultracel YM-30, Millipore, Amsterdam, 
The Netherlands). The coefficient of variation of the inter- and intraday precision of the 
used method was less than 5% and 3%, respectively, for the total plasma MPA concentra-
tions (range: 0.2–50 mg/L) and were less than 13% and 7%, respectively, for the unbound 
plasma MPA concentration (range: 0.001–1.0 mg/L).
Clinical outcome
Patients were suspected of an acute rejection episode based on clinical grounds and all 
acute rejections were confirmed by a core biopsy. All biopsies were read by a pathologist 
and graded according to the Banff classification.28 Adverse events were graded accord-
ing to the standard response and toxicity criteria.29 Gastrointestinal adverse events (nau-
sea, vomiting, diarrhea, and abdominal cramps) were pooled and evaluated together. 
Hematological adverse events (leukopenia, thrombocytopenia, and anemia) were also 
pooled and evaluated together. Leukopenia was defined as a leukocyte count less than 
3.0 x 109 cells per liter, thrombocytopenia as a thrombocyte count less than 75.0 x 109 
cells per liter, and anemia as a hemoglobin concentration below 5.8 millimoles per liter 
for men and women.
Statistical analysis
All statistical tests were performed using SPSS software version 16.0 (SPSS, Chicago IL) 
and a P value less than 0.05 was considered significant. Bivariated correlations coef-
ficients between data were analyzed using Pearson. Unrelated data was tested by a 
Mann-Whitney U test, related data by a Wilcoxon signed ranks test. A one-way analysis 
of variance test was used to analyze data with more than 2 variables. Values are reported 
as mean ± SD for normally distributed data or as geometric mean (95% confidence 
interval) for non-normally distributed data, unless otherwise stated.
reSultS
Patient characteristics
In our cohort of patients, 101 individuals were included presenting a total of 319 visits. 
Due to logistic problems, no mRNA samples were drawn on 83 visits, mostly at visit 1 
(day 6). Seventy-eight samples were excluded from the analyses because of impurities 
in the samples. In total, 158 patient visits were included in the analyses, representing 
77 patients. Table 1 shows the patient characteristics of the 77 included patients whose 
mRNA data was used for the analysis. Laboratory results of each visit of the included 
130
patients and the analyzed number of samples at each visit are summarized in Table 
2. Biopsy proven acute rejection (BPAR) was diagnosed in 13 patients. In 10 of these 
patients, BPAR occurred within the first month after transplantation.
IMPDH activity and MPA concentrations
The daily MMF dose decreased from 2000 ± 224mg on day 6 to 1115 ± 401 mg on day 
140, whereas the total plasma MPA trough level did not alter (Table 2). Total IMPDH 
activity pre dose was correlated to IMPDH gene expression of both type I and type II, 
measured pre transplantation and at all 4 posttransplant visits separately using linear 
regression. The correlation coefficients were weak (ranged from -0.28 to 0.058) and none 
of the correlations were significant (P values are ranged between 0.11 and 0.77). IMPDH 
activity pre dose was also correlated to the sum of both types of IMPDH gene expres-
sion, but no significant linear correlations were found (correlation coefficients ranged 
from 0.055 to 0.24; P values ranged from 0.13 to 0.75). Significant correlations were also 
not found at any visit between total and unbound predose MPA levels and the IMPDH 
type I and type II gene expression (correlation coefficients ranged from -0.30 to 0.10; P 
values ranged from 0.073 to 0.95).
table 1. Characteristics of included patients
characteristics n=77
Age (years) 51.8 ± 14.9
Weight (kg) 80.6 ± 17.1
Height (cm) 174 ± 10
Gender Male 57 (74%)
Ethnicity
 Caucasian 64 (83%)
 Black 10 (13%)
 Hispanic 2 (3%)
 Asian 1 (1%)
Diabetes Mellitus present pre-TX 12 (16%)
Donor Living/Deceased 48/29 (62/38%)
Mismatches 0/1-3/4-6 4/39/34 (5/51/44%)
Patients with previous Tx 6 (8%)
PRA 0/1-25/26-100 59/12/6 (77/16/8%)
Delayed graft function 22 (29%)
ATG induction therapy 23 (30%)
ATG, anti-thymocyte globulin; PRA, panel-reactive antibodies; Tx, transplantation.
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Clinical outcomes
Pretransplant IMPDH type I and type II mRNA levels were higher in patients with a BPAR 
(n = 13) compared with patients without a BPAR episode (n = 47) after transplantation, 
and this difference showed a trend towards statistical significance (Fig. 1; P = 0.052 for 
IMPDH type I and P = 0.058 for IMPDH type II). On day 6 after transplantation, IMPDH 
mRNA type I and type II were significantly lower in patients with a BPAR (n = 13) com-
pared to patients without a BPAR (n = 28) [Fig. 2; IMPDH type I: 4.7 (95%CI: 1.9–11.3) 
versus 11.5 (95%CI: 6.8–19.4) x 103 copies; P = 0.026 and IMPDH type II: 2.3 (95%CI: 
0.9–5.9) versus 7.9 (95%CI: 4.5–13.8) x 103 copies; P = 0.007]. This difference was also 
significant when only patients with a BPAR within the first 30 days post-transplantation 
(n = 10) were analyzed [IMPDH type I: 6.1 (95%CI: 3.0–12.5) x 103 copies; P = 0.044 and 
IMPDH type II: 3.1 (95%CI: 1.4–6.9) x 103 copies; P = 0.018]. No significant differences 
were found in total and unbound MPA trough levels between patients with and without 
a BPAR [total MPA 1.98 (95%CI: 1.36–2.86) versus 1.84 (95%CI: 1.30–2.61) mg/L; P = 0.57 
and unbound MPA 0.08 (95%CI: 0.04–0.17) versus 0.03 (95%CI: 0.01–0.06) mg/L; P = 
0.28]. The IMPDH activity pre dose on day 6 was also not different between patients with 
and without a BPAR [23.4 (95%CI: 15.3–35.7) versus 20.3 (95%CI: 15.8–26.1) μmol·s-1·mol-1 
AMP; P = 0.26]. The ROC analysis of the IMPDH type I mRNA level showed a significant 
AUC of 0.72 (P = 0.027). A cutoff value for IMPDH type I mRNA of 10.4 x 103 copies had a 
specificity of 67.9% (95% CI: 47.7–84.1%) and a sensitivity of 76.9% (95% CI: 46.2–95.0%) 
with a likelihood ratio of 2.39. The ROC analysis of the IMPDH type II mRNA level showed 
a significant AUC of 0.76 (P = 0.008). A cutoff value for IMPDH type II mRNA of 2.49 x 103 
copies had a specificity of 89.3% (95% CI: 71.8–97.7%) and a sensitivity of 61.5% (95% CI: 
31.6–86.1%) with a likelihood ratio of 5.74.
   


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Figure 1. The expression of IMPDH mRNA type I (squares) and type II (circles) before transplantation in patients with a BPAR (n = 13) and 
without a BPAR (n = 47) episode after transplantation. The bars present the log-transformed mean with 95% confident interval.
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At visit 4, patients who had lower IMPDH type I and type II mRNA levels had sig-
nificantly more hematological adverse events (n = 8) compared to patients without 
these adverse events (n = 31) [IMPDH type I: 7.7 (95% CI: 3.5–16.7) versus 23.7 (95% CI: 
13.3–42.3) x 103 copies; P = 0.012 and IMPDH type II: 6.9 (95% CI: 2.16–18.6) versus 22.3 
(95% CI: 11.9–41.9) x 103 copies; P = 0.027]. No significant correlations were found for 
type I or type II for adverse events at all other visits (P values ranged from 0.17 to 0.94).
IMPDH gene expression over time
IMPDH gene expression changed over time after transplantation as shown in Figure 3. 
IMPDH type I and type II mRNA levels decreased directly after transplantation on day 6 
compared with the mRNA levels before transplantation. The IMPDH type II mRNA expres-
sion decreased significantly from 12.1 (95% CI: 8.6–17.0) x 103 copies pre transplant to 
5.3 (95% CI: 3.2–8.8) x 103 post transplant on day 6 (P = 0.005). After transplantation, the 
mRNA expression of IMPDH type I and type II increased from day 6 to day 140 (Table 3; P 
= 0.061 and P = 0.004, respectively). Predose IMPDH activity was higher before transplan-
tation compared to all post transplant visits but did not change over time at the 4 visits 
after transplantation (Table 3; P = 0.49). The IMPDH mRNA levels reached a maximum 
level at day 140 and were not significantly different compared to the mRNA levels pre 
transplant. ATG induction therapy directly after transplantation did not influence the 
IMPDH mRNA type I and type II levels on day 6 [type I: 9.6 (95% CI: 2.6–35.9) versus 8.3 
(95% CI: 5.2–13.4); P = 0.33 and type II: 3.9 (95% CI: 0.9–17.6) versus 5.9 (95% CI: 3.5–9.8); 
P = 0.82 for patients who received ATG versus those that not received ATG, respectively].
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Figure 2. The expression of IMPDH mRNA type I (squares) and type II (circles) on day 6 after transplantation in patients with a BPAR (n = 13; 
within 30 days after transplantation n = 10) and without a BPAR (n = 28) episode after transplantation. The bars present the log-transformed 
mean with 95% confident interval.
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DIScuSSIoN AND coNcluSIoN
In this prospective longitudinal study, we have investigated the correlation between 
mRNA levels of the IMPDH type I and type II enzymes and total IMPDH activity and clini-
cal outcomes in renal transplant recipients treated with MMF. The incorporation of PK 
and PD variability by monitoring of the MPA-mediated IMPDH activity might introduce 
a more accurate prediction of the therapeutic response than monitoring of the MPA 
plasma concentration alone. Monitoring IMPDH mRNA expression levels might be a 
more attractive method of monitoring the biologic effect of MMF treatment,23 as RT-PCR 
is less labor intensive and less time consuming compared to the IMPDH activity assays.
This study confirms the upregulated expression of IMPDH type I mRNA over time 
after transplantation.24,25 For IMPDH type II, mRNA conflicting data have been reported. 
Some studies showed stable IMPDH type II mRNA levels after transplantation,25 whereas 
others found a decrease over time.24 Our study showed a significant increase in IMPDH 
type II mRNA levels over time after transplantation, and the changes in type II paral-
leled those in type I mRNA. Our findings are in line with previously reported results that 
induction of IMPDH activity after prolonged exposure to MPA may be partially explained 
by the upregulation of both IMPDH type I and type II mRNA in PBMC.25 The decreased 
expression of IMPDH mRNA levels of both types on day 6 compared with pretransplant 
expression may be due to the administration of high dose corticosteroids, as also sug-
gested by others.24 In a study in healthy volunteers, MPA induced a decrease in IMPDH 
type I expression but stable type II expression.30 The rise in mRNA expression after day 
6 in our study is presumably due to the MPA-induced inhibition of IMPDH activity. 
IMPDH mRNA expression is regulated by a negative feedback mechanism by guanine 
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Figure 3. Changes in total IMPDH activity pre dose (bars), IMPDH mRNA type I (squares) and type II (circles) expression in patients over time 
after transplantation. The bars present the mean with 95% confident interval (log transformed for mRNA data).
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nucleotides. The inhibition of IMPDH activity by MPA leads to a decrease in the intracel-
lular depots of guanine nucleotides.11 According to the studies performed by Jain et al,15 
IMPDH inhibitors do not seem to alter the regulation of IMPDH type I or type II mRNA or 
protein levels directly but may have an indirect role in the regulation. Considering the 
role of MPA on this feedback mechanism on IMPDH expression, it is not surprising that 
we could not find a correlation between mRNA levels and IMPDH activity in the blood 
samples drawn after transplantation. However, we expected to find a better correlation 
before transplantation, as at that time point no MPA was present, and IMPDH activity 
should be better correlated to gene expression. Also pretransplantation mRNA levels for 
IMPDH type I and type II were not related to IMPDH activity.
It was thought that IMPDH type I enzymes were constitutively present in the cells 
and that IMPDH type II would appear after immune activation.4,5 However, in this study, 
IMPDH type I was also upregulated in PBMCs after immune activation by organ trans-
plantation. Hence, both isoforms of IMPDH are responsible for the proliferation of the 
lymphocytes after transplantation and, therefore, both isoforms should be inhibited 
to decrease the proliferation of the lymphocytes and to prevent the graft for acute 
rejections. Also Dayton et al14 concluded that both type I and type II IMPDH should be 
considered important targets for immunosuppressive therapy.
Previous studies used area under the mRNA–time curve (AUC) as variable for the 
IMPDH gene expression,25,31 whereas other studies expressed the IMPDH gene expres-
sion as relative numbers compared to the expression before transplantation.24,32 We 
chose here to use IMPDH mRNA predose levels because we were mostly interested in 
the changes in IMPDH mRNA gene expression over time. IMPDH mRNA levels fluctuate 
less over a dose interval than over a period of several months after transplantation. 
In this same patient cohort, we did find a correlation between exposure to IMPDH 
activity over 12 hours and the incidence of BPAR,33 with higher IMPDH activity being a 
risk factor for more BPAR. On day 6, IMPDH type I and type II mRNA levels were lower in 
patients with a BPAR compared with patients without a BPAR, and this difference was 
statistically significant (P = 0.026 and P = 0.007, respectively). It would seem plausible 
that patients with less mRNA have higher IMPDH activity and therefore higher immuno-
reactivity and higher rejection rates. However, the already mentioned MPA-induced in-
hibition of IMPDH activity and the resulting upregulation of mRNA expression obscures 
the correlation between mRNA levels and IMPDH activity. For the pre transplant time 
point, in the absence of MPA, the IMPDH mRNA levels in rejectors were higher compared 
to nonrejectors and this difference showed a trend towards statistical significance (P = 
0.052 and P = 0.058 for IMPDH type I and type II, respectively). As shown in Figures 2 
and 3, there is a considerable overlap in mRNA levels in rejectors and nonrejectors and 
it would be difficult to propose a cutoff level for use in clinical practice. Although the 
ROC analyses recommended cutoff values for IMPDH type I and type II mRNA levels, 
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the sensitivity and specificity for the cutoffs was poor (ranged from 62% to 89%). More 
studies are needed to evaluate the added value of monitoring IMPDH mRNA levels in 
patient management. We would also suggest performing such studies in patients not 
treated with MPA as especially in these patients IMPDH mRNA levels may reflect immune 
activation.
Only at visit 4, lower IMPDH type I and type II mRNA expression were significantly 
correlated to hematological adverse events (leukopenia, thrombocytopenia and/or 
anemia). No other significant correlations with IMPDH mRNA levels were found for he-
matological and gastrointestinal adverse events. MPA-related adverse events have also 
been found to have a poor correlation with MPA plasma concentrations.34 Unfortunately, 
mRNA monitoring is not going to solve the unmet need for a biomarker that may assist 
in preventing MPA-induced toxicity.
The present study has also some limitations. From a cohort of 101 patients, only 77 
patients were analyzed of whom mRNA samples were obtained. Due to logistic prob-
lems and impurity of samples, only a half of all samples was included and analyzed. This 
resulted in a maximum of up to 41 samples per post transplant visit and 60 samples pre 
transplant. This unintentional selection of the samples has introduced a selection bias. 
Because an overlap in the results of IMPDH mRNA expression between rejectors and 
nonrejectors was noticed, a patient cohort with less selection bias is needed to confirm 
our results.
In conclusion, in this prospective longitudinal study, IMPDH type I and type II mRNA 
levels were found to increase from day 6 to day 140 after renal transplantation. IMPDH 
activity was not correlated to mRNA levels, possibly due to the fact that the lower gua-
nine nucleotide levels caused by MPA-related enzyme inhibition induce the expression 
of the IMPDH gene. However, also before transplantation in an MPA-free situation, mRNA 
levels were not correlated to IMPDH activity. Nevertheless, we did find a trend towards 
significantly higher IMPDH mRNA levels pre transplantation in rejectors compared with 
nonrejectors, and post transplant significantly lower IMPDH mRNA levels in rejectors. 
Although the regulation of the expression of the 2 isoforms is presumed to be different, 
in this study, the changes in the expression of type I mRNA closely paralleled those of 
type II.
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AbStrAct
Mycophenolate mofetil (MMF) is used more frequently in hematopoietic SCT (HSCT) re-
cipients to prevent acute GVHD. The active metabolite mycophenolic acid (MPA) inhibits 
the activity of the target enzyme inosine monophosphate dehydrogenase (IMPDH). 
In this pilot study we aim to explore for the first time the pharmacodynamics of MPA 
by measuring IMPDH activity in a prospective, unselected cohort of allogeneic HSCT 
recipients.
Patients suffering from serious neutropenia, thrombocytopenia and anemia had a 
significantly lower IMPDH activity. No significant differences were found in IMPDH activ-
ity compared to patients developed GVHD.
However IMPDH activity was not significantly different, MPA concentrations in renal 
transplant were significantly higher than in HSCT recipients. IMPDH enzymes could be 
more sensitive for MPA inhibition in HSCT patients. Over all visits it is shown that the 
inter-patient variability for the concentration-effect correlation is large.
We showed significant correlations between IMPDH activity and the toxicity of MMF 
therapy in HSCT patients. We hypothesis IMPDH enzymes are more sensitive for the 
inhibition of MPA in HSCT patients compared with renal transplant patients. The clinical 
relevance of the results of this pilot study has to be confirmed in a more selected and 
larger cohort of HSCT patients.
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INtroDuctIoN
Mycophenolate mofetil (MMF) is a prodrug for the pharmacologically active compound 
mycophenolic acid (MPA). MMF has been used for more than a decade as a immunosup-
pressive agent in the treatment after kidney transplantation to prevent acute rejection.1 
MPA is rapidly absorbed from the gut, maximum MPA concentrations generally occur 
within 1 hour after oral MMF administration.2 MPA is primarily metabolized in the liver 
into the inactive metabolite phenolic MPA glucuronide (MPAG) and into the lesser extent 
but active metabolite acyl MPA glucuronide (AcMPAG). The glucuronide metabolites are 
excreted into the bile, and in the intestine MPAG is deconjugated back to MPA. In the co-
lon, MPA is reabsorbed to complete the enterohepatic recirculation (EHC), which causes 
a second MPA peak concentration approximately 6 to 12 hours after administration.2,3 
Finally, the metabolites are mainly excreted by the kidneys.2
MPA is a non-competitive, reversible inhibitor of inosine monophosphate dehydro-
genase (IMPDH), which has a crucial role in the proliferation of lymphocytes. IMPDH is 
the key enzyme in the de novo synthesis of the purine nucleotide guanosine triphos-
phate (GTP) and induces the rate-limiting step in the synthesis.4,5 Previous studies in 
renal transplantation recipients have shown that determination of IMPDH activity may 
be a relevant pharmacodynamic parameter.6-10 An inverse relation between MPA con-
centration and IMPDH activity was seen in renal transplant recipients.11,12 There is a great 
inter-individual variability in the activity of IMPDH pre and post transplantation.6,7 A high 
IMPDH activity pre-transplant was associated with MMF dose reduction and acute rejec-
tion after renal transplantation.7 Post-transplant, an elevated exposure to IMPDH activity 
was also correlated to acute rejection.9
MMF has been shown to be a potent immunosuppressive drug with beneficial 
effects on acute rejection rates and on long-term outcomes in comparison with azathio-
prine in kidney transplantation.1,13,14 Due to this success, MMF is also used in allogeneic 
hematopoietic stemcell transplantation (HSCT) recipients to prevent acute and chronic 
graft-versus-host disease (GVHD) as well as to promote engraftment.15-17 For this indica-
tion, it is supported that MMF has a more favorable toxicity profile then methotrexate, 
which induces mucositis.15,17,18 Pharmacokinetic research showed that standard MMF 
dosing in HSCT patients based on data from renal transplantation recipients resulted 
in low MPA trough levels compared to levels from renal transplantation patients.15,16,19-22 
Van Hest et al found that the total MPA exposure in HSCT recipients is low because of 
high MPA clearance and short apparent MPA half-life in comparison with reference 
values from renal transplantation.23 MMF dose and dose interval applied in HSCT re-
cipients are largely based on pharmacokinetic data from renal transplant studies. The 
starting daily MMF dose generally is 30 mg/kg orally divided over two or – as used more 
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frequently – over three doses, which in most HSCT patients results in the standard MMF 
dose recommended in renal transplantation (1000 mg twice daily).19,20,22-25
MPA is extensively bound to albumin (97–99%) in healthy patients;26 however, bind-
ing is altered in patients with significant renal dysfunction, liver disease, or other cause 
of hypoalbuminemia. Increased percentage unbound MPA has been associated with 
decreased plasma albumin levels in pediatric renal transplant recipients.27-28 Similarly, 
in vitro studies have demonstrated increased percentage unbound MPA when plasma 
albumin decreased.29 The pharmacological activity of MPA, which is the inhibition of 
IMPDH, is a function of unbound MPA. However, for this crucial role for unbound MPA, 
only in vitro data are currently available.28,29 The measurement of free, pharmacologically 
active MPA would therefore appear to be the correct approach for therapeutic drug 
monitoring.
In this pilot study we aim to explore for the first time the pharmacodynamics by 
measuring IMPDH activity in an unselected cohort of allogeneic HSCT recipients. We 
studied the correlations of IMPDH activity to MPA concentrations, clinical outcome, and 
adverse events.
PAtIeNtS AND MetHoDS
Patients
For the purpose of this study in a prospective cohort of allogeneic hematopoietic SCT 
(HSCT) patients we preformed a MPA pharmacokinetic and pharmacodynamic assess-
ment at one and two or at two and four weeks after transplantation. Patients were 
recruited in the Erasmus University Medical Center – Daniel den Hoed Cancer Center. 
Patients were included regardless of underlying disease, conditioning regimen, donor 
type, or patient condition. The study complied with the Declaration of Helsinki and all 
patients gave informed consent. 
Conditioning regimens and co-medication
The day of the HSCT is designated day 0. Patients up to 40 years of age with a related 
HLA-identical siblings (Sib) donor received a standard myeloablative conditioning regi-
men consisting of cyclophosphamide 60 mg/kg i.v., on days –5 and –4 and TBI, 6 Gy on 
day –2 and –1. A non-myeloablative, reduced intensity conditioning (RIC) regimen was 
applied in patients older than 40 years. This regimen consisted of fludarabine 30 mg/m2 
i.v. on days –5 to –3 (total 3 doses) and TBI, 2 Gy on day –1. An alternative RIC regimen 
consisted of fludarabine 25 mg/m2 i.v. and cyclophosphamide 500 mg/m2 i.v. on days 
–7 to –3 (total 5 doses). Patients who received HSCT from a matched unrelated donor 
(MUD) underwent the same conditioning regimens as patients with a Sib donor. In ad-
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dition, they were given rabbit anti-thymocyte (rATG) 2 mg/kg i.v. on days –7 to –4 (total 
4 doses).
Patients with cord blood donor transplantation received a RIC regimen. This regi-
men consisted of fludarabine 40 mg/m2 i.v. on days –5 to –2 (total 4 doses), cyclophos-
phamide 60 mg/kg i.v. on day –6 and TBI, 2 Gy on day –1.
For prevention of serum sickness, prednisone was administered in patients receiv-
ing rATG 0.5 mg/kg twice daily i.v. on days –7 to –4 (total 8 doses) and once daily on days 
–3 to +7.
Immunosuppressive therapy for prophylaxis of GVHD consisted of CsA and MMF. CsA 
was started on day –3. Patients who were undergoing the myeloablative conditioning, 
CsA i.v. (Sandimmune, Novartis Pharma BV, Arnhem, The Netherlands) was administered 
in doses of 1.5 mg/kg twice daily. When these patients could tolerate oral medication, 
they were converted to oral CsA (Neoral, Novartis, Arnhem, The Netherlands) in an 
identical dose. In patients receiving non-myeloablative conditioning, oral CsA was given 
twice daily in doses of 6.25 mg/kg. CsA trough levels, determined in whole blood by the 
EMIT assay, were targeted at 250-350 mg/L, but higher levels were accepted during the 
first week in patients treated with non-myeloablative conditioning. Oral MMF (CellCept, 
Roche, Woerden, The Netherlands) was started 5 to 10 hours after transplantation with 
a dose of 10 mg/kg three times daily oral (daily dose 30mg/kg), rounded up or down to 
the nearest 250 mg MMF increment. Patients with severe mucositis received MMF i.v. The 
higher frequency used in HSCT patients compared to the standard twice daily frequency 
in kidney transplant patients was used because several studies proved that the MPA 
concentrations and area under the curve (AUC) in HSCT patients were significant lower 
with the standard dosing frequency compared to in kidney transplant patients.15,16,19-22 
Higher dosing frequencies resulted in higher MPA concentrations.22
Infection prophylaxis consisted of ciprofloxacin, 500 mg orally twice daily, and 
fluconazole, 200 mg orally once daily, started on the first day of the conditioning regi-
men, until the granulocyte count was above 0.5x109/L. All patients received valcyclovir, 
500 mg three times daily, from the first day of the conditioning regimen until 1 year 
post-transplantation. For the prevention of a Pneumocystis carinii infection, all patients 
received co-trimoxazole, 480 mg once daily, when the administration of ciprofloxacin 
and fluconazole was stopped, until 1 year after transplantation.
Sampling procedure
Samples for analysis MPA level were collected in EDTA-containing 4 mL tubes. Samples 
for pharmacodynamic analysis of IMPDH activity were collected in lithium heparin (Li-
hep)-containing 4 mL tubes. Samples were drawn pre-dose and 2 hours after dosing, 
at days +7 and +14 or days +14 and +28. After collection, EDTA blood samples were 
centrifuged at 3000g, and plasma was stored frozen at –80 oC until analysis. PBMCs were 
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isolated form the Li-hep blood within 24 hours after collection. The PBMCs were lysated 
with ice-cold water and the cell lysate was stored at –80oC until analysis.11
Measurement of IMPDH activity and MPA concentrations
A validated non-radioactive HPLC method by Glander et Sombogaard11 was used to mea-
sure the IMPDH activity. In summary, PBMC were isolated from lithium heparin-antico-
agulated whole blood using Leucosep tubes with Ficoll-Paque (Greiner Bio-One, Alphen 
a/d Rijn, The Netherlands). After one washing step, the aliquot was resuspended in 250μL 
ice-cold water and stored at –20°C to lysate. To 50μL PBMC lysate 130μL reaction buffer 
with inosine monophosphate (IMP) and β-nicotinamide adenine dinucleotide (β-NAD+) 
was added to start the incubation of enzyme reaction at 37°C and moderately shaken at 
800 rpm (Thermomixer, Epperndorf, Hamburg, Germany) for 2.5 hours. The reaction was 
stopped by adding ice-cold perchloric acid. After centrifugation potassium carbonate 
was added to the supernatant to neutralize the solution. The supernatant was transferred 
into HPLC injection vials for determination of produced xanthine monophosphate (XMP) 
and present AMP. The rate of XMP production by IMPDH from PBMCs was measured and 
was normalized to the measured intracellular AMP. Enzyme activity was expressed as 
produced XMP (μmol) per time unit (s) per present AMP (mol) for normalizing the activity 
to the destructed cells. The imprecision of the IMPDH activity assay was 6.6 to 11.9% and 
the coefficient of variation of the IMPDH activity ranged from 0.6 to 3.4%.
For the purpose of this study MPA plasma concentrations were measured with a 
validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method 
optimized for our equipment.30 To a sample of 50μL plasma 200μL zinc sulfate 0.1mol/L 
and 500μL acetonitrile with 3mg/mL of the internal standard carboxy butoxy ether of 
MPA (MPAC) was added for determination of the total plasma concentrations of MPA. 
The coefficient of variation of the inter- and intraday imprecision of the used method 
was less than 5% and 3% respectively for the total plasma MPA concentrations (range: 
0.2 to 50 mg/L). 
Clinical outcome
Patients were suspected of GVHD episode based on clinical grounds or biopsy proven 
were graded according to the standard response and toxicity criteria.31 Hematological 
adverse events (neutropenia, leukopenia, thrombocytopenia and anemia) were also 
graded according this standard. Neutropenia grade 3 and 4 was defined as absolute 
neutrofil count less than 1.0 and less than 0.5x109/L respectively. Leukopenia was 
defined as a leukocyte count less than 2.0 and less than 1.0x109/L for grade 3 and 4 
respectively. Thrombocytopenia was defined as a thrombocyte count less than 50.0 and 
less than 25.0x109/L and anemia as a hemoglobin concentration below 5.0 and below 
4.0mmol/L for men and women for grade 3 and 4 respectively.
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Statistical analysis
All statistical tests were performed using SPSS software version 16.0 (SPSS, Chicago IL, 
USA) and a P-value less than 0.05 was considered significant. Bivariated correlations 
coefficients between data were analyzed with Pearson’s. Unrelated data was tested by 
a Mann-Whitney U test for two variables and by a Kruskal-Wallis test for more than two 
variables. Related data was tested by a Wilcoxon Signed Ranks test. Post-hoc analyzes 
on the data was preformed by a Dunnett’s test. Values are reported as median (range), 
unless otherwise stated.
reSultS
Patient characteristics
From May 2007 until May 2008, a total of 24 patients were included into the study, 
from which in total on 45 occasions samples were taken. On 8/45 occasions (6 differ-
ent patients) MMF was administered i.v. on the day of sampling and these data were 
excluded, because of different pharmacokinetics of the i.v. formulation. Two patients 
were only receiving MMF i.v. and not oral at the days of sampling, so these patients 
were also excluded from the study. Finally, data of 37 occasions from 22 patients were 
analyzed. Baseline characteristics of these patients and the kind of transplantation are 
summarized in Table 1. Due to the non-interfering inclusion of the patient, a dispropor-
tional distribution of patients over the visits was accomplished: 7 patients were sampled 
7 and 14 days post-transplant, 8 patients at day 14 and 28, 5 patients only at day 14 and 
2 patients only at day 28 post-transplant.
Laboratory data and adverse events
Patients who have received a HSCT could have seriously adverse events, some induced 
by medication such as MMF. Figure 1 shows the corresponding IMPDH activity for four 
common hematological adverse events after HSCT and the use of MMF. Laboratory 
results and severe or life-threatening hematological toxicity (grade 3 or 4) of each visit 
are summarized in Table 2. For each adverse event grade 3 and 4 (severe and life-threat-
ening) were pooled together and compared to the pooled data of adverse effect grade 
0 to 2. Patients suffering from serious neutropenia, thrombocytopenia and anemia had a 
significantly lower IMPDH activity compared to the group of patients with none or a mild 
grade of these adverse events (P-values <0.01, 0.02 and 0.03 respectively). There was no 
significantly difference in IMPDH activity observed for leukopenia (P = 0.43). Since there 
was a significant difference between the visit for leukopenia and neutropenia (table 2), 
these adverse events were also analyzed separately for each visit. At visit day 7 and day 
14 IMPDH activity was also significantly lower in patients suffering from serious neutro-
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penia (grade 3 and 4) compared to neutropenia grade 0 to 2 (P = 0.05 for both visits). At 
these visit days, no differences were found for IMPDH activity for leukopenia.
table 1. Patient baseline and transplantation characteristics
characteristics n=22
Gender Male van (n) 15 (68%)
Age (yr) 53 (18 - 65)
Body weight (kg) 80 (58 - 105)
Diagnosis van (n)
 Acute myeloid leukemia / Myelodysplastic syndrome 10
 Acute lymphoblastic leukemia 3
 Non-Hodgkin’s lymphoma 2
 Waldenström’s macroglobulinemia 2
 Myelofibrosis 2
 Chronic myeloid leukemia 1
 Multiple myeloma 1
 Aplastic anemia 1
Conditioning regimen van (n)
 Myeloablative 5
 Non-myeloablative 17
Donor Sib/MUD/Cord van (n) 5/14/3
MUD, matched unrelated donor; Sib, sibling.
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Figure 1. IMPDH activity in patients suffering from none to mild adverse events (grade 0-2) compared with patients suffering from severe 
to live-threatening (grade 3-4). Significant differences were seen for neutropenia, thrombocytopenia and anemia. The IMPDH activity was not 
significantly correlated to leukopenia. The bars are presenting the interquartile interval and the horizontal lines the median of the IMPDH activity 
of the groups.
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In the first six months after transplantation grade I (mild moderate) acute GVHD was 
developed in 4 patients (18%), 10 patients (45%) had grade II (severe) and 1 patient (5%) 
developed grade III (life-threatening) GVHD. In the first month after transplantation 7 
patients (32%) developed a GVHD and in the second month 4 patient (18%). The median 
time to GVHD was 39 days after transplantation and ranged from 12 to 177 days. IMPDH 
activity on day 14 in patients developed a GVHD grade II or higher within 40 days after 
sampling (n=7) was compared with patients without a GVHD (n=13) (Figure 2). There 
were no significant differences found in IMPDH activity measured pre-dose and 2 hours 
after administration of MMF comparing patients without GVHD to patient with GVHD.
IMPDH activity and MPA concentrations
IMPDH activity on t=2h was inhibited compared to t=0h as a result of the increased MPA 
concentrations on t=2h compared to t=0h (Table 3). Figure 3 showed the IMPDH activity 
for all three visits. On every visit the IMPDH activity at 2h post MMF dose is inhibited 
compared to 0h (pre-dose). The median IMPDH activities at 2h are 10.6, 10.5 and 13.0 
µmol/s/mol AMP respectively for the three visits. No significant differences are observed 
pre- and post-dose over the visits for IMPDH activity levels and MPA concentrations and 
the daily MMF dose did not significantly changed over the visits. In Figure 3 it is notice-
table 2. Laboratory results of the patients on each of the three visits
visit (day) 7 (n=7) 14 (n=20) 28 (n=10) P-value2
Serum albumin (g/L) 38 (30 - 40) 35 (25 - 42) 38 (30 - 41) 0.49
Bilirubin (μmol/L) 23 (17 - 56) 15 (7 - 132) 12 (6 - 51) 0.09
Alkaline phosphatase (U/L) 57 (37 - 151) 84 (50 - 553) 87 (25 - 111) 0.28
Y-glutamyl transferase (U/L) 54 (24 - 67) 42 (19 - 269) 43 (21 - 100) 0.96
Serum creatinine (μmol/L) 84 (53 - 94) 86 (38 - 141) 113 (56 - 271) 0.36
Glomerulair filtration rate 
(ml/min/1.73m2)1
74 (60 -147) 68 (35 - 237) 59 (16 - 151) 0.37
Cyclosporin trough level (μg/L) 398 (300 - 551) 366 (234 - 722) 3 277 (232 - 380) 3 0.01
Haemoglobin (mmol/L) 6.0 (5.5 - 7.6) 5.4 (4.6 - 7.9) 6.0 (4.4 - 7.2) 0.21
Haematocrit (I/L) 0.27 (0.25 - 0.34) 0.24 (0.19 - 0.33) 0.28 (0.19 - 0.33) 0.09
Thrombocytes (109/L) 64 (6 - 297) 48 (12 - 503) 112 (30 - 334) 0.48
Leukocytes (109/L) 0.49 (0.06 - 6.0)3 0.65 (0.15 - 3.3)4 3.2 (1.2 - 10.2)3,4 <0.01
Neutrocytes (109/L) 0.38 (0.05 - 5.8) 0.37 (0.05 - 1.5)4 2.2 (0.6 - 9)4 <0.01
Neutropenia (grade 3 or 4) 5 (71%)3 17 (85%)4 2 (20%)3,4 <0.01
Leukopenia (grade 3 or 4) 6 (86%)3 18 (90%)4 3 (30%)3,4 <0.01
Thrombocytopenia (grade 3 or 4) 3 (43%) 10 (50%) 2 (20%) 0.30
Anemia (grade 3 or 4) 0 (0%) 3 (15%) 1 (10%) 0.55
1 Estimated GFR using MDRD; 2 A Kruskal-Wallis test was used to compare the means over all three visits. Significant differences were tested post-
hoc using a Dunnett’s test; 3 P < 0.01 post-hoc analysis, compared to the value with the same symbol; 4 P < 0.05 post-hoc analysis, compared to 
the value with the same symbol.
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able that patients with a relative high IMPDH activity pre-dose have a stronger inhibition 
(per cent) of IMPDH activity at t=2h. The slope of the curves of these patients is in Figure 
3 steeper than patients with already a lower IMPDH activity, what results in a gentler to 
almost horizontal slope of the curve.
In Figure 4 the concentration-effect curves of each visit are showed. Over all visits 
it is shown that the inter-patient variability for the concentration-effect correlation is 
large. Some patients showed small differences in MPA concentration between pre- and 
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Figure 2. IMPDH activity in patients who developed GVHD grade II or higher (n=7) within 40 days after sampling on day 14 compared to 
patients who did not develop GVHD (n=13). IMPDH activity measured pre-dose are for each individual patient connected to the corresponding 
IMPDH activity measured 2 hours post-dose.
table 3. IMPDH activity and MPA and MPAG pharmacokinetic of each visit
visit (day) 7 (n=7) 14 (n=20) 28 (n=10) P-value1
Daily dose MMF (mg) 2500 (1750 - 3000) 2500 (1500 - 3500) 2625 (2000 - 3500) 0.77
Dose MMF at t=0h (mg) 750 (750 – 1000) 750 (500 – 1500) 875 (500 – 1500) 0.75
IMPDH Activity 
t=0h (µmol/s/mol AMP)
19.7 (11.0 - 27.6) 17.2 (8.2 - 43.4) 20.0 (3.1 - 35.7) 0.75
IMPDH Activity 
t=2h (µmol/s/mol AMP)
10.6 (2.8 - 20.3) 10.5 (6.3 - 43.2) 13.0 (3.2 - 25.8) 0.98
 P-value2 t=0h vs. t=2h 0.001 <0.001 <0.001 N.A.
MPA concentration t=0h (mg/L) 0.73 (0.20 - 1.70) 0.54 (0.10 - 1.18) 0.76 (0.22 - 2.32) 0.40
MPA concentration t=2h (mg/L) 2.50 (0.71 - 5.27) 2.66 (1.08 - 11.45) 2.22 (0.92 - 20.23) 0.90
 P-value2 t=0h vs. t=2h 0.011 <0.001 0.009 N.A.
1 Kruskal-Wallis test; 2 Wilcoxon Signed Ranks test.
N.A., not applicable.
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post-dose, other large differences. This phenomenon was also seen in IMPDH activity. It 
was not obvious that patients with a small difference in MPA concentration also had a 
small difference in IMPDH activity.
DIScuSSIoN
The last years MMF is used more frequently after HSCT for the prevention and treat-
ment of acute GVHD with successful results.15-17 The applied dose and dose interval of 
MMF were based on those used in renal transplant recipients. So, information from new 
pharmacokinetic studies of MMF in HSCT patients has been gathered to find a specific 
dose regimen of MMF for this patient group.16,22,32 The interest in pharmacodynamic 
monitoring of MMF in renal transplant recipients by measuring IMPDH activity has been 
increased over the last years. Several correlations have been found in clinical outcomes 
and IMPDH activity.7,9 Therefore, a pharmacodynamic approach to monitoring MMF 
therapy in HSCT patients may also applicable. This pilot study in 22 HSCT patients had 
the aim to investigate the pharmacodynamics of MMF by measuring IMPDH activity in 
HSCT patients under oral MMF therapy.
The present study showed a direct inverse relationship of MPA concentrations 
and IMPDH activity, which already have been seen in renal transplant recipients.12 In a 
prospective study of 101 de novo renal transplant recipients the IMPDH activity at day 6 
after transplantation was in the same range; pre-dose IMPDH activity was 20.7 µmol/s/
mol AMP and 2 hours post-dose 13.5 µmol/s/mol AMP.33 The observed IMPDH activities 
in HSCT patients in this study are similar to renal transplant patients, pre-dose IMPDH 
activity was 19.7 and 2h post-dose was 10.6 µmol/s/mol AMP at day 7 (p=0.22 and p=0.10 
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Figure 3. The inhibition of IMPDH activity per patient per visit after administration of MMF. Individual curves showed in general a lower IMPDH 
activity on 2h post-dose compared to 0h (pre-dose).
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respectively). However, a comparison of total MPA concentrations in renal transplant 
and HSCT recipients showed a vast difference: pre-dose 2.41 mg/L and 2h post-dose 
4.34 mg/L for renal transplant recipients and pre-dose 0.73 mg/L and 2h post-dose 2.50 
mg/L for HSCT recipients (p<0.001 and p<0.01 respectively). It is remarkable that lower 
MPA levels in HSCT recipients resulted in the same IMPDH activity levels compared to 
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Figure 4. Concentration-effect curves for IMPDH activity vs. MPA concentrations at day 7 (A), day 14 (B) and day 28 (C) after transplantation. In 
each curve the individual patients are showed as dotted lines, connecting the pre-dose point with the 2h post-transplant point.
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renal transplant recipients. A possible reason could be that the IMPDH enzymes in HSCT 
patients are more sensitive for MPA inhibition. To establish this hypothesis, more so-
phisticated analyzing methods are suggest for determining baseline IMPDH activity (E0) 
and the sensitivity of IMPDH enzymes for MPA (IC50) in MMF treated patients after renal 
and stem cell transplantation. The pharmacodynamic effect of both MMF regimens is 
the same; the inhibited IMPDH activity was equal in both patient groups using 1000mg 
twice daily in renal transplant recipients and 10mg/kg thrice daily in HSCT recipients.
In renal transplant recipients it is already confirmed that there is a large inter-patient 
variability in IMPDH activity.6,7 This small cohort of HSCT patients showed also a large 
inter-patient variability in IMPDH activity and the concentration-effect correlation.
Because of the small sample size of this pilot study, adverse events of all three visits 
were pooled together for these analyzes. A significant correlation was found between 
IMPDH activity and hematological adverse events. Patients who suffered from severe 
(grade 3) or live-threatening (grade 4) neutropenia, thrombopenia or anemia had a 
significantly lower pre-dose IMPDH activity. IMPDH activity was measured in PBMCs 
(lymphocytes and monocytes) and corrected for lysated cells in the samples by using 
AMP concentration.11 However, no significant relation was found for leukopenia with 
IMPDH activity. Based on this pilot study, IMPDH activity could be a useful tool to deter-
mine MMF toxicity in HSCT patients.
Of the 22 included patients, 11 patients developed GVHD grade II or III within six 
months after transplantation. For the comparison of IMPDH activity between patients 
with and without GVHD, data of day 14 after transplantation was used. Patients who 
developed GVHD 40 days after sampling were scored as non-GVHD patients. No signifi-
cant correlations were found for IMDPH activity, neither with pre-dose IMPDH activity 
nor 2 hours post-dose IMPDH activity. It is still uncertain whether IMPDH activity – pre-
dose and minimal activity – could be a tool to predict GVHD in HSCT recipients. A more 
selected and larger cohort of patients has to give more clarity if IMPDH monitoring in 
HSCT patients could be a useful tool to predict and establish the efficacy and toxicity of 
MMF therapy.
This pilot study is the first study in HSCT patients where MMF treatment was moni-
tored using IMPDH activity. We showed significant correlations between IMPDH activity 
and the toxicity of MMF therapy in HSCT patients. A pharmacodynamic approach to 
monitoring the treatment of MMF in HSCT patients could be useful. IMPDH activity 
was similar to renal transplant recipients, but MPA levels were lower in HSCT patients. 
Therefore, we hypothesized that IMPDH enzymes are more sensitive for the inhibition of 
MPA in HSCT patients compared with renal transplant patients. The clinical relevance of 
the results of this pilot study has to be confirmed in a more selected and larger cohort 
of HSCT patients.
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Chapter 6
General discussion

163
G
en
er
al
 d
is
cu
ss
io
n
Ch
ap
te
r 6
INtroDuctIoN
Immunosuppressive drugs are used after organ transplantation to prevent acute rejec-
tion of the graft by the immune system of the recipient. The balance between the efficacy 
and the toxicity of the used dosing regimens of immunosuppressive drugs is fragile and 
gives ample reasons to search for the optimal combination of drugs and dosing levels. 
Under-immunosuppression may lead to acute rejection and over-immunosuppression 
will lead to serious adverse events and toxicity, and often presents as renal failure, 
malignancies or infections. To find this balance, therapeutic drug monitoring (TDM) 
strategies measuring drug levels or dosing based on body weight are routinely used to 
find the optimum dose for the applied immunosuppressive drugs.1 However, for one of 
the most frequently used immunosuppressive drugs – mycophenolate mofetil (MMF) – a 
fixed dose of 1000 mg twice daily is recommended by the manufacturer. If dose adjust-
ments are made, they are typically based on the clinical situation of the patient when 
adverse events occur or when an acute rejection is suspected. Over the last decade, 
more and more research has been done to develop TDM strategies for MMF to balance 
efficacy and toxicity.1,2 Pharmacokinetic (PK) research has shown that (i) an area under 
the concentration-time curve (AUC) of the active moiety mycophenolic acid (MPA) 
below 30 h·mg/L is associated with an increased risk for acute rejection,3,4 (ii) standard 
dose therapy will result in a 10-fold variability in MPA exposure between patients3,5,6 
and (iii) despite a stable MMF dose an increase in MPA exposure is found over time after 
transplantation.5-7 The high observed inter-patient variability in MPA exposure and the 
relatively narrow therapeutic window of MPA plead for good TDM strategies. Initially 
such strategies were strictly focused on the PK of MMF.
PHArMAcoDyNAMIc MoNItorING oF MMF
A pharmacodynamic (PD) approach for monitoring MMF therapy may be useful besides 
PK monitoring. MPA exerts its immunosuppressive effect by inhibition of the enzyme 
inosine 5’-monophosphate dehydrogenase (IMPDH), which leads to a decreased pro-
liferation of T- and B-lymphocytes.8 Over the years various IMPDH activity assays have 
been developed to measure the IMPDH activity. A large inter-patient variability in 
IMPDH activity has been observed in several studies. In pre-transplant blood samples 
as well as in post-transplant samples the inter-patient variability in IMPDH activity is 
more than 10-fold measured in dialysis patients, renal transplant recipients and healthy 
volunteers. The intra-patient variability varied from 7.1 to 26.0% measured over one 
month. A 2-fold increase of IMPDH activity was observed over two years in long-term 
MMF treated patients.9-11 It is thought that the non-protein bound MPA concentration 
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is the pharmacologically active fraction that inhibits IMPDH.12 MPA is highly bound 
to plasma proteins for 97% to 99% in patients with normal renal and liver function,12 
but unbound fractions up to 18.3% in a patient who suffered from biliary obstruction 
have also been reported.13 Therefore, measuring IMPDH activity could better reflect the 
immunosuppressive action than measurement of the total or unbound MPA plasma 
concentrations. Monitoring IMPDH activity could be an attractive approach to monitor 
MMF therapy, because it integrates the variability of the PK and the PD of MMF.
The measurement of PD effects of MMF by determination of IMPDH activity may 
provide a more direct insight in the immunosuppressive activity of MMF therapy in vivo. 
Dosing MMF based on IMPDH activity may help to increase the efficacy and decrease 
the toxicity of MMF therapy. We aimed to investigate whether differences in IMPDH 
activity could predict effectiveness and toxicity of MMF, and how total and unbound 
MPA concentration affects IMPDH activity. We here discuss how the combined main 
findings of the presented studies can contribute to novel methods that aim to optimize 
and individualize MMF therapy.
MeASurING IMPDH ActIvIty
As a first requirement for the establishment of a prospective study in PD monitoring 
of IMPDH activity in transplanted patients we needed to develop a precise, accurate 
and practical method to measure the IMPDH activity. All published IMPDH activity as-
says are based on an ex vivo transformation of the added substrate IMP to the enzyme 
product xanthine monophosphate (XMP). Firstly, the IMPDH enzyme has to be isolated 
and purified from the patient’s blood. Secondly, the isolated IMPDH enzyme facilitated 
the biotransformation of inosine monophosphate (IMP) into XMP and the product XMP 
has to be measured. Finally, the measured amount of product needs to be normalized 
for the amount of IMPDH enzyme and the reaction time. In order to develop a reliable 
method to measure the IMPDH activity, these three major steps of the IMPDH activity 
assay were optimized.
The first step is to choose the right cell fraction to measure the effect of MPA and 
isolate these cells from whole blood. High-quality isolation is characterized by minimiz-
ing manipulation of the cells and preventing washing out intracellular MPA. We chose to 
isolate peripheral blood mononuclear cells (PBMCs), which contain most of the immune 
cells on which MPA has its immunosuppressive effect. We modified the isolation using 
Ficoll-Paque by reducing the number of washing steps mentioned in the manufacturer’s 
protocol of the cells so that there was a limited manipulation of cells. For our assay only 
2.5 mL heparinized whole blood was required per sample, which forms an advantage 
compared to previously developed assays that required higher volumes of blood (4 to 30 
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mL). The method we developed for isolation of the IMPDH enzyme from PBMCs is easier 
than the method isolating CD4+ T-cells (Vethe et al14) which needs more sophisticated 
laboratory equipment and trained employees. Using PBMCs approaches the target cells 
of MPA better than using whole blood (Albrecht et al15) or erythrocytes (Montero et al16). 
We found a strong correlation between the MPA concentration in the lysate samples 
and MPA plasma concentration. This demonstrates that the used enzyme lysates have a 
MPA concentration that is directly correlated to the MPA concentration in plasma. This 
correlation is necessary to correlate the IMPDH activity measured in an ex vivo setting 
to the in vivo MPA plasma concentration. Nevertheless, the correlation does not mean 
automatically that the intracellular MPA concentration is equal to the MPA concentra-
tion in the lysate samples.
The second step in the IMPDH activity assay is the ex vivo incubation of the IMPDH 
enzyme lysate and the measurement of the enzyme product XMP. The composition of 
the used reaction mixture and the reaction conditions were close to the in vivo environ-
ment regarding temperature, pH, salts and physiological buffer. The mixture contained 
surplus substrate, co-substrate and potassium to contribute the enzymatic reaction 
of IMPDH. Different assay conditions were tested to investigate the influence of the 
incubation time and the dilution of the samples on the reaction. The time of incuba-
tion of the enzyme lysate has no influence on the formation rate of the product XMP, 
but disturbed significantly the new used internal standard adenosine monophosphate 
(AMP). We therefore chose an incubation time of 2.5 hours. An important disadvantage 
of this method is this long incubation time. After terminating the incubation, an ion-pair 
high-performance liquid chromatography (HPLC) method was used for the determina-
tion of XMP and AMP. The sensitivity and lower limit of quantification was sufficient for 
the tested patients groups (healthy volunteers, dialysis patients and renal transplant 
recipients). By using gradient elution the runtime per sample was decreased to 17 min 
and is now the shortest runtime of all published IMPDH activity assays so far.17
The biggest contribution to the increase in the robustness and reproducibility was 
made in the last step of the assay with the introduction of the new normalization factor 
AMP for the IMPDH activity. We showed that the so far known methods to normalize 
the enzyme activity, namely cell count and protein concentration, introduce measure-
ment errors in the estimated IMPDH activity. The intracellular substance AMP is released 
together with the IMPDH enzymes in the process of cell disruption by osmosis during 
the isolation of the enzymes from PBMCs. By using AMP as a so-called internal standard 
for the method to normalize the enzyme product XMP, IMPDH activity is only corrected 
for the number of cells that had released their content including the IMPDH enzyme. 
This is not the case when cells are counted or protein concentration is determined, since 
the not yet lysed cells are included as well in these procedures. The AMP concentration 
shows fewer fluctuations over time and is more equal over different patient groups 
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compared with protein concentration. Therefore, IMPDH activity normalized to AMP 
concentration is suitable to compare the IMPDH activity over different patients and 
different patient groups.
By making the above described changes, we have developed a method with less 
variability and at the same time improved practicability for the measurement of IMPDH 
activity in PBMCs. The within-day and between-days reproducibility of the IMPDH activ-
ity values as obtained by our modified HPLC method were less than 10.8%. Only the 
IMPDH activity assay of Albrecht et al15 using whole blood and the assay of Glander et 
al18 using PBMCs showed less variability between days (6.8% and 9.5%, respectively). 
The between-days reproducibility of all other known assays is higher and ranged from 
12.8% to 25%.14,16,19,20 Compared with these assays our assay is one of the most precise 
assays and only our assay allows comparison of values between different patient groups.
Despite the many advantages of this assay, the procedure is still time-consuming 
and labor-intensive in routine clinical practice. Therefore we have investigated the pos-
sibility to use the easier real-time polymerase chain reaction (RT-PCR) method to deter-
mine IMPDH mRNA levels as alternative biomarker for IMPDH activity. The correlations 
pre-transplantation and at all visits were examined between pre-dose IMPDH activity 
and IMPDH gene expression of both type I and type II. The correlation coefficients were 
weak and not significant. The rise in mRNA expression after day 6 in our study is presum-
ably due to the MPA induced inhibition of IMPDH activity. IMPDH mRNA expression is 
regulated by a negative feedback mechanism by guanine nucleotides. The inhibition 
of IMPDH activity by MPA leads to a decrease in the intra-cellular depots of guanine 
nucleotides.21-23 According to the studies performed by Jain et al IMPDH inhibitors do 
not appear to alter the regulation of IMPDH type I or II mRNA or protein levels directly,24 
but may have an indirect role in the regulation. Considering this role of MPA on the feed-
back mechanism of IMPDH mRNA expression, it was not unexpected we could not find a 
direct correlation. But also pre-transplantation – in the absence of MPA – we did not find 
a good correlation between IMPDH activity and IMPDH mRNA levels. Based on these 
findings we can conclude that more factors are involved in the regulation of IMPDH 
mRNA expression besides IMPDH activity and the inhibition of IMPDH enzymes by MPA 
alone. We conclude that IMPDH mRNA levels are not correlated to IMPDH activity, and 
therefore measuring IMPDH mRNA levels is not an alternative for IMPDH activity assays.
Using the improved IMPDH activity assay we have performed a longitudinal prospective 
study in 101 de novo renal transplant recipients, the IMPDH Activity Study. The data of 
this study was analyzed with the aim to create a basis for MMF dose optimization and 
individualization based on IMPDH activity measurements.
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MPA coNceNtrAtIoN – IMPDH ActIvIty correlAtIoN
We have investigated the correlation between IMPDH activity and PK parameters to 
determine the PK/PD relationship for MMF. Previous studies have shown that plasma 
MPA concentrations are well correlated to IMPDH activity,25,26 and this was supported 
by the observation that the IMPDH activity–time curve is the inverse of the MPA con-
centration–time curve. Nevertheless, the correlation between MPA concentrations and 
IMPDH activity was never characterized in an integrated PK/PD model to describe the 
PD parameters of the IMPDH inhibition by MPA. Furthermore, it is generally thought 
that the non-protein bound fraction is responsible for the pharmacological effect.12 
For this reason the unbound MPA concentration should have a better correlation with 
IMPDH activity compared to total MPA concentration. However, a comparison between 
unbound and total MPA concentrations in correlation with IMPDH activity had never 
been done.
A nonlinear mixed effects modeling (NONMEM) was used to describe the concentra-
tion–effect relationship between total MPA concentration and IMPDH activity. The PK of 
MPA were described using a 2-compartment model. An inhibitory Emax model adequately 
described the relationship between total MPA concentration and IMPDH activity. The 
maximal inhibition of IMPDH activity (Emax) was 89%. Baseline activity (E0) increased from 
55 (day 6) to 92 µmol/s/mol AMP (day 49 and 140) and the MPA concentrations which 
inhibit Emax to 50% activity (IC50) were decreased from 0.76 to 0.17 mg/L. As a reaction 
to the inhibition of IMPDH by MPA, the baseline activity of IMPDH increased over time 
after transplantation. But at the same time, IMPDH become more sensitive for the inhibi-
tion by MPA respected the decrease of IC50. In clinical practice, MPA concentrations are 
generally far above the IC50 so therefore the maximal inhibition of IMPDH activity is still 
achieved. It is already reported that the exposure to MPA increases over time after trans-
plantation due to a decreased MPA clearance.2,3,7 Combining those PK results (decrease 
of MPA clearance) together with our PD results (decrease of IC50), it is more reasonable 
to reduce the MPA doses over time after transplantation. Before the factor time after 
transplantation can be used to adjust MMF dose, more information is needed about the 
optimal window for IMPDH activity at different time intervals after transplantation. Thus 
far, our results confirm that IMPDH activity changes over time after transplantation in 
patients using MPA.
Besides using total MPA concentration to investigate the PK/PD relation with IMPDH 
activity, using the unbound MPA concentration is probably better to describe this 
relation, because the unbound fraction is presumed to be the pharmacologically active 
fraction. Therefore, unbound and total MPA concentrations were correlated with IMPDH 
activity by naïve pooling. A PK/PD analysis showed a significant correlation between 
IMPDH activity with total MPA and IMPDH activity with unbound MPA concentrations 
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measured at time points just before the next MMF dose administration. The 12-hours 
exposure to total and unbound MPA (AUC MPA) was also significantly correlated to 
IMPDH activity measured pre-dose. However, these correlation coefficients were poor 
and the estimated PD parameters E0 and IC50 showed large confidence intervals. Based on 
these results, we can not determine whether or not IMPDH activity measured on single 
time points is better correlated with bound or unbound MPA. A significant correlation 
was found for the 12-hours exposure to IMPDH activity (AUC IMPDH) with unbound MPA 
AUC using the therapeutic window 2.1 to 4.2 h·mg/L. The upper and lower limit of this 
window were obtained by multiplying the limits of the therapeutic window of total MPA 
AUC of 30 to 60 h·mg/L with the median unbound fraction of 7.0% found in our cohort of 
patients. Patients with high unbound MPA AUC had a significantly lower IMPDH activity. 
At the same time, there was no significant correlation for total MPA AUC correlated to 
IMPDH activity. Based on these findings, it seems that the AUC of IMPDH activity is better 
correlated to unbound MPA AUC than to total MPA AUC. These findings strengthen the 
hypothesis that unbound MPA is responsible for the inhibition of IMPDH. Nevertheless, 
before accepting this hypothesis, more extended population PD analyzes using total 
and unbound MPA, MPAG and AcMPAG concentrations should be made for a better and 
more precise comparison between unbound and total MPA concentrations in relation to 
IMPDH activity inhibition.
In the same study, we also found that patients with a serum albumin level below 
32 g/L had a significantly lower IMPDH activity compared to patients with a normal 
serum albumin. It is known from PK studies that patients with lower serum albumin have 
lower total MPA concentrations, and higher unbound MPA concentrations compared 
with patients with normal serum albumin.12,27,28 In our analysis we also found lower total 
MPA concentrations and lower IMPDH activity in patients with a low serum albumin, 
but we did not find higher unbound MPA concentrations. Actually, the unbound MPA 
concentration was not different between patients with low or normal serum albumin 
level, despite lower IMPDH activity in patients with low serum albumin. The PK in the 
present study is confirming previously reported studies, but the PD is not confirming the 
pharmacology of MPA. It remains unclear how the stronger inhibition of IMPDH activ-
ity in patients with low albumin levels is explained. Possibly patients with low albumin 
levels are in a poor general clinical condition and perhaps this poor condition induces a 
state of reduced immunoreactivity that is reflected in reduced IMPDH activity. It would 
be interesting to study the IMPDH activity in transplant patients not treated with MMF 
and see if IMPDH activity is a reflection of the immune status.
This present study is the first study which compared unbound and total MPA 
concentrations with IMPDH activity. Unfortunately, we found conflicting PD results, 
thus it is still unclear how unbound and total MPA concentrations are related to the 
inhibition of IMPDH and which concentration should be measured in clinical practice for 
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appropriate MMF therapy monitoring. To enlarge the knowledge of unbound and total 
MPA concentrations in correlation with IMPDH activity more investigation in this subject 
is necessary. Data collected in this study could be used in extended multivariate PK/
PD population analyses using also unbound MPA and MPAG concentrations and patient 
characteristics. These analyses could give more understanding which concentration of 
MPA – total or unbound – is responsible for the in vivo inhibition of IMPDH.
PAtIeNt vArIAbIlIty IN IMPDH ActIvIty
The PK/PD analyses of our data showed large inter-patient variability in IMPDH activity. 
Previous studies have also shown more than 10-fold inter-patient variability in IMPDH 
activity,9,11,18 but it is still unknown if any patient characteristics or clinical laboratory data 
can explain the variability. To optimize individual dose regimens it is necessary to deter-
mine which factors explain the inter-patient variability. Therefore, we have investigated 
if patient variability in IMPDH activity could be explained by genetic, demographic and 
pathophysiologic factors.
Single nucleotide polymorphisms (SNPs) are substitutions in the genetic DNA code 
of an enzyme and could change the amino acid sequence or folding of enzymes. In that 
way SNPs could change the activity of an enzyme. In humans there are two isoforms of 
IMPDH, type I and type II. IMPDH type I is constitutively present in cells, while type II is 
expressed in cells stimulated to proliferation.29,30 We studied eight different SNPs in the 
IMPDH type II gene in blood samples drawn from 80 renal transplant patients treated 
with MMF. Only the polymorphism IMPDH type II 3757T>C SNP was present with an allele 
frequency of 6.9%. The seven other polymorphisms in this gene were not observed in 
our patients. Despite the fact that IMPDH type II 3757T>C SNP is located on an intron 
of the IMPDH gene, we showed a significant difference in the IMPDH activity over 12 
hours (AUC IMPDH). Patients with a variant allele had a higher IMPDH activity compared 
to patients with a wild type allele, and one patient who was homozygous for this SNP 
had the highest IMPDH activity. This SNP explains 8.0% of the inter-patient variability in 
total IMPDH activity. Patients homozygous for IMPDH type II 3757T>C had 55% higher E0 
compared to wild type patients. The IMPDH type II 3757T>C polymorphism in the IMPDH 
type II gene was not associated with IMPDH activity pre-transplantation. This may 
be explained by the constitutive expression of mainly IMPDH type I in non-activated 
lymphocytes, and induction of expression of IMPDH type II following allo-recognition. 
IMPDH activity in pre-transplantation samples mainly reflects type I activity. It is 
remarkable that a polymorphism in the IMPDH type II gene showed significant differences 
in the IMPDH activity measured with an assay that can not distinguish between isoforms 
type I and type II. This fact, the similar MPA AUCs and the same proportion of use of 
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anti-thymocyte globulin (ATG) induction therapy in patients of the different genotypes 
strengthens the importance of polymorphisms in the IMPDH gene for clinical outcome 
after transplantation. The IMPDH type II 3757T>C polymorphism seems to be the most 
interesting polymorphism, because a recent study has already shown that this SNP is 
correlated to acute rejection.31 Based on genotyping the IMPDH type II gene, the clinical 
response to MMF treatment could be enlarged by increasing the MMF doses in patients 
having a variant type of this polymorphism. A higher MMF dose will decrease the IMPDH 
activity and will give more protection from acute rejections, where this polymorphism 
is associated to.
The influence of demographic characteristics on inter- and intra-patient variability 
was evaluated using an inhibitory Emax model. The analysis showed a high inter-patient 
variability in IC50 of 99%. The inter-patient variability in E0 was low (9%), however the 
intra-patient variability was considerable with a value of 39%. Introducing demographic 
patient parameters into the model showed a significant 12% lower E0 value in black 
patients compared to other ethnicity. It is reported that black patients require higher 
MMF doses than Caucasians to have the same effect.32 Our results showed a difference in 
the PD of MMF in black patients, but this difference is not explaining the higher required 
doses of MMF; a lower E0 value implicates a lower MMF doses is needed. To explain both 
differences in PK and PD in black patients, other factors need to be investigated. 
The covariate analysis showed a significant difference in the PD parameters for 
the clinical laboratory parameters leukocyte count and serum albumin. A decrease in 
leukocytes was associated with a decrease in E0. As MMF decreases the proliferation of 
lymphocytes by inhibition of IMPDH enzymes in the same cells, a decreased number of 
leukocytes might be the result of the decreased IMPDH activity measured at the same 
time. Increased albumin levels resulted in increased IC50 values for total MPA concentra-
tion. Previous studies have shown that lower albumin levels are associated with higher 
unbound MPA concentration.12,27,28 Nevertheless, no higher unbound MPA concentra-
tions were measured in patients with low albumin levels. Although we found evidence 
for a relationship between albumin levels and IMPDH activity, the role for unbound MPA 
concentration remains uncertain, as discussed before.
No other patient or physiologic characteristics were significantly correlated to the 
PD parameters (E0 and IC50) characterizing the relationship between inhibition of IMPDH 
activity and MPA plasma concentration. Besides the discussed polymorphism IMPDH 
type II 3757T>C, no other characteristics could contribute to optimize and individualize 
MMF therapy after renal transplantation as shown in this study. The present analyses 
provide only more information to understand and explain the patient variability in 
IMPDH activity.
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Acute rejectIoNS AND ADverSe eveNtS
The clinical use of monitoring IMPDH activity would be strengthened if IMPDH activity 
is also a predictor of biopsy proven acute rejections (BPAR) and adverse events. Glander 
et al10 showed that pre-transplant IMPDH activity is a predictor for post-transplant 
dose adjustments of MMF, mostly due to adverse effects of MMF. Therefore, we have 
investigated the correlation between IMPDH activity and the clinical outcomes BPAR 
and adverse events.
In our prospective observational study patients with a BPAR had a 23% significantly 
higher E0 and a 75% significantly higher IC50 at the first visit. The IMPDH AUC was slightly 
but not significantly higher in rejectors compared to non-rejectors with median values 
of 241 and 201 h·µmol/s/mol AMP. Patients with higher E0 and a higher IC50 are less sensi-
tive for the inhibitory effect of MPA and have therefore higher IMPDH activity and hence 
an increased risk of BPAR. Patients who suffer from leukopenia and serious anemia had 
significantly lower IMPDH AUC. Lower IMPDH activity will cause a reduced proliferation 
of lymphocytes, because of a decrease in GTP synthesis. This can be the reason for leuko-
penia. Erythrocytes do not depend on IMPDH activity for de novo GTP synthesis, because 
they have a salvage pathway. However, given the low hemoglobin levels in patients with 
low IMPDH activity, we have also shown that the inhibition of IMPDH has a suppressive 
effect on erythrocytes. 
In this study we showed PD monitoring of MMF therapy is related to several clinical 
outcomes. The IC50 and E0 are increased at visit 1 in patients with a BPAR. These patients 
need more inhibition of IMPDH by a higher dose of MMF to prevent rejection of the 
transplanted kidney. Nevertheless, we could not propose a clear threshold value of 
IMPDH activity with sufficient sensitivity and specificity, as there was considerable 
overlap in IMPDH activity between patients with a BPAR and patients without a BPAR, 
despite the significant differences in IC50 and E0.
No correlation was found between BPAR and the IMPDH type II 3757T>C SNP, de-
spite the fact that Grinyo et al31 recently reported that variant carriers for this SNP were 
3.4 times more likely to experience BPAR. They used a cohort of 237 renal transplant 
recipients, so we concluded that our cohort of 80 patients was underpowered to show 
a significant difference.
Though IMPDH mRNA levels were not correlated to IMPDH activity, IMPDH mRNA 
levels were significantly correlated to BPAR. Increased IMPDH mRNA type I and type II 
levels were observed pre-transplantation, while both types IMPDH mRNA levels were 
significantly decreased in rejectors compared to non-rejectors post-transplantation. We 
suggest that patients with less IMPDH mRNA have higher IMPDH activity and therefore 
higher immunoreactivity and higher rejection rates. Nevertheless, there is a consider-
able overlap in mRNA levels in rejectors and non-rejectors. The sensitivity and specificity 
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for the calculated cut-off level for IMPDH mRNA were poor (62-89%). Only at visit 4 lower 
IMPDH type I and type II mRNA expression was significantly correlated to pooled hema-
tological events. Since no other significant correlations were found for adverse events at 
other visits, unfortunately, mRNA monitoring is not going to solve the unmet need for a 
biomarker that may assist in preventing MPA induced toxicity.
Despite the fact that many studies have investigated the relationship between 
adverse events and pharmacodynamic parameters, there is still no parameter that has 
sufficient sensitivity and specificity to be of use for clinical practice.4,5,33 We have cor-
related the PD parameters IMPDH activity and IMPDH mRNA with adverse events, but 
unfortunately also did not find a useful clinical tool to guide MMF dose adjustments in 
the management of drug-related toxicity. Despite the significant correlations between 
some parameters and adverse events, the clinical relevance is too low given the low 
sensitivity and specificity.
exPreSSIoN oF mrNA over tIMe
The expression of mRNA correlated to adverse events and BPAR showed no differences 
between type I and type II mRNA expression. It is thought that IMPDH type I is con-
stitutively present in several cells, and IMPDH type II is expressed in cells stimulated 
to proliferation, mainly in cells in the growth or differentiation phase. Therefore, it is 
assumed that only expression of IMPDH type II is increased after immune activation by 
organ transplantation.26,34 Studies have evaluated the expression of the IMPDH type I 
and type II gene after kidney transplantation. The expression of both isoforms was up-
regulated within several weeks after transplantation using MMF treatment compared 
with values before transplantation and without MMF therapy. The expression of IMPDH 
mRNA over a longer time after transplantation has never been studied yet.
Changes in the expression of IMPDH type I mRNA in our study closely paralleled 
those of type II. We did not find any evidence that only IMPDH type II was increased 
after transplantation, as both levels altered. In this study decreased mRNA levels of 
both IMPDH type I and type II were shown directly after transplantation and both types 
increased over time after transplantation. Induction of IMPDH activity after prolonged 
exposure to MPA may be partially explained by the up-regulation of both IMPDH type 
I and type II mRNA in PBMCs. IMPDH mRNA expression is regulated by a negative feed-
back mechanism by guanine nucleotides. The inhibition of IMPDH activity by MPA leads 
to a decrease in the depots of guanine nucleotide. Based on these finding, we conclude 
that both IMPDH isoforms are induced after immune activation.
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IMPDH ActIvIty IN HSct recIPIeNtS
MMF is a frequently used immunosuppressive drug after solid organ transplantation 
but is also more frequently used in hematopoietic stem cell transplant (HSCT) patients 
to prevent acute graft-versus-host disease (GvHD).35 In HSCT patients we have found 
in previous studies that the clearance of MPA is higher compared to kidney transplant 
patients. In a 1000 mg twice daily dosing regimen the total MPA concentrations in HSCT 
patients are below what is considered efficacious. However, in many of the HSCT pa-
tients a low albumin level may result in high unbound MPA exposure. The high unbound 
MPA would then result in a substantial inhibition of IMPDH activity, which obviates the 
need for increased dosing.36 To optimize the dose regimen in this patient group, a PD ap-
proach could be useful, and could solve the dilemma of adjusting the MMF dose or not.
In the HSCT patients of our pilot study, a large inter-patient variability in IMPDH 
activity was observed. IMPDH activity of HSCT patients compared to renal transplant 
patients did not show significant differences and was comparable at pre-dose time 
point and 2 hours after MMF dosing. However, a significant difference was found in MPA 
concentrations. HSCT patients showed 70% lower pre-dose concentrations and 60% 
lower 2 hours concentrations compared to renal transplant patients. Based on these 
findings we conclude that IMPDH in HSCT patients is more sensitive to the inhibitory 
effect of MMF compared to renal transplant patients. Whether this difference is the 
result of a lower Emax and/or a higher IC50 of IMPDH and a different unbound concentra-
tion of MPA needs to be investigated with more sophisticated analytical methods than 
used in this study. No significant differences were found in IMPDH activity in patients 
who developed GvHD compared to patients without GvHD. Nevertheless, significantly 
lower IMPDH activity was found in patients suffering from serious adverse events like 
neutropenia, thrombopenia and anemia.
Based on the significant correlations we have found between IMPDH activity and 
adverse events, this pilot study showed that PD monitoring of MMF therapy could be 
useful in HSCT patients to find a more accurate dose regimen for this patient group. 
Low total MPA exposure is associated with a higher incidence of GvHD,37 and therefore 
an average MPA steady state concentration of 2.5 to 5.0 mg/l is suggested as the thera-
peutic range for MPA in these patients.38 But still, there are potential inaccuracies and 
difficulties in interpreting total MPA concentrations into clinical dose adjustments.38,39 
It is also not possible to adopt doses regimens of renal transplant patients, because the 
physiologic differences peri-transplant between renal transplant and HSCT patients that 
alter drug disposition. These differences include renal function, chemotherapy effects, 
cyclosporine A co-treatment, prophylactic antibiotic use and higher severity of illness 
which result in large variability in PK between renal transplant and HSCT patients. By 
measuring the PD parameter IMPDH activity these differences will partly be eliminated 
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for it is representing the direct effect of MPA. Studying the PK/PD relationship of MMF 
will provide more specific information in HSCT patients which could help to optimize 
the treatment with MMF. 
In the present pilot-study, significant correlations between IMPDH activity and the 
toxicity of MMF were observed. A reduction of the MMF dose could result in less toxicity 
in patients with low IMPDH activity, while there is still accurate prophylaxis to GvHD. 
Because it is already shown that low MPA exposure is associated with an increase of 
the incidence of GvHD, it is not rational to reduce in general the MMF dose for all HSCT 
patients. In our study large inter-patient and inter-disease variability has also been 
observed. Potential reasons for the variability could be found in the wide diversity of the 
characteristics of the patients, which include the diagnoses for transplantation, stadium 
of disease, conditioning regimens (chemotherapy and body irradiation), CMV status, 
and donor characteristics. The findings of the PD of IMPDH activity after MMF therapy 
of the present study have to be confirmed in more selected and larger cohorts of HSCT 
patients. Further studies are needed to show if there is any clinical relevance of monitor-
ing IMPDH activity in these patient group to increase efficacy and decrease toxicity.
FurtHer INveStIGAtIoNS
Besides the new relevant information that our studies have given on the PD monitoring 
of IMPDH activity after MPA treatment, several questions emerged which require further 
research. This could be carried out to get more insight in the relationship between the PK 
and PD of MPA. The clinical application of the extended PK/PD model should investigate 
whether it could help to optimize and individualize MMF therapy after transplantation 
and other diseases that are treated with MMF like autoimmune diseases. 
The present thesis has enlarged the knowledge of the PK/PD relation between 
MPA concentration and IMPDH activity. Nevertheless, it is still not clear if unbound MPA 
concentrations are really better correlated to IMPDH activity compared with total MPA. 
Also, we have not investigated the role of the total and unbound concentration of the 
active metabolite acyl 7-O-MPA-glucuronide (AcMPAG) in the inhibition of IMPDH. In our 
studies, we have not sampled the patients during the enterohepatic circulation (EHC) 
between 6 and 12 hours after administration of MMF. When MMF is co-administrated 
with tacrolimus, the exposure to MPA is determined for 10 to 60% by the EHC40,41 There-
fore, sampling between those time points is necessary to have a correct IMPDH AUC. 
For a better understanding of the complicated inhibition of IMPDH more research on 
the PK/PD relationship could be done using total and unbound concentrations of MPA 
and AcMPAG in relation to IMPDH activity. This could be useful to find better targets to 
optimize and individualize MMF therapy. Another interesting field of further research 
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is the performance of IMPDH activity prior to rejection. It is still not known whether 
IMPDH activity alters only by inhibition of MPA or if other promoters of lymphocyte ac-
tivation – e.g. infection, co-morbidity, and primary disease – also induce IMPDH activity. 
The present studies did not sample the patients prior to acute rejections, so it would 
be of great interest to investigate the behavior of IMPDH activity prior rejection. For 
a better understanding of transcription and translation of IMPDH mRNA in transplant 
recipients, we suggest studying IMPDH mRNA in renal transplant recipients who are not 
on MMF treatment. Combining the results of both patient groups, the effect of MPA on 
the complex pathway of transcription and translation of IMPDH mRNA could be clarified.
Besides IMPDH type II also IMPDH type I is increased after transplantation. There-
fore, it is likely that overall IMPDH activity after transplantation is determined by IMPDH 
type I and type II. For that reason, pharmacogenetic polymorphisms in IMPDH type I 
gene could also contribute to the inter-patient variability of IMPDH activity. Research 
on IMPDH type I SNPs might be useful, as well haplotyping of all SNPs in the IMPDH 
type I and type II gene. More knowledge of the influence of these SNPs may help to 
comprehend the inter-patient variability of IMPDH activity.
The IMPDH activity assay used in this thesis was modified, but can still be improved 
further. Using the assay in clinical research did show that the lower limit of quantifica-
tion could be further optimized to measure XMP and AMP also in lower concentrations. 
Especially in patients suffering from leukopenia – where harvesting PBMCs is difficult – a 
lower limit of quantification will improve the accuracy and precision of the measured 
IMPDH activity. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) ana-
lytical techniques are the right choice of method for this purpose. The IMPDH activity 
assay has to be improved to monitoring IMPDH activity in daily clinical practice. For that 
purpose, a less labor-intensive and more rapid IMPDH activity assay is needed.
Besides research to enlarge the knowledge of the PK/PD relationship, further 
research could also be done with the purpose to optimize and individualize the MMF 
therapy based on this knowledge. Monitoring IMPDH activity does not have an excellent 
specificity and sensitivity for the clinical practice to define adverse events and acute 
rejections. Nevertheless, combining PD monitoring with PK monitoring could have the 
potency to improve MMF therapy by dose adjustments. Our data and conclusions, as 
well as new insights could be used for this clinical application.
FINAl coNcluSIoNS
In the studies presented in this thesis we have extensively investigated the PD of MMF 
therapy by monitoring IMPDH activity with the aim to find a basis for the optimization 
and individualization of MMF therapy after transplantation. Focused on the activity of 
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the enzyme IMPDH we have studied the correlations with several outcome parameters 
and we have expanded the knowledge of the PK/PD relationship between MPA concen-
tration and IMPDH activity. Unfortunately, based on our data IMPDH activity monitoring 
can not yet be recommended to optimize and individualize the MMF therapy. In the 
previous paragraphs we have discussed that the studied IMPDH enzyme is inhibited by 
many more factors than we have investigated and shows a large unexplained variabil-
ity within and between patients. Nevertheless, this thesis has given a basis of a better 
understanding of the IMPDH activity and IMPDH inhibition by MPA in patients treated 
with MMF. Our findings can serve as a starting point for future studies in the fascinating 
relationship between PK and PD. To understand all the details of the complicated way of 
inhibition of IMPDH, more information and studies are necessary. A better understand-
ing of the PK/PD relation could be a first step to optimize and individualize MMF therapy 
based on the results of IMPDH activity studies.
Summarized, the main conclusions of this thesis are:
- Inter-patient variability in IMPDH activity is partly explained by the genetic 
 polymorphism IMPDH type II 3757T>C, ethnicity, leukocyte count and serum 
 albumin,
- Leukocyte count and serum albumin also partly explained the intra-patient 
 variability in IMPDH activity,
- Baseline IMPDH activity (Emax) increases and the IC50 decreases over time after
 transplantation,
- Patients with increased IC50 and increased E0 in the first week after transplantation 
 have a higher risk of BPAR and patients with lower IMPDH activity have more MMF 
 related adverse events, and
- Patients with decreased IMPDH mRNA type I and type II have a higher risk of BPAR, 
 but IMPDH mRNA levels are not correlated to adverse events.
- Both IMPDH type I and type II isoforms are induced after immune activation,
- It seems that IMPDH activity is better correlated to the exposure of unbound MPA 
 than to total MPA.
- We have improved the IMPDH activity assay to a more precise and practical assay, 
 that can used to monitor MPA therapy in different patient groups, but
- Measuring IMPDH mRNA is not an alternative for IMPDH activity assays.
- IMPDH seems to be more sensitive to the inhibitory effect of MPA in HSCT patients 
 compared with renal transplant patients, and
- In HSCT patients, IMPDH activity is not correlated to GvHD, but patients with low 
 IMPDH activity suffer from serious adverse events.
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The enzyme inosine 5’-monophosphate hydrogenase (IMPDH) is the key enzyme in the 
de novo synthesis of nucleotides and induces the rate-limiting step in this synthesis. 
The proliferation of lymphocytes depends on this pathway of synthesis of nucleotides, 
which makes it an attractive pharmacological target of immunosuppressive therapy. My-
cophenolic acid (MPA) – the active moiety of mycophenolate mofetil (MMF) – decreases 
the proliferation of T- and B-lymphocytes. For that reason MMF is used as immunosup-
pressive drug after solid organ transplantation to prevent rejection of the graft. MMF is 
also increasingly used after haematopoietic stem cell transplantation to prevent acute 
graft-versus-host disease. The recommended dose regimen for MMF is 1000mg twice 
daily, but more and more it is thought that a patient tailored regimen is better for the 
balance between efficacy and toxicity. Pharmacokinetic (PK) studies have shown that 
MMF exhibits large between- and within-patient variability in PK, whereas MPA plasma 
concentrations were found to correlate with efficacy. However, randomized trials com-
paring fixed dose versus concentration controlled regimens found contradicting results. 
An attractive approach to optimize and individualize the MMF therapy in transplant 
recipients could be pharmacodynamic (PD) monitoring by measuring IMPDH activity. 
IMPDH activity may better reflect the individual biological response to the drug, because 
it combines PK and PD variability. Several studies have demonstrated that IMPDH activ-
ity has a large inter-patient variability, a small intra-patient variability and that activity 
alters over time after transplantation. Only one study has correlated IMPDH activity with 
clinical endpoints and has demonstrated a correlation between pre-transplant IMPDH 
activity and post-transplant dose adjustments, MPA related adverse events and acute 
rejections. At the start of this project we aimed to investigate the added value of IMPDH 
monitoring in transplant patient management.
After a general introduction to PK monitoring of MPA and PD monitoring of IMPDH ac-
tivity in chapter 1.1, the scope and aims of this thesis were formulated. The overall aim 
of this thesis was to explore the usefulness of monitoring IMPDH activity in MPA treated 
transplant patients to optimize and individualize the MPA therapy. More specifically, 
separate objectives were also addressed and formulated in chapter 1.2.
An important tool in the studies presented in this thesis is the newly modified IMPDH 
activity assay described in chapter 2.1. In the first step of the assay peripheral blood 
mononuclear cells (PBMCs) are isolated from 2.5 mL whole blood using a Ficoll-Paque 
gradient without manipulating the cells extensively and without washing out the intra-
cellular MPA concentration which is responsible for the inhibition of IMPDH. Secondly, 
cell lysates containing the IMPDH enzyme are incubated ex vivo in a reaction mixture 
close to the in vivo environment containing potassium, IMP as substrate and nicotin-
amide adenine dinucleotide (NAD) as hydrogen acceptor at 37°C. One disadvantage of 
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the presented assay was the relatively long incubation time of 2.5 hours. After the reac-
tion was terminated, xanthine monophosphate (XMP) and adenosine monophosphate 
(AMP) levels in the samples were measured using a validated high-performance liquid 
chromatography (HPLC) method. In other IMPDH activity assays, the production rate of 
XMP is expressed per cell or per amount protein. A new factor to normalize the formed 
IMPDH enzyme product XMP was introduced in the third step. Using the intra-cellular 
substance AMP to normalize XMP production produced better results for the assessed 
IMPDH activity than using cell count and protein concentration. In several experiments 
it has been shown that by using AMP the derived IMPDH activity is less sensitive to 
contamination of plasma, residual supernatant of the washing step, extra-cellular pro-
tein and erythrocytes. The reproducibility of IMPDH activity normalized to AMP is better 
compared to normalize to cell count, even in increased enzyme concentration in the 
samples and in different patient groups.
The modified assay is capable of reducing the variability and at the same time 
improving the practicability of the enzymatic assay for assessment of IMPDH activity in 
PBMCs. The within-run and within-day reproducibilities of the IMPDH activity values as 
produced by this modified HPLC method were less than 11% and are for such a complex 
method really within the generally accepted limit of 15%.
The modified IMPDH activity assay was thereafter used in the IMPDH Activity study, a 
prospective, longitudinal PK-PD study in 101 de novo kidney transplant patients. Blood 
samples were drawn pre-transplantation and on 4 visits after transplantation for PK 
and PD monitoring, determination of IMPDH mRNA levels and for pharmacogenetic 
purposes. Clinical outcome, clinical laboratory data and occurred adverse events were 
collected during all visits. Collected data was analyzed with different aims in chapters 3 
and 4.
In chapter 3.1 all patient data were analyzed simultaneously by using the nonlinear 
mixed effects modelling. Pharmacokinetic parameters for MPA were estimated using 
Bayesian analysis and the parameters were fixed in the second step where the phar-
macodynamic parameters were estimated using an Emax-model. A large inter-patient 
variability (102%) was found for the IC50, the concentration at half maximum inhibition 
(Emax) of IMPDH activity. Furthermore a considerable intra-patient variability of baseline 
activity (E0) was detected (41%). A significant increase of E0 from 55 to 92 h·µmol/s/mol 
AMP was observed over time, while IC50 decreased from 0.76 to 0.17 mg/L. E0 of black 
patients was 12% lower that for Caucasian, Asian and Hispanic patients. Patients with 
a homozygous variant type of IMPDH type II 3757T>C exhibited an E0 which was 55% 
higher than for homozygous wildtype and heterozygous patients. IC50 was significantly 
lower in patients with decreased leukocytes or decreased albumin. The inter- and intra-
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patient variability in E0 and IC50 was not explained by other patient characteristics or 
clinical laboratory outcomes. Variability in the pharmacodynamic parameters partly 
predicted clinical outcome and adverse events. Patients with a biopsy proven acute 
rejection (BPAR) had significantly a 23% higher E0 and 75% higher IC50 6 days after 
transplantation compared with patients without a BPAR. Patients with lower IMPDH 
AUC had significantly more leukopenia and/or anemia compared to patients with higher 
IMPDH AUC. These findings emphasize the importance of adequate inhibition of IMPDH 
to prevent acute rejections. Although high IMPDH activity was associated with the oc-
currence of BPAR and low IMPDH activity was correlated with the presence of adverse 
reactions, a target value for the inhibition of IMPDH activity has still to be defined. In our 
study we observed that BPAR was better associated with IMPDH activity than with MPA 
plasma concentrations. As a result, we conclude that monitoring of IMPDH activity could 
contribute to optimize MMF therapy. 
To investigate the relevance of unbound MPA concentrations in causing the biological 
effect of MPA, we correlated total and unbound MPA concentrations to IMPDH activity 
and albumin levels in chapter 3.2. Using an Emax model, significant, but poor, correla-
tions were found between IMPDH activity and MPA total and unbound concentrations 
and exposure on day 6. The pharmacodynamic parameters E0 and IC50 showed large 
confidence intervals, due to the large inter-patient variability of IMPDH activity. Dividing 
MPA concentrations into three groups using the therapeutic window of total MPA AUC 
(30 to 60 h·mg/L) and of unbound MPA AUC (2.1 to 4.2 h·mg/L; limits were multiplied 
with 7.0% median unbound fraction) showed a significant difference in IMPDH activity 
for only unbound MPA AUC. A higher unbound MPA AUC gave a significantly higher 
inhibition of IMPDH activity, whereas no associated was detected for total MPA AUC. 
IMPDH activity was significantly lower in patients with low serum albumin compared 
to patients with high albumin levels despite the fact that both patient groups exhibited 
comparable unbound MPA AUC values. Patients with a low albumin level exhibited 
a significantly lower total MPA AUC. We conclude that unbound MPA AUC described 
inhibition of IMPDH activity better than total MPA concentrations. However, we have 
no explanation for the fact that IMPDH activity is decreased more in patients with low 
albumin levels despite the comparable unbound MPA concentrations. 
The aim of chapter 4.1 was to correlate eight different single-nucleotide polymorphisms 
(SNPs) of the IMPDH type II gene to IMPDH activity to explain inter-patient variability. 
In the studied cohort only the SNP IMPDH type II 3757T>C was observed with an allele 
frequency of 6.9%. Two percent of the patients were homozygous for variant type of the 
SNP. A comparison between wild type and variant carrier patient showed that IMPDH 
activity pre-transplantation was not significantly different between the patients. On day 
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6 post-transplantation the exposure to IMPDH activity was significantly 49% higher in 
variant carrier patients. We concluded that IMPDH type II 3757T>C polymorphism is as-
sociated with an increased IMPDH activity in MMF treated renal transplant patients and 
explains 8.0% of the inter-patient variability in IMPDH activity.
IMPDH activity assays are time-consuming and labor-intensive. In chapter 4.2 we 
have therefore investigated the quantification of IMPDH mRNA as alternative method 
for monitoring MMF therapy. The study was designed to correlate IMPDH mRNA levels 
with IMPDH activity and clinical outcome in renal transplant recipients. No correlations 
were found between IMPDH type I and type II mRNA levels and IMPDH activity both 
pre- and post-transplantation. Determination of IMPDH mRNA levels is therefore no 
alternative for measuring IMPDH activity. Patients with an increased pre-transplantation 
IMPDH mRNA level exhibited an increased, but not significant, risk of BPAR. On day 6 
post-transplantation, decreased IMPDH type I and type II mRNA levels were significantly 
correlated to the occurrence of BPAR. Although the regulation of the expression of the 
two isoforms is presumed to be different, IMPDH type I as well as type II mRNA levels 
increased in parallel over time after transplantation.
MMF is used more frequently in hematopoietic stem cell transplantation (HSCT) 
recipients to prevent acute graft-versus-host disease. In chapter 5.1 we performed a 
pilot-study in HSCT patients to explore for the first time the pharmacodynamics after 
MMF treatment by measuring IMPDH activity. Patients with a higher IMPDH activity 
pre-dose had a stronger inhibition of IMPDH activity at 2 hours. The inter-patient 
variability for the concentration-effect relationship was large, similar as in renal 
transplant recipients. Inhibition of IMPDH activity in HSCT patient was similar as for renal 
transplant patients despite the fact that MPA levels were lower in the latter group. We 
hypothesize that IMPDH enzymes of HSCT patients are more sensitive for the inhibition 
of MPA than IMPDH enzymes of renal transplant recipients. No significant correlations 
were found between IMPDH activity and the occurrence of graft-versus-host disease 
(GvHD), but IMPDH activity was significantly lower in patients who suffered from serious 
neutropenia, thrombocytopenia and anemia compared to patients with none or mild 
grade adverse events. The clinical relevance of this pilot study has to be confirmed in a 
larger cohort of HSCT patients.
chapter 6 discusses to what extent the combined main finding of the presented studies 
are in agreement with the specific aims formulated in chapter 1.2. In addition, some 
comments are given with regard to the applied study design.
We have improved the IMPDH activity assay, but the assay is still too time-consum-
ing and labor-intensive for daily clinical use. Unfortunately, measuring IMPDH mRNA 
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levels is not an alternative for IMPDH activity assays. An integrated pharmacokinetic-
pharmacodyanmic model was developed to describe the correlation between total 
MPA concentration and IMPDH activity. We have shown that IMPDH activity is better 
correlated to unbound MPA concentration than to total MPA concentrations. More 
extended population PD analyzes should be made for more precise comparisons be-
tween unbound and total MPA concentrations in relation to IMPDH activity inhibition. 
The genetic polymorphism IMPDH type II 3757T>C, patients of black ethnicity, leukocyte 
count and serum albumin explained some of the intra- and/or inter-individual variability 
in IMPDH activity. Patients with increased IC50 and increased E0 had a higher risk on BPAR, 
and patients with lower IMPDH activity showed more MMF related adverse events. We 
found decreased levels of both IMPDH type I and type II directly after transplantation 
and both types increased over time after transplantation. Therefore, both isoforms 
should be inhibited to decrease the proliferation of the lymphocytes and to prevent the 
graft for acute rejection. Several new research questions have risen during the overview 
and discussion of the results presents in this thesis. Therefore, suggestions for further 
investigations are also given.
Based on our data, IMPDH activity monitoring can not yet be recommended to 
optimize and individualize the MMF therapy. In this thesis we have discussed that the 
studied IMPDH enzyme is inhibited by many more factors than we have investigated 
and shows a large unexplained variability within and between patients. To understand 
all the details of the complicated way of inhibition of IMPDH, more information and 
studies are necessary. This thesis has given a basis of a better understanding of the 
IMPDH activity and IMPDH inhibition by MPA in patients treated with MMF. Our findings 
can serve as a starting point for future studies in the fascinating relationship between 
PK and PD.

Chapter 7.2
Samenvatting voor niet-ingewijden
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Wanneer bij een patiënt de nieren niet meer goed werken, is het soms mogelijk om 
een nier van iemand anders te krijgen door middel van een transplantatie. Het lichaam 
van de patiënt ziet echter deze nieuwe nier als een lichaamsvreemd orgaan en zal het 
proberen af te stoten. Daarom worden transplantatiepatiënten altijd behandeld met 
medicijnen die afstotingen proberen te voorkómen. De juiste dosering van deze me-
dicijnen wordt bijna altijd per patiënt vastgesteld, om zo de optimale balans te krijgen 
tussen het gewenste effect en de bijwerkingen. De dosering van het veel gebruikte me-
dicijn mycofenolaatmofetil (MMF, merknaam CellCept®) wordt echter niet per patiënt 
vastgesteld. De aanbevolen dosering voor MMF is tweemaal daags 1000 mg voor elke 
willekeurige patiënt. Maar steeds meer denkt men dat een dosering berekend voor elke 
patiënt afzonderlijk beter is om een juiste balans tussen werkzaamheid en bijwerking te 
krijgen. Het onderzoek beschreven in dit proefschrift heeft zich gericht op het optimali-
seren en individualiseren van de dosering van MMF.
Het onderzoek heeft zich specifiek gericht op het enzym inosine 5’-monofosfaat de-
hydrogenase (IMPDH). Enzymen zijn eiwitten die zich in het lichaam bevinden en die 
zorgen dat stoffen omgezet worden in specifieke, andere stoffen. Het enzym IMPDH is 
een belangrijk enzym dat zorgt voor de aanmaak van nucleotiden: stoffen die nodig 
zijn bij het maken van cellen. De snelheid waarmee IMPDH deze stoffen maakt is de 
snelheidsbeperkende stap voor het ontstaan van deze nucleotiden. De ontwikkeling 
van de witte bloedcellen (lymfocyten) die het afweersysteem in het lichaam vormen, 
zijn afhankelijk van deze stoffen die door het enzym IMPDH gemaakt worden. Hoe 
actiever IMPDH is, hoe meer nucleotiden gemaakt kunnen worden en des te beter witte 
bloedcellen ontwikkeld kunnen worden en hoe sterker het afweersysteem is.
Na bijvoorbeeld een transplantatie is het nodig om de afweer van het lichaam juist 
te verminderen. Op die manier kan worden voorkomen dat het lichaam het getransplan-
teerde orgaan afstoot. Om dit te bereiken is het verminderen van de snelheid waarmee 
IMPDH stoffen maakt een aantrekkelijk doel voor geneesmiddelen. De behandeling om 
het afweersysteem te verminderen wordt immunosuppressieve therapie genoemd.
De stof mycofenolzuur (MPA) is de actieve vorm van het medicijn MMF en vermindert 
de ontwikkeling van twee soorten witte bloedcellen, de T- en B-lymfocyten. Om die re-
den wordt MMF gebruikt als immunosuppressief geneesmiddel na orgaantransplantatie 
om afstoting van het getransplanteerde orgaan tegen te gaan. Ook wordt MMF steeds 
meer gebruikt na transplantatie van bloedstamcellen (ook wel beenmergtransplantatie 
genoemd) om acute graft-versus-host (transplantaat tegen patiënt) reacties te voorko-
men. Zoals elk geneesmiddel heeft ook MMF bijwerkingen. De meest voorkomende bij-
werkingen zijn misselijkheid, braken, diarree, bloedarmoede, verminderde hoeveelheid 
witte bloedcellen, diverse infecties en zelfs bepaalde soorten kwaadaardige gezwellen.
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Wat het líchaam doet met het medicijn wordt farmacokinitiek genoemd. Farmacokine-
tische studies hebben aangetoond dat tussen verschillende patiënten (inter-patiënt) 
en in één dezelfde patiënt (intra-patiënt) grote verschillen zijn in wat het lichaam doet 
met de stof MPA. Dit heeft bijvoorbeeld als gevolg dat er grote verschillen zijn in de 
concentratie van MPA in het bloedplasma bij een gelijke dosering van het geneesmid-
del. En dat terwijl de MPA concentratie juist samenhangt met de werkzaamheid van het 
geneesmiddel. Toch zijn de uitkomsten van wetenschappelijke onderzoeken, waar een 
vaste dosering van het geneesmiddel is vergeleken met een dosering aangepast op de 
individuele patiënt, tegenstrijdig met elkaar. Een andere aanpak om de behandeling 
met MMF bij transplantatie patiënten te optimaliseren en te individualiseren is door te 
kijken wat het míddel met het lichaam doet. Dit wordt farmacodynamiek genoemd. Het 
meten van de activiteit van het enzym IMPDH is een manier om de behandeling met 
MMF farmacodynamisch te volgen.
Veronderstelt wordt dat het meten van IMPDH activiteit beter de individuele reactie 
van het lichaam op het geneesmiddel MMF weergeeft. Het combineert de verander-
lijkheid van farmacokinetiek en farmacodynamiek in en tussen patiënten (intra- en 
inter-patiënt variabiliteit). Diverse farmacodynamische studies hebben aangetoond dat 
IMPDH activiteit een grote inter-patiënt variabiliteit en een kleine intra-patiënt variabi-
liteit heeft. Er is ook gezien dat de IMPDH activiteit verandert in de loop van de tijd na 
transplantatie. Er is slechts één onderzoek dat gekeken heeft naar de samenhang van 
IMPDH activiteit met klinische eindpunten, zoals afstoting van het getransplanteerde 
orgaan. Dit onderzoek heeft aangetoond dat patiënten die al voor de transplantatie 
een hoge IMPDH activiteit hebben vaker een verlaging van de dosis MMF na trans-
plantatie krijgen. Ook hadden patiënten met een hoge IMPDH activiteit gemeten voor 
transplantatie vaker last van bijwerkingen en hadden meer acute afstotingen van het 
getransplanteerde orgaan. Bij de start van dit promotieonderzoek hebben we als doel 
gesteld om te kijken of het meten van IMPDH activiteit bij transplantatiepatiënten een 
toegevoegde waarde heeft op de behandeling met het geneesmiddel MMF.
Na een algemene inleiding over het farmacokinetisch monitoren van de stof MPA en het 
farmacodynamisch monitoren van IMPDH activiteit in hoofdstuk 1.1, is de strekking 
en zijn de doelstellingen van dit proefschrift verwoord in hoofdstuk 1.2. Het algemene 
doel van dit proefschrift is het onderzoeken van de bruikbaarheid van IMPDH activiteit 
monitoring om de behandeling met MPA te optimaliseren en te individualiseren in pa-
tiënten na een transplantatie. Dit algemene doel is verder uitgewerkt in meer specifieke 
en afzonderlijke doelstellingen, die ook in hoofdstuk 1.2 zijn vermeld. 
Een belangrijk instrument dat in de studies in dit proefschrift is gebruikt, is de gewij-
zigde analysemethode die de IMPDH activiteit meet. Deze methode is beschreven in 
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hoofdstuk 2.1. De eerste stap van deze analysemethode bestaat uit het halen van 
bepaalde witte bloedcellen – perifeer bloed mononucleaire cellen (PBMCs) – uit 2,5 ml 
bloed. Hiervoor is gebruik gemaakt van een Ficoll-Paque gradiënt, een soort vloeibare 
suikerlaag waarbij de PBMCs gescheiden worden van de rode bloedcellen, bloedplaatjes 
en het bloedplasma. Door deze techniek zo aan te passen, hebben we ervoor gezorgd 
dat de cellen zo min mogelijk bewerkt en gewassen werden. Op deze manier wordt de 
MPA concentratie in de cellen die verantwoordelijk is voor het remmen van de IMPDH 
activiteit minimaal veranderd. De cellen zijn vervolgens kapot gemaakt, zodat het 
IMPDH enzym vrijgekomen is.
De tweede stap is het plaatsen van het IMPDH enzym in een reactiemengsel van 
37°C dat sterk lijkt op de natuurlijke, lichamelijke omgeving. In het reactiemengsel zet 
het IMPDH enzym de stof inosine monofosfaat (IMP) om in de stof xanthine monofosfaat 
(XMP). Hoe meer van dit XMP wordt gemaakt, hoe actiever het IMPDH is. Het IMPDH 
kreeg 2,5 uur de tijd om XMP te maken. Deze lange periode was nodig om een goede 
herhaalbaarheid van de metingen te krijgen, maar is tevens een nadeel van de beschre-
ven analysemethode. Na deze periode is de concentratie van de gevormde stof XMP en 
de concentratie van de stof adenosine monofosfaat (AMP) – een stof uit de gebruikte 
cellen – gemeten met een gevalideerde High Performance Liquid Chromatography 
(HPLC) methode.
De derde stap is om de gemeten concentratie van het gevormde product XMP weer 
te geven per cel die gebruikt is in de meting. Hierdoor kan de gemeten IMPDH activi-
teit vergelijken worden met IMPDH activiteit gemeten in andere monsters. In andere 
beschreven IMPDH activiteit analysemethodes is deze productiesnelheid uitgedrukt 
per getelde cel in het totale monster of per hoeveelheid eiwit in het totale monster. 
Een nieuwe factor om de door het IMPDH enzym gevormde stof XMP weer te geven is 
de stof AMP. Deze stof komt uit dezelfde cellen waaruit de gebruikte IMPDH enzymen 
komen. Deze nieuwe manier van het berekenen van IMPDH activiteit geeft daarom 
beter aan wat de totale activiteit is van het IMPDH enzym per cel in vergelijking met het 
totale aantal cellen in het monster of de totale hoeveelheid eiwit in het monster, waar 
tot nu toe mee werd gerekend. In diverse experimenten is vervolgens aangetoond dat 
door het gebruik van AMP de berekende IMPDH activiteit minder gevoelig is voor ver-
ontreiniging, eiwitten en rode bloedcellen die ook in het monster kunnen zitten. Zelfs 
wanneer het monster hoge concentraties enzym bevat is de reproduceerbaarheid van 
de gemeten IMPDH activiteit juist en precies. Ook is het nu mogelijk om IMPDH activiteit 
van verschillende patiëntengroepen met elkaar te vergelijken.
De gewijzigde analysemethode om IMPDH activiteit te meten in PBMC’s geeft 
minder variabiliteit tussen de metingen en is tegelijkertijd praktisch beter uitvoerbaar-
heid. De reproduceerbaarheid van de IMPDH activiteit gemeten op dezelfde dag en op 
verschillende dagen was kleiner dan 11%, en is zeker voor een zo’n complexe analyse-
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methode goed te noemen omdat ze binnen de algemeen aanvaarde grens van 15% 
vallen.
Vervolgens is de gewijzigde analysemethode om IMPDH activiteit te meten gebruikt 
in de IMPDH Activity study (IMP-Act study); een prospectieve, longitudinale farmacoki-
netiek-farmacodynamiek studie in 101 nieuwe niertransplantatie patiënten. Bloed-
monsters werden vóór transplantatie en op 4 momenten na transplantatie afgenomen 
voor het monitoren van de farmacokinetiek en farmacodynamiek van MPA, het meten 
van IMPDH mRNA concentraties en voor farmacogenetische doeleinden. Klinische 
resultaten, klinisch laboratorium gegevens en het optreden van bijwerkingen werden 
verzameld tijdens alle bezoeken. De verzamelde data zijn vervolgens met verschillende 
doelstellingen geanalyseerd en beschreven in de hoofdstukken 3 en 4.
In hoofdstuk 3.1 zijn alle gegevens van de patiënten gelijktijdig geanalyseerd met be-
hulp van het computerprogramma NONMEM (nonlinear mixed effects modelling). Eerst 
zijn de farmacokinetische variabelen aan de hand van de gemeten MPA concentraties 
geschat met behulp van Bayesiaanse analyse. Hierna zijn met gebruik van deze farma-
cokinetische variabelen de farmacodynamische variabelen geschat aan de hand van de 
gemeten IMPDH activiteit. Hiervoor is gebruik gemaakt van een zogenoemd maximaal 
effect model, het Emax-model. Dit model beschrijft hoe het basale effect (E0) van een 
enzym –hier de maximale IMPDH activiteit van een patiënt– wordt geremd naarmate de 
concentratie van het remmende geneesmiddel –hier de MPA concentratie– toeneemt. 
De concentratie waarbij 50% van de maximale remming (Emax) van het enzym wordt 
bereikt is de IC50-waarde. Onze studiegroep liet een grote inter-patiënt variabiliteit van 
102% zien voor IC50. Verder werd een aanzienlijke variabiliteit van 41% per patiënt gezien 
in E0 in de periode na transplantatie. E0 steeg van 55 tot 92 μmol/s/mol AMP in de tijd 
na transplantatie, terwijl de IC50 tegelijkertijd daalde van 0,76 tot 0,17 mg/L. De E0 van 
patiënten van het negroïde ras was 12% lager in vergelijking met blanken, Aziatische en 
Ibero-Amerikaanse patiënten.
Tevens is er gekeken naar de genetische code van het gen dat codeert voor het 
IMPDH enzym. Op plaats 3757 in het gen werd bij sommige patiënten in plaats van 
de gebruikelijke ‘T’ een ‘C’ gezien. Dit type van verschillende verschijningsvormen van 
een gen wordt een enkelvoudige nucleotide polymorfisme (SNP) genoemd. Door een 
SNP kan de werking van het enzym worden versneld, vertraagd of zelfs geheel geïnac-
tiveerd worden. De hier onderzochte SNP wordt aangegeven als IMPDH type II 3757T>C. 
Patiënten waarvan beide genen deze variatie hadden, vertoonden een 55% hogere E0 in 
vergelijking met patiënten waarvan één of geen gen deze variatie had. De IC50-waarde 
was significant lager bij patiënten met een laag aantal witte bloedcellen of een lage 
albumine concentratie in het bloed. De variabiliteit tussen patiënten en in individuele 
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patiënten in E0 en IC50 werd niet verklaard door andere kenmerken van patiënten of 
klinisch laboratorium resultaten.
De variabiliteit in de farmacodynamische variabelen E0 en IC50 voorspelde deels de 
klinische resultaten en bijwerkingen. Patiënten met een zogenoemde biopsie bewezen 
acute afstoting (BPAR) van het getransplanteerde orgaan hadden een 23% significant 
hogere E0 en een 75% significant hogere IC50 op dag 6 na de transplantatie in vergelij-
king met patiënten zonder een BPAR. Patiënten met een lagere blootstelling aan IMPDH 
activiteit over 12 uur hadden meer bijwerkingen van MMF in vergelijking met patiënten 
met een hogere blootstelling aan IMPDH activiteit. Deze patiënten leden vaker aan een 
te kort aan witte bloedcellen en/of bloedarmoede.
Deze bevindingen onderstrepen het belang van voldoende remming van het IMPDH 
enzym om acute afstotingen te voorkomen. Maar ook dat het IMPDH enzym niet te veel 
geremd moet worden om zo bijwerkingen te verminderen. Hoewel de hoge IMPDH ac-
tiviteit samenhangt met het optreden van afstotingen en lage IMPDH activiteit met het 
optreden van bijwerkingen, moet een bruikbare streefwaarde voor de remming van de 
IMPDH activiteit nog worden vastgesteld. In ons onderzoek hebben we waargenomen 
dat afstoting beter samenhing met IMPDH activiteit dan met MPA concentraties in het 
bloed. Daarom concluderen we dat het monitoren van IMPDH activiteit kan bijdragen 
om de behandeling met MMF te optimaliseren.
In het bloed kunnen stoffen –en dus ook het geneesmiddel MPA– gebonden en niet-
gebonden zijn aan eiwitten die in het bloed zitten. Men gaat er van uit dat alleen het 
gedeelte dat ongebonden is ook daadwerkelijk werkzaam is. Om de relevantie van de 
ongebonden MPA concentratie te onderzoeken, hebben we in hoofdstuk 3.2 de totale 
(gebonden plus ongebonden) en de ongebonden MPA concentraties gecorreleerd aan 
IMPDH activiteit en albumine concentraties. Met behulp van het Emax-model werd op 
dag 6 een significante, maar zwakke samenhang gevonden van IMPDH activiteit met 
totale en ongebonden MPA concentraties en met de blootstelling aan IMPDH activiteit 
over 12 uur. De farmacodynamische variabelen E0 en IC50 waren moeilijk te schatten 
vanwege de grote variabiliteit van IMPDH activiteit tussen de patiënten. Vervolgens zijn 
de patiënten verdeeld over drie groepen met als grens de grenzen die aan de blootstel-
ling van totaal MPA over 12 uur zijn gesteld (30 tot 60 h·mg/L) en aan de blootstelling 
van ongebonden MPA zijn gesteld (2,1 tot 4,2 h·mg/l; de grenzen van totaal MPA zijn 
vermenigvuldigd met 7,0%, de gevonden mediaan ongebonden fractie). Nu bleek dat er 
een significant verschil in IMPDH activiteit waarneembaar was voor de blootstelling aan 
ongebonden MPA. Een hogere blootstelling aan ongebonden MPA gaf een significant 
hogere remming van de IMPDH activiteit, terwijl dit niet gezien werd bij de blootstelling 
aan totaal MPA.
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De IMPDH activiteit was significant lager bij patiënten met een lage albumine concen-
tratie in vergelijking met patiënten met een hoge albumine concentratie. De ongebon-
den MPA concentratie vertoonde geen verschil tussen beide groepen, terwijl verwacht 
werd dat patiënten met een lage albumine concentratie juist een hogere ongebonden 
concentratie zouden hebben. Deze veronderstelde hogere ongebonden concentratie 
zou het IMPDH meer kunnen remmen, dat de significant lagere IMPDH activiteit zou 
verklaren bij deze patiënten. Echter, er werd bij patiënten met een lage albumine 
concentratie juist een lagere totale MPA concentratie gevonden. Dit is zeer opmerkelijk 
omdat hier de niet-logische verklaring uit volgt dat een lagere MPA concentratie juist 
een verlaging van de IMPDH activiteit zou veroorzaken. We concluderen daarom ook 
dat ongebonden MPA beter de remming van IMPDH activiteit beschrijft dan totale MPA. 
We hebben echter geen verklaring voor het feit dat IMPDH activiteit sterker daalt bij 
patiënten met een lage albumine concentratie, terwijl de ongebonden MPA concentra-
ties niet verschilden.
Het doel van hoofdstuk 4.1 is acht verschillende SNP’s –de verschillende verschijnings-
vormen van een gen– van het IMPDH type II gen te correleren aan IMPDH activiteit 
om de variabiliteit tussen patiënten verklaren. Door het voorkomen van een SNP kan 
IMPDH actiever of juist minder actief zijn. In de bestudeerde patiëntengroep werden 
alleen variaties van de SNP IMPDH type II 3757T>C waargenomen en deze variatie kwam 
met een frequentie van 6,9% voor. Van de patiënten had 2% de variatie van het gen op 
beide genen. Een vergelijking tussen patiënten zonder variatie en patiënten met een 
variatie van het gen liet geen significant verschil in IMPDH activiteit vóór transplantatie 
zien. Op dag 6 na de transplantatie was de blootstelling aan IMPDH activiteit over 12 
uur significant 49% hoger bij patiënten met een variatie van het gen. Wij concluderen 
dat het IMPDH type II 3757T>C polymorfisme is geassocieerd met een verhoogde IMPDH 
activiteit in niertransplantatie patiënten die worden behandeld met MMF. Deze SNP 
verklaart voor 8,0% de variabiliteit in IMPDH activiteit tussen de patiënten.
IMPDH activiteit analysemethoden zijn tijdrovend en arbeidsintensief. In hoofdstuk 4.2 
hebben we daarom onderzoek gedaan of het bepalen van IMPDH mRNA als alternatieve 
methode kan dienen bij het monitoren van MMF therapie. IMPDH mRNA (messenger 
–‘boodschapper’– RNA) wordt afgelezen van het DNA in de cel en zorgt vervolgens 
dat het enzym IMPDH gemaakt kan worden. mRNA is dus de boodschapper tussen het 
erfelijke DNA in de kern en het gedeelte in de cel dat de enzymen maakt. De studie was 
ontworpen om IMPDH mRNA concentraties in de cel te correleren met IMPDH activiteit 
en klinische uitkomsten bij niertransplantatie patiënten. Er werden geen correlaties ge-
vonden tussen IMPDH type I en type II mRNA concentraties en IMPDH activiteit gemeten 
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vóór en na transplantatie. De bepaling van IMPDH mRNA concentraties is dan ook geen 
alternatief voor het monitoren van IMPDH activiteit.
Patiënten met een verhoogde IMPDH mRNA concentratie vóór transplantatie 
hadden een verhoogd risico op een acute afstoting, maar dit was niet significant. Op 
dag 6 na transplantatie waren verlaagde IMPDH type I en type II mRNA concentraties 
significant gecorreleerd met het optreden van acute afstotingen. 
Het aflezen van de twee verschillende types IMPDH genen verloopt via andere 
routes en daarom werd aangenomen dat ook een verschil in het verloopt van de beide 
concentraties zou worden gezien. Maar in ons onderzoek stegen de concentraties van 
zowel IMPDH type I als type II mRNA gelijk ten opzicht van elkaar na transplantatie.
MMF wordt behalve na orgaantransplantaties steeds vaker gebruikt na transplantatie 
van bloedstamcellen om acute graft-versus-host reacties te voorkomen. In hoofdstuk 
5.1 hebben we een verkennend onderzoek uitgevoerd bij patiënten na een bloedstam-
cel transplantatie. De behandeling van MMF is in deze studie voor het eerst farmacody-
namisch gemonitord door het meten van de IMPDH activiteit. Patiënten met een hogere 
IMPDH activiteit voor inname van MMF hadden een sterkere remming van de IMPDH 
activiteit 2 uur na inname. De variabiliteit tussen patiënten in de concentratie-effect 
relatie was groot, zoals reeds gezien is bij niertransplantatie patiënten. Ook de remming 
van de IMPDH activiteit in patiënten na bloedstamcel transplantatie was vergelijkbaar 
met de remming in patiënten na een niertransplantatie. Maar ondanks de gelijke IMPDH 
activiteit waren de MPA concentraties hoger in patiënten na een niertransplantatie. We 
veronderstellen daarom dat het IMPDH enzym bij patiënten na bloedstamcel transplan-
tatie gevoeliger is voor het remmende effect van MPA dan bij niertransplantatie patiën-
ten; er is minder MPA nodig om dezelfde remming van IMPDH te krijgen in vergelijking 
met niertransplantatiepatiënten.
Er werden geen significante correlaties gevonden tussen IMPDH activiteit en het 
ontstaan van graft-versus-host reacties. De IMPDH activiteit was wel significant lager in 
patiënten die leden aan ernstige bijwerkingen van MMF in vergelijking met patiënten 
met geen of milde bijwerkingen. Bijwerkingen die werden waargenomen waren een 
te kort aan bloedplaatjes, neutrofielen (een bepaalde soort witte bloedcellen) en/of 
bloedarmoede. Gezien de kleine groep onderzochte patiënten en de grote verscheiden-
heid van patiënten in deze pilot-studie, dient de klinische relevantie van onze conclusies 
bevestigd te worden in een studie met meer patiënten.
Hoofdstuk 6 bespreekt de belangrijkste resultaten en conclusies van de gepresen-
teerde onderzoeken in dit proefschrift. In dit hoofdstuk is ook gekeken in hoeverre deze 
een antwoord geven op de specifieke doelstellingen die zijn geformuleerd in hoofd-
stuk 1.2. Tijdens het samenvatten en bespreken zijn naar aanleiding van de verrichte 
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onderzoeken ook verschillende nieuwe onderzoeksvragen gesteld. Suggesties voor 
vervolgonderzoek naar het IMPDH enzym zijn in dit hoofdstuk weergegeven.
Op basis van onze resultaten kan het monitoren van IMPDH activiteit nog niet wor-
den aanbevolen om de behandeling van MMF te optimaliseren en te individualiseren. 
Het IMPDH enzym wordt geremd door veel meer factoren dan wij hebben onderzocht. 
Toch heeft dit proefschrift een basis gegeven om IMPDH activiteit en de remming van 
IMPDH door MPA beter te begrijpen in patiënten die worden behandeld met MMF. Onze 
bevindingen kunnen dienen als uitgangspunt voor toekomstige studies naar de fascine-
rende relatie tussen farmacokinetiek en farmacodynamiek van het geneesmiddel MMF.

Chapter 8
Appendices

Chapter 8.1
Dankwoord
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Drie en een half jaar IMPDH activiteit meten, analyseren en bediscussiëren betekent 
heel veel activiteit. In deze jaren hebben vele mensen naast mij ook veel activiteit ge-
leverd om dit onderzoek tot een goed einde te brengen. De overeenkomsten met deze 
activiteit en IMPDH activiteit zijn groot: er is een grote inter-individuele variabiliteit en 
de activiteit is de sleutel tot het eindproduct. Het is mij daarom ook een groot genoegen 
dat ik hier een aantal mensen mag bedanken voor de activiteit die ze hebben geleverd 
voor het onderzoek en mijn proefschrift.
Allereerst wil ik mijn promotor Prof. Dr. A.G. Vulto en mijn co-promotoren Dr. T. van 
Gelder en Dr. R.A.A. Mathôt bedanken. Beste Arnold, bedankt voor het faciliteren van 
mijn promotieonderzoek in de apotheek van het Erasmus MC. Je schat aan informatie 
en parate kennis (je weet altijd feilloos het juiste artikel uit de immens grote stapels te 
halen) heeft me de complexiteit van het wetenschappelijk onderzoek meer doen inzien. 
Jouw inzicht gaf soms een hele andere kijk op de zaken. Bedankt voor de tijd die je hebt 
genomen in het begeleiden, zelfs tot mijn stellingen toe.
Beste Teun, volgens mij zijn wij elkaar steeds meer gaan waarden en respecteren 
in ons zijn. De snelheid waarmee je jouw scherpe, maar terechte commentaar op on-
derzoeksvragen en manuscripten leverde, heb ik zeer gewaardeerd. Je wist mij op de 
juiste momenten te motiveren en te activeren door soms slechts hele kleine subtiele 
opmerkingen of mailtjes. En tot op heden blijft het voor mij nog steeds een raadsel waar 
jij de energie vandaan haalt om na een zware congresdag nog tot diep in de nacht te 
stappen. Daar waar ik halverwege al afhaakte. Beste Ron, in twee grote projecten binnen 
mijn onderzoek heb ik van jouw expertise gebruik mogen maken. Dit heeft geleidt tot 
twee mooie papers die de basis en de kroon van mijn proefschrift zijn geworden. Een 
andere passie die we delen is het motorrijden. Maar helaas is het nooit gekomen tot een 
gezamenlijke motorrit.
Prof. Dr. J. Lindemans, Prof. Dr. W. Weimar en Dr. K. Budde dank ik voor hun bereidwillig-
heid om zitting te nemen in mijn kleine commissie en voor de inhoudelijke beoordeling 
van dit proefschrift.
Prof. Dr. H.J. Guchelaar, Prof. Dr. J.N.M. IJzermans en Prof. Dr. J.J. Cornelissen wil ik 
bedanken voor hun deelname aan de grote commissie.
Ontzettend veel dank ben ik verschuldigd aan alle patiënten die hebben deelgenomen 
aan deze studie. Ik waardeer het zeer dat ik deelgenoot mocht zijn van de spannende 
tijden rondom hun transplantatie en de tijd erna, om zo ook de praktische en emo-
tionele kant van een transplantatie van dichtbij mee te kunnen maken. Het was een 
bevoorrechte positie waarin ik alle ups (eindelijk weer haring eten) en downs (toch weer 
mogelijk een afstoting) mee mocht maken.
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Voor de afname van de vele bloedmonsters heb ik ontelbaar veel hulp gekregen van 
researchverpleegkundige Margaret Nierop. Ik weet zeker dat zonder jouw hulp en 
enthousiasme een stuk minder patiënten meegedaan zouden hebben. Je bent een 
meester in het bloed afnemen, waar alle patiënten je om roemen en waar ik veel van 
geleerd heb. Voor mij was het altijd weer een feest om even langs te komen op je kamer 
op 9 Zuid om naast alle afdelingsperikelen ook even te horen hoe het in Engeland was.
Ook de researchverpleegkundigen Bianca van der Velde, Evelien van Beugen en 
Marjolein Gerrits van de onderzoekskamer Bd 248 hebben ontzettend veel betekend 
in dit onderzoek. Jullie toegewijde aandacht voor de patiënten maakten de lange poli-
bezoeken voor hen een stuk aangenamer. Jullie waren zeer flexibel wanneer afspraken 
verschoven werden of wanneer patiënten spontaan bij jullie aan de balie stonden. Mede 
daardoor zijn er slechts weinig patiënten uitgevallen in de loop van de studie. Het was 
fantastisch om met jullie samen te werken, en heerlijk om de beslommeringen rondom 
het onderzoek bij jullie kwijt te kunnen.
Tijdens het includeren van de patiënten heb ik veel hulp gehad van de zaalartsen Robert 
Nette, Marcia Kho, Mario Korte, Han Yo Ie en Madelon van Agteren en nurse practitioner 
Mirjam Tielen. Bedankt voor jullie helpende hand in het vragen van de patiënten en de 
klinische lessen die ik van jullie kreeg rondom transplantaties. Voor het poli-klinische 
gedeelte van het onderzoek ben ik veel dank schuldig aan de dames van de poli interne 
geneeskunde – niertransplantatie, en in het bijzonder aan Marja Swijnenburg. Bedankt 
voor het plannen van de afspraken op de juiste momenten, het klaarleggen van de 
statussen en het meedenken wanneer er weer eens logistieke problemen waren. 
Veel tijd heb ik doorgebracht in het laboratorium van de apotheek. Mijn dank gaat 
daarom uit naar de analisten Angela, Bart, Chelesta, Christien, Frans, Joram, Manuel, 
Mark, Regina, Ruben, Ruud, Sandra en Wilfred. Door jullie gastvrijheid en gezelligheid 
is mijn tijd op het lab een geweldige tijd geweest. Het heeft mij goed gedaan tijdens 
het opzetten van de methoden en het meten van de monsters. Speciale dank gaat uit 
naar Bart, Ruben, Frans en Mark voor hun hulp bij het opzetten van de methoden. Jullie 
kennis over de apparaten en analysetechnieken hebben mij enorm geholpen.
Carla Baan, Annemiek Peeters en Monique Quaedackers, bedankt dat jullie alle IMPDH 
mRNA concentraties in mijn monsters hebben gemeten.
Ron van Schaik en Marloes van der Werf, bedankt voor de farmacogenetische ana-
lyse van alle polymorfismen in mijn patiëntenpopulatie.
De studenten Maurits de Rotte en Marianne Vos wil ik bedanken voor hun bijdrage 
in het onderzoek bij het stemcel transplantatie patiënten tijdens hun onderzoeksstage.
206
Petra Glander, Klemens Budde und Pia Hambach, ich bedanke mich sehr für die Gast-
lichkeit. Während meinen Aufenthalt bei Ihnen im Labor hat es mir sehr gut gefallen. Sie 
haben mir eine riesige Erklärung über der IMPDH Aktivität assay gegeben. Außerdem 
habe ich zusammen mit dir beiden auch sehr genossen. Die Stattführung durch Berlin 
und das Schlittschuhlaufen stellte sicher dass ich der Trip als sehr besonderes erfuhr.
Ik bedank mijn mede-onderzoekers Reinier, Maurice en Brenda voor onze samenwer-
king. Hoewel het voor velen leek of wij altijd zeeën van tijd hadden om koffie (of thee 
voor Maurice) te drinken, hebben we ook vele discussies met elkaar gehad over onze 
onderzoeken. Maar ook waren we er voor elkaar om de onvermijdelijke onderzoeks-
dippen (of software problemen) te bespreken, zodat we weer met frisse moed verder 
konden gaan. Brenda, jij speciaal bedankt voor de hulp en steun tijdens mijn onderzoek 
als ‘sparring-partner’, en alle gezellige tijden buiten het onderzoeken als goede vriend. 
Vandaag sta je me bij als paranimf, wat een mooie weerspiegeling is van onze samen-
werking. En hierna weer heerlijk skiën en feesten met elkaar, want ‘jij bent zo’.
Ook mijn andere kamergenoten, Anouk, Bregje, Laureen, Liselotte en Maren bedan-
ken voor de gezellige tijd met elkaar op de kamer. Mensen maken voor mij het werk, 
en jullie hebben dat voor mij zeer aangenaam gemaakt. Hopelijk zijn jullie ook nog aan 
jullie werk toegekomen op onze niet-altijd-rustige kamer.
Samen met alle andere jonge apothekers Anna, Asmar, Carolien, Claartje, Delia, 
Jan-Dietert, Lyonne, Matthijs, Mila, Monique, Ryan, Satu, Savita, Sonja, Tessa, Valentina, 
Vincent en Yves heb ik een prachtige werksfeer gehad. Onze jaarlijks weekendje weg 
en de spontane vrijdagmiddagborrels bij Coenen hebben zeker bijgedragen aan de 
gezelligheid onderling. Verder wil ik alle andere collega’s in de apotheek (ziekenhuis-
apotheker, apothekersassistenten en administratief, secretarieel, kwaliteits, logistiek, 
farmaceutisch en ICT medewerkers) bedanken voor mijn tijd in het Erasmus MC.
In het verlengde hiervan wil ik ook alle nieuwe collega’s van mij in het OLVG bedan-
ken, en speciaal Eric Franssen. Bedankt voor je interesse in mijn onderzoek, de ruimte 
die je gaf en de motivatie die je bij mij hoog hield om ook het laatste gedeelte van mijn 
promotie af te maken. Ik ben bevoorrecht dat jij mijn opleider bent voor mijn opleiding 
tot ziekenhuisapotheker. 
Een promotieonderzoek is vaak een lange en eenzame gebeurtenis. Eén ding is zeker, 
het kost ongelofelijk veel tijd, tijd die ik helaas daardoor al te vaak niet aan mijn vrien-
den, familie en schoonfamilie kon besteden. Vrienden, jullie zeker ook bedankt voor 
jullie morele steun en toeverlaat in deze tijden. Ik hoop dat er wat dat betreft weer 
rustigere tijden aanbreken om elkaar weer meer te zien en te spreken. Erik, in de tijd 
dat we collega’s waren heb ik ooit tegen je gezegd dat je mijn paranimf moest zijn als ik 
zou promoveren, toen nog niet gedacht dat die dag ook echt zou aanbreken. Ik ben blij 
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dat je die taak op je hebt genomen. En het is een mooi resultaat dat ik je tijdens onze 
avonden in de kroeg zo enthousiast voor het onderzoek heb gemaakt, dat jij nu ook 
bezig bent met jouw promotieonderzoek. Daniël, bedankt voor het ontwerpen van de 
voorkant van dit proefschrift. Judith, vielen Dank für Ihre Eingabe.
Lieve mam, bedankt voor je onvoorwaardelijke support en je moederlijke bezorgd-
heid tijdens mijn proefschrift, ondanks dat het in Rotterdam was. Zonder je positief 
bemoedigende woorden en je kaartjes op het juiste moment zou het een stuk zwaarder 
geweest zijn. Lieve Cynthia en Merik, bedankt voor jullie interesse in wat ik nu precies 
allemaal deed en waar ik nu weer naar toe moest voor congres.
En wat is een man zonder sterke, lieve en zorgzame vrouw naast zich? Marijke, wat ben 
ik ongelofelijk gezegend met jou naast me! Dit werk hebben we samen gedaan, want 
jij hebt hier ook veel tijd in zitten. Je hebt mij vaak moeten missen -meer dan ik wilde- 
wanneer ik avonden en weekenden lang bezig was het mijn onderzoek. Bedankt voor 
je liefde en begrip hiervoor. Samen met jou ben ik compleet, en daar hoef ik echt geen 
doctor voor te zijn om dat zeker te weten. Ik houd van je!
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AcMPAG Acyl MPAG
ALAT Alanine aminotransminase (ALT)
AMP Adenosine monophosphate
ASAT  Aspartate aminotransaminase (AST)
ATG Anti-thymocyte globulin
AUC Area under the curve
b.i.d. Lat: bis in die; twice daily
BCA  Bicinchoninic acid
BPAR Biopsy proven acute rejection
cDNA Complementary DNA
CNI Calcineurin inhibitor
Ct Cycles threshold
CL Clearance
CrCl Creatinine clearance
CRP C-reactive protein
CsA Ciclosporine A
CV Coefficient of variation
DNA Deoxyribonucleic acid
DPN Diphosphophyridine nucleotide
E0 Baseline activity
EC-MPS Enteric-coated mycophenolate sodium
EHC Enterohepatic circulation
Emax Maximum inhibitory effect
F Bioavailability
FK Tacrolimus
FO First order
FOCE First order conditional estimate
GFR Glomerulair filtration rate
GGT γ-glutamyltransferase
GTP Guanosine triphosphate
GvHD Graft-versus-host disease
HLA Human leukocyte antigen
HPLC High-performance liquid chromatography
HSCT  Hematopoietic stem cell transplant
IBD Inflammatory bowel disease
IC50 Concentration which inhibits Emax to 50%
IMP Inosine monophosphate
IMPDH Inosine 5’-monophosphate dehydrogenase
Ka Absorption rate constant
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KCl Potassium chloride
LC-MS/MS Liquid chromatography-tandem mass spectrometry
Li-Hep Lithium heparin
MMF Mycophenolate mofetil
M-MLV RT Moloney murine leukemia virus reverse transcriptase
MPA Mycophenolic acid
MPAG 7-O-MPA-glucuronide
mRNA Messenger ribonucleic acid
MRP-2 Multidrug resistant protein-2
MUD Matched unrelated donor
MVOF Minimum value of objective function
N.A. Not available
NAD Nicotinamide adenine dinucleotide
NADH Reduced NAD
NONMEM Nonlinear mixed effects modeling
PBMC Peripheral blood mononuclear cells
PBS Phosphate-buffered saline
PD Pharmacodynamics
PK Pharmacokinetics
PRA Panel-reactive antibodies
Q Intercompartmental clearance
QCS Quality control sample
r2 Correlation coefficient
RIC Reduced intensity conditioning
RT-PCR Real-time polymerase chain reaction
SCS Spiked control sample
Sib Siblings
SNP Single nucleotide polymorphisms
Tlag Lag time
TBAS Tetra-N-butylammonium hydrogen sulfate
TDM Therapeutic drug monitoring
Tx Transplantation
UGT Uridine diphosphate glucuronosyltransferase
UTR Untranslated region
UV Ultraviolet
V Volume of distribution
WBC Whole blood cell
XMP Xanthine monophosphate
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Ferdi Sombogaard was born on 10 January 1979 in Bangert, The Netherlands. He com-
pleted secondary school (Athenaeum) at the Marcus College in Grootebroek in 1997. 
Subsequently, he started his Pharmacy study at the University of Groningen. During his 
study, he performed a research project titled ‘Pharmacokinetics and toxicity of oxalipla-
tin and irinotecan in the treatment of patients with advanced colorectal carcinoma’ at 
the Isala Clinics in Zwolle under supervision of Prof.Dr. J.R.B.J. Brouwers and Dr. F.G.A. 
Jansman. In 2003 he obtained his Master of Science degree in Pharmacy, main subject 
pharmacokinetics and drug delivery, followed by his Pharmacist’s degree in 2004. There-
after, he worked as a pharmacist in hospital in Het Groene Hart Hospital in Gouda.
Ferdi started in 2005 his PhD research at the department of Hospital Pharmacy, unit 
Clinical Pharmacology of the Erasmus University Medical Center in Rotterdam. Under 
supervision of Prof.Dr. A.G. Vulto, Dr. T. van Gelder and Dr. R.A.A. Mathôt he worked on 
the research project ‘Pharmacodynamics of inosine monophosphate dehydrogenase’ of 
which the results are described in this thesis. This project was in close affiliation with 
the departments of Internal Medicine – Nephrology and Clinical Chemistry. He received 
in 2006 the ESOT-Novartis study grant of the European Society of Transplantation for a 
co-research project with the department Internal Medicine – Nephrology of the Charité 
University Medical Center Berlin, Germany. In 2008 he received the Young Investigator 
Award of the American Society of Transplantation for parts of his research.
Ferdi is currently working in the Onze Lieve Vrouwe Gasthuis in Amsterdam as hospital 
pharmacist trainee. In June of this year, Ferdi will marry Marijke.
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Name: Ferdi Sombogaard
PhD Period: December 2005 – May 2009
Promotor: Prof. Dr. A.G. Vulto, Dept. of Hospital Pharmacy
Copromotors: Dr. Ron Mathôt, Dept. of Hospital Pharmacy
 Dr. Teun van Gelder, Dept. of Hospital Pharmacy, Dept. of Internal Medicine
1. PhD trAINING
1.1 General academic skills
· Biomedical English Writing and Communication Aug-Nov 2008
· Methodology of patient research and preparation of allowance requests    Mar 2006
1.1 Research skills
· Biomedical Research Techniques VII Oct 2008
· Masterclass Clinical Research Oct 2006
1.1 In-depth courses
· Hesperis course of the ESOT (Malmö, Sweden) May 2007
  (Lyon, France) Nov 2006
· 6th European Transplant Fellow Workshop ESOT (Wroclaw, Poland) Dec 2005
1.1 Presentations
· IMPDH type I and II gene expression and IMPDH activity correlated to 
 clinical outcomes in MMF treated kidney transplant patients. 
 NVKF&B, Mar 2009
oral
· IMPDH type I and II gene expression and IMPDH activity correlated to 
 clinical outcomes in MMF treated kidney transplant patients. 
 Annual Meeting NTV, Mar 2009
oral
· IMPDH activity on day 6 after kidney transplantation is significantly re 
 lated to the risk of acute rejection in MMF treated patients. 
 NVKF&B, Oct 2008
oral
· IMPDH activity is correlated with the 3757T>C polymorphism in the 
 IMPDH type II gene in MMF treated kidney transplant patients. 
 FIGON medicines Days, Oct 2008
poster
· IMPDH activity on day 6 after kidney transplantation is significantly 
 related to the risk of acute rejection in MMF treated patients. 
 ImmunoTDM - IATDMCT, Sept 2008
oral
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· IMPDH activity on day 6 after kidney transplantation is significantly 
 related to the risk of acute rejection in MMF treated patients. 
 8th ATC Jun 2008
oral
· IMPDH activity is correlated with the 3757T>C polymorphism in the 
 IMPDH type II gene in MMF treated kidney transplant patients. 
 8th ATC, May 2008
poster
· IMPDH activity on day 6 after kidney transplantation is significantly 
 related to the risk of acute rejection in MMF treated patients. 
 Annual Meeting NTV, Mar 2008
oral
· IMPDH activity is correlated with the 3757T>C polymorphism in the 
 IMPDH type II gene in MMF treated kidney transplant patients. 
 Annual Meeting NTV, Mar 2008
oral
· IMPDH genotype-phenotype correlation in lymphocytes drawn from 
 healthy volunteers. 
 2nd NZVA Day, Oct 2007
poster
· The Influence of Albumin on the Activity of IMPDH in Haematopoietic 
 Stem Cell Transplant Recipients Treated with Mycophenolate Mofetil. 
 2nd NVZA Day, Oct 2007
poster
· IMPDH genotype-phenotype correlation in lymphocytes drawn from 
 healthy volunteers. 
 8th Congress of EACPT, Aug 2007
poster
· Pharmacokinetics of Mycophenolate Mofetil in Haematopoietic Stem Cell 
 Transplant Recipients. 
 6th European Transplant Fellow Workshop ESOT, Dec 2005
oral
1.1 (inter)national Conferences
· Biannual meeting NVKF&B Mar 2009
· Annual meeting NTV Mar 2009
· 3rd NVZA Day Nov 2008
· Biannual meeting NVKF&B Oct 2008
· FIGON Medicines Days Oct 2008
· ImmunoTDM IATDMCT (Warsaw, Poland) Sept 2008
· 8th ATC (Toronto, Canada) Jun 2008
· Annual meeting NTV Mar 2008
· 2nd NVZA Day Oct 2007
· 8th Congress of EACPT (Amsterdam, The Netherlands) Aug 2007
· Biannual meeting NVKF&B Mar 2007
· FIGON Medicines Days Sept 2006
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1.1 Seminars and workshops
· Pharmacogenetics in clinical practice Sep 2007
· Pharmacokinetic future of MPA Jan 2007
· World Transplantation Congress Review Sep 2006
1.1 Prizes and awards
· FIGON poster prize Oct 2008
· Poster of distinction ATC Jun 2008
· Young Investigator Award ASTS/AST May 2008
· ESOT Novartis Study Grant Apr 2006
2. teAcHING ActIvItIeS
1.1 Lecturing
· Graduate level Medical students, ‘Practical Pharmacotherapy’ 2006-2009
· Monitoring mycophenolate mofetil therapy by IMPDH activity 
 measuring; interim results of a PK/PD study, dept. of nephrology 2008
1.1 Supervising MSc-theses
· M. Vos – MSc student Medicine - Erasmus University Rotterdam 2008
· M.C.F.J. de Rotte – MSc student Pharmacy - University of Groningen 2007
AST   American Society of Transplantation
ASTS  American Society of Transplant Surgery
ATC   American Transplantation Congress
EACPT  European Association for Clinical Pharmacology and Therapeutics
IATDMCT International Association of Therapeutic Drug Monitoring and Clinical Toxicology
NTV   Nederlandse Transplantatie Vereniging (Dutch Transplantation Society)
 VKF&B  Nederlandse Vereniging van Klinsiche Farmacologie & Biofarmacie (Dutch Society of Clinical 
 Pharmacology & Biopharmacy)
NVZA  Nederlandse Vereniging voor Ziekenhuis Apothekers (Dutch Association for Hospital 
 Pharmacists)
